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Aim of research 
 
The present research activity is focused on the development of a new class of biomaterials 
and device for application in regenerative medicine, particularly in the repair/regeneration 
of hard tissue such as bone and osteochondral regions. 
The new biomaterials were designed to provide new solutions towards the local treatment 
of hard tissues affected by degenerative diseases such as Osteoarthritis (OA) and 
Osteoporosis (OP) or serious traumas. These pathologies affect an ever increasing number 
of people worldwide with huge socio-economic impact. Although the incidence of such 
diseases has historically been linked to ageing, more recently the number of relatively 
young people affected by these diseases has increased, due to new life-styles (e.g. intense 
sport activity, obesity, alcohol consumption). In the most serious cases, lesions involving 
osteocartilaginous regions or vertebral bodies can lead to severe complications affecting 
the neuro-muscular system and can significantly impair the patient’s quality of life and 
longevity. The current therapies mainly aim at blocking the progress of the diseases 
and/or to provide a physical sustains, in case of vertebral weakening. Such approach, 
however, has several limitations and drawbacks, and does not provide tissue regeneration 
and the recovery of the original functions. 
During the last decade the scientific research has increasingly pushed towards the 
development of tissue-mimicking constructs addressed to tissue regeneration. In 
particular, it is widely accepted that the regeneration of hard connective tissues requires 
the implantation of porous bio-resorbable scaffolds exhibiting chemical-physical and 
morphological mimicry with the target tissues so to provide environmental cues for cell 
adhesion, proliferation and specific differentiation.  
With regard to bone, biomimetic apatites, i.e. nanostructured calcium phosphates 
mimicking the composition and the nanostructure of the mineral bone, are considered the 
golden biomaterials for regenerative bone scaffolds. In this respect, the Research Group 
on Biomaterials at ISTEC-CNR has 20 years of experience in the synthesis and 
characterization of nano-apatites with different crystal order and ionic substitutions, 
suitable to activate specific biologic functions relevant for bone tissue regeneration. 
With regard to complex osteochondral regions, ISTEC-CNR developed in 2001 a 
biologically-inspired mineralization processes mimicking the cascade of events yielding 
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new bone formation, that enabled the synthesis of biomimetic hybrid 
hydroxyapatite/collagen composites mimicking multifunctional osteocartilaginous 
regions. By this process, biomimetic, ion-substituted nanoapatites can be heterogeneously 
nucleated on collagen fibrils, the assembling and organization of which is mediated by 
several physical, chemical, morphological and structural control mechanisms, activated 
by pH and temperature control. These scaffolds demonstrated very high regenerative 
potential and were subsequently patented, scaled up and brought to the market as bone 
and osteochondral scaffolds.  
With respect to this previous knowledge, the present work intended to develop new 
improved scaffolds for bone and osteochondral tissue regeneration, aimed to achieve 
faster regeneration and improved texturing of the newly formed tissues. Indeed scientific 
research is increasingly being devoted to develop new approaches for stimulating cell 
activity, including the design of specific 3D morphologies and the development of smart, 
stimuli-responsive, drug delivery systems. A particularly intriguing approach is based on 
the use of magnetism: recent findings show that the local application of weak magnetic 
fields may stimulate cells to produce new bone tissue in a more ordered manner.  
With this in mind the present research thesis was specifically focused on the synthesis and 
physico-chemical-morphological characterization of: 
i) a new iron-substituted apatite phase (FeHA) with intrinsic superparamagnetic 
properties; 
ii) new biomimetic hybrid scaffolds with superparamagnetic properties for bone and 
osteochondral regeneration, obtained by biologically-inspired mineralization processes; 
iii) new self-setting injectable pastes based on calcium phosphates functioning as apatitic 
bone cements for regenerative vertebroplasty. 
More specifically, in the present work a new apatite phase with superparamagnetic 
properties was developed, by performing ionic substitutions in the apatite lattice, 
particularly of bi- and tri-valent iron ions replacing calcium, achieved by fine control of 
the synthesis conditions. The new apatite phase resulted of great potential, due to the 
possibility of using biocompatible, bioactive and bio-resorbable superparamagnetic 
phases for a number of applications, spanning from regenerative medicine to theranostics 
and imaging, thus overcoming the current use of magnetite nanoparticles, which raise 
several concerns for their long-term cyototoxicity.  
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The development of this new phase was exploited in the generation of biologically-
inspired mineralization process enabling the heterogeneous nucleation of 
superparamagnetic nano-apatite on collagen fibrils. By reproducing the conditions of 
formation of new bone tissue, thus obtaining highly biomimetic bone, osteochondral 
scaffolds with intrinsic superparamagnetic properties were synthesized. This approach 
may open the way to the generation of new scaffolds with multiple functionality, i.e. the 
possibility to activate the scaffold by remote magnetic control and provide local signals to 
enhance the regenerative processes. Additionally, the remote magnetic activation can 
enable the recall and controlled delivery of osteogenic and angiogenic growth factors 
linked to magnetic nanoparticles so to achieve scaffolds functioning as a flexible 
“workstation” able to regulate and guide tissue regeneration on the basis of the personal 
needs of the patient. 
In the view of specific treatments for patients affected by osteoporosis or traumas 
involving vertebrae weakening or fracture, the present work was also dedicated to the 
development of new self-setting injectable pastes based on strontium-substituted calcium 
phosphates, able to harden in vivo and transform into strontium-substituted 
hydroxyapatite. The addition of strontium may provide an anti-osteoporotic effect, aiding 
to restore the physiologic bone turnover. The ceramic-based paste was also added with 
bio-polymers, able to be progressively resorbed thus creating additional porosity in the 
cement body that favour cell colonization and osseointegration. This approach may 
enable innovative therapies against the weakening of vertebral bodies due to osteoporosis 
or serious traumas. In this respect, the current clinical approach is mainly the 
percutaneous injection of acrylic bone cements, which can harden in few minutes and 
allow the early dismission of the patient after surgery. However, due to several drawbacks 
related to the exothermy of the polymerization reaction, the bioinertness of acrylic phases 
and the excessive stiffness of the cement in relationship with the surrounding bone, this 
solution is not suitable for relatively young patients (<60-65 years) and/or severe patients, 
and reliable regenerative solutions for vertebroplasty are still missing. The set up and 
development of regenerative bone cements were made difficult so far by the high 
complexity of the processes required to establish pastes characterized, at the same time, 
by high bioactivity, osteogenic and osteoconductive character, the absence of any adverse 
reactions, in association with good injectability, low setting times (in the order of 
minutes) and sufficient compression strength allowing stable fixation upon injection. 
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The new bio-devices developed in the present work may enable new tissue regeneration-
based treatments and minimally-invasive surgical approach that have the potential to 
overcome the limitations and drawbacks associated with the current therapies. In these 
clinical situations, the development of biomimetic, bioresorbable scaffolds with 
regenerative ability is regarded by clinicians as breakthrough solutions in the cure of these 
debilitating pathologies. In fact, autologous bone grafts are not always readily available in 
sufficient amounts, and its use poses concerns on the patient health and pain, bone 
allografts are inferior to autologous bone, are expensive, and have known risks of 
bacterial contamination, viral transmission and immunogenicity. Moreover the use of the 
new superparamagnetic iron-substituted apatite nanoparticles and hybrid scaffolds may 
pave the way to the establishment of newly conceived therapies for tissue regeneration, as 
well as novel applications in theranostics and imaging characterized by virtual absence of 
any drawbacks related to the cytotoxicity of nanoparticles. 
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 Biomaterials 
In the last few years the biomedical research area is going towards materials science 
aiming applications of materials to health care, the so-called biomaterials. They can be 
defined as implantable materials that must be in contact with living tissues with the final 
aim of achieving a correct biological interaction between the material and the host1. In the 
first Consensus Conference of the European Society for Biomaterials (ESB) in 1976, a 
biomaterial was defined as “a nonviable material used in a medical device, intended to 
interact with biological systems”; however the ESB’s current definition is a “material 
intended to interface with biological systems to evaluate, treat, augment or replace any 
tissue, organ or function of the body”. This subtle change in definition is indicative of 
how the field of biomaterials has evolved. Biomaterials have moved from merely 
interacting with the body to influencing biological processes toward the goal of tissue 
regeneration. However, a more recent definition has been published: A biomaterial is a 
substance that has been engineered to take a form which, alone or as part of a complex 
system, is used to direct, by control of interactions with components of living systems, the 
course of any therapeutic or diagnostic procedure, in human or veterinary medicine2.  
 
1.2 Biomaterials for bone substitution 
Biomaterials for bone substitution are employed mainly as fillers, or as structural 
substitutes or as coating for screws or similar device. The ultimate aim of biomaterials for 
bone substitution is to restore the structural integrity of the damaged bone.  
The substitution of bone intends mainly to restore the structural functionality of the 
missing part, but it is not able to completely restore all its properties; the very complex 
composition and morphology of the bone tissue are responsible of its unique ability to 
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continuously adapt to the ever changing mechanical solicitations, so to be simultaneously 
light, tough and elastic and able to locally regenerate after traumas of limited extension. 
Thus, with the increasing of the expectance of life and well-being, the development of 
bone substitutes able to restore the whole functionality of the original tissue was of 
increasing importance in the last decades; beyond the commercial aspects, the problem 
has a highly social relevance as the patients can regain a more active and satisfactory life 
and sooner than in the past. 
An ideal bone substitute should be biomimetic, i.e. able to perfectly mimic in vivo the 
behaviour of the natural bone. For this reason, not only biocompatibility is required, but 
features of bioactivity, osteoinductivity, osteoconductivity and bio-resorbability are also 
strongly needed. 
Biocompatibility is the ability of a material to perform with an appropriate host response 
in a specific application, without having any toxic or injurious effects on biological 
systems. The scope of this definition is very wide and many subgroups of applications can 
be found to make more narrow definitions of biocompatibility. Anyway, for a long-term 
implantable medical device, like a bone substitute, the biocompatibility refers to the 
ability of the device to perform its intended function, with the desired degree of 
incorporation in the host, without eliciting any undesirable local or systemic effects in 
that host. 
Bioactivity is the ability of the implant to bond to bone tissue. The process of bone 
bonding is the result of multiple, parallel and sequential reactions at the material-tissue 
interface. These interactions are related to either physicochemical phenomena that occur 
in the presence or absence of cells, or are related to reactions affected by cellular activity. 
Osteoinductivity is the ability of a material to induce cell differentiation oriented to the 
synthesis of a bone matrix, able to mineralize in bone tissue.  
Osteoconductivity is a passive property of the implant consisting in the ability of making 
easy the formation and diffusion of the new bone both through its chemical (presence of 
ions and substances able to enhance the cell activity for osteogenesis, the process of new 
bone development) and morphological (hierarchically organized porous structure able to 
host the growing bone tissue and the vascular system) features. 
Bioresorbability is the ability of the implant to be dissolved by the in vivo processes of 
bone remodelling and to be replaced by the new bone tissue. 
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1.2.1 Biomimetic materials  
Biomimetics is a new, very important, field of science that studies how Nature designs, 
processes and assembles/disassembles molecular building blocks to fabricate high 
performance mineral-polymer composites (e.g. mollusc shells, bone, tooth) and/or soft 
materials (e.g. skin, cartilage, tendons) and then applies these designs and processes to 
engineer new molecules and materials.  
In nature, living organisms synthesize mineralized tissues and this process of 
biomineralization is under strict biological control. It involves the interactions of several 
biological macromolecules among themselves and with the mineral components. 
Generally, natures design principles are based on a “Bottom-Up” strategy. Such processes 
lead to the formation of hierarchically structured organic-inorganic composites with 
mechanical properties optimized for a given function. A common theme in mineralized 
tissues is the intimate interaction between the organic and inorganic phases and this leads 
to the unique properties seen in biological materials. Therefore, understanding natures 
design principles and ultimately mimicking the process may provide new approaches to 
synthesize biomaterials with unique properties for various applications. 
In fact, in the last decades the activity of material scientists was more and more directed 
to the development of biomimetic scaffolds, able to drive and address cell activity 
towards proper differentiation and the repair of diseased human tissues3. In case of bone, 
this requires the synthesis of three-dimensional constructs able to exchange chemical 
signals promoting osteogenesis and to progressively be resorbed during the formation and 
remodelling of new bone. Besides, particularly for the regeneration of extensive portions 
of bone, a morphological and mechanical biomimesis is also required, to allow cell 
colonization and formation of a proper vascularization tree. The healing of load-bearing 
bones also requires scaffolds with a hierarchically organized morphology, to provide 
improved biomechanical behaviour and allow a proper mechano-transduction of the 
mechanical stimuli down to the cell level4. 
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1.3 Bone tissue 
Bone is a bioceramic composite that has long held the attention of the materials engineer 
who seeks to duplicate its enviable mechanical properties, in which both high strength 
and fracture toughness can be achieved due to the unique architecture of this organic-
inorganic composite. 
 
1.3.1 Biology of bone tissue 
Bone is a specialised connective tissue which forms the basis of the skeleton and, as such, 
its functions are numerous and complex. One of these functions, although not necessarily 
the most important, is to protect the internal organs from damage which could result from 
the physical trauma of everyday life. In combination with the associated musculature, the 
bones of the skeleton also provide a means of physical support, locomotion and related 
movement. One further role is that of a reservoir for a multitude of inorganic ions. 
Three distinctly different cell types can be found within bone (Fig.1): the matrix-
producing osteoblast, the tissue-resorbing osteoclast, and the osteocyte, which accounts 
for 90% of all cells in the adult skeleton5.  
Osteoblasts (from the Greek words for "bone” and "germ" or embryonic) are the cells 
within bone that lay down the extracellular matrix and regulate its mineralization. 
Morphologically, these cells are cuboidal in shape and located at the bone surface 
together with their precursors, where they form a tight layer of cells. Osteoblasts are 
located on the surface of osteoid seams and also manufacture hormones, such as 
prostaglandins, to act on the bone itself. They robustly produce alkaline phosphatase, an 
enzyme that has a role in the mineralisation of bone, as well as many matrix proteins. 
Osteoblasts are the immature bone cells. When osteoblasts are trapped in the bone matrix, 
which they themselves produced, they become star-shaped cells named osteocytes, the 
most abundant cell found in bone. 
Osteocytes are osteoblasts that remain in bone matrix until they degrade according to 
natural cycle of life. They are set both in cortical and trabecular bone localizing in 
hollows or bone gaps, among one lamella and the other. They have a flat and long shape 
with cytoplasmatic prolongations. Their function is to guarantee the survival of the 
surrounding tissue taking nourishing substances from the medullar hollow through 
cytoplasmatic channels (canaliculi)6. Osteocytes are not active producers or destroyers of 
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bone matrix, but are able to feel mechanical solicitations and, if necessary, control the 
other bone-cells activity such as deposition and reabsorption processes of mineral phase. 
Osteoclasts (from the Greek words for "bone" and "broken") are multinucleated cells, 
like macrophages, derived from the hematopoietic lineage. They degrade the mineralized 
bone tissue giving rise to isolated micro-ambients where they release acid products 
dissolving organic and inorganic bone matrixes7. Their activity can be controlled, both 
from chemical signals (hormones, vitamins, low levels of calcium) and mechanical 
stresses. Those signals stimulate the bone remodelling: the demolition of some lamellae 
and rebuilding of others differently oriented to better compensate the applied load8. In 
brief, osteoclasts digest while osteoblasts reconstruct again bone tissue9.  
 
 
 
 
Fig. 1. Bone cells 
 
 
Osteoid is comprised of type I collagen (~94%) and noncollagenous proteins. The 
hardness and rigidity of bone is due to the presence of mineral salt in the osteoid matrix, 
which is a crystalline complex of calcium and phosphate (hydroxyapatite). Calcified bone 
contains about 25% organic matrix (2-5% of which are cells), 5% water and 70% 
inorganic mineral (hydroxyapatite). 
 
1.3.2 Morphology and structure of bone tissue 
There are three different types of bone tissue, compact (cortical bone), trabecular 
(cancellous bone), and subchondral (Fig. 2). The compact one is the harder, outer tissue 
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of bones, the trabecular one is the sponge-like tissue inside bones, and the subchondral 
tissue is the smooth one at the apical and basal parts of bones, which is covered with 
cartilage (made up in turn of chondrocytes, collagen fibers and proteoglycans). Although 
macroscopically and microscopically different, cortical bone and cancellous bone are 
identical in their chemical composition.  
Cortical bone, synonymous with compact bone, is one of the two types of osseous tissue 
that form bone. Cortical bone facilitates bone's main functions: to support the whole 
body, protect organs, provide levers for movement, and store and release chemical 
elements, mainly calcium. As its name implies, cortical bone forms the cortex or outer 
shell, of most bones. Cortical bone contributes about 80% of the weight of a human 
skeleton. The primary anatomical and functional unit of cortical bone is the osteon. Each 
osteon consists of concentric layers, or lamellae, of compact bone tissue that surround a 
central canal, the Haversian canal. The Haversian canal contains the bone's nerve and 
blood supplies. The boundary of an osteon is the cement line. 
 
 
 
Fig. 2. Schematic drawing of the bone structure 
 
Cancellous bone, synonymous with trabecular bone or spongy bone, is the other type 
of osseous tissue that forms bones. Compared to compact bone, it has a higher surface 
area but is less dense, softer, weaker, and less stiff. It typically occurs at the ends of long 
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bones, proximal to joints and within the interior of vertebrae. Cancellous bone is highly 
vascular and frequently contains red bone marrow where hematopoiesis, the production of 
blood cells, occurs. The primary anatomical and functional unit of cancellous bone is the 
trabecula, that is a small tissue element usually composed of dense collagenouse tissue.  
Subchondral bone region is the zone of epiphyseal bone just beneath the articular 
cartilage, and includes the subchondral plate and the underlying trabecular and 
subarticular bone. The subchondral plate comprises the deepest area of the articular 
cartilage, which is the calcified cartilage, and a thin cortical bone layer. The calcified 
cartilage is separated from the overlying hyaline cartilage by a line of demarcation called 
the tidemark.  
Nevertheless, subchondral bone is recognised as a key factor in normal joint protection. In 
fact, subchondral bone has been shown to exert important shock-absorbing and supportive 
functions in normal joints. Subchondral bone can attenuate about 30% of the joint load, 
providing a mechanical base for joint cartilage10. Moreover, subchondral bone supplies 
nutrients to cartilage and facilitates the removal of metabolic waste products11,12.  
 
1.3.3 Articular bone region 
Cartilage is a flexible connective tissue found in many areas in the bodies of humans and 
other animals, including the joints between bones, the rib cage, the ear, the nose, the 
bronchial tubes and the intervertebral discs.  
The cartilaginous tissue, together with the bone tissue, belongs to the support skeletal 
tissues or connective tissues that have high mechanical properties. The cartilaginous 
tissue has high specific mechanical-elastic properties that allow to constantly reducing the 
friction induced by the loads on the articular surface during the normal movement 
activities of the human body. Moreover, the cartilaginous tissue is able to dissipate the 
peaks of mechanical stress on the sub-chondral bone. The connective tissue surrounding 
the cell cartilaginous component, namely the chondrocytes, (2% of the total volume of the 
cartilage) is dipped in an extracellular matrix/lattice consisting of collagen, proteogly- 
cans and glycoproteins. For example, 2-40% of the connective tissue includes: 50-60% of 
collagen, 25-35% of proteoglycans and 10-15% of glycoproteins. The collagen molecules 
are uniformly distributed throughout the tissue and are responsible of its shape and 
mechanical strength. The proteoglycans and the glycoproteins bind to the collagen by 
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trapping the water within the matrix.  
Cartilage is classified in three types that differ in the biochemical composition and 
structure of their extracellular matrix (ECM), the resulting mechanical properties and 
therefore their occurrence in the human body: elastic cartilage, hyaline cartilage and 
fibrocartilage. 
Elastic cartilage is characterized by chondrons with only a few cells, a small 
concentration of proteoglycans (PGs), but much elastin. Elastin is interwoven into the 
collagen mesh and the more this protein is present, the more Xexibility is provided to the 
tissue. Elastic cartilage is surrounded by perichondrium and appositional growth is 
guaranteed through cell differentiation of the connective tissue. This tissue type is less 
vulnerable to degenerative changes. Elastic cartilage is suitable to resist bending and so it 
can be found in the epiglottic cartilage, the smaller laryngeal cartilage, the external ear 
and auditory tube, or the small bronchi13.  
A second type of cartilage is the fibrocartilage, providing other physical characteristics. 
Like the elastic type it contains a small concentration of PGs, but by contrast far less 
elastin. The meniscus is a fibrocartilaginous tissue composed primarily of an interlacing 
network of collagen fibers with a longitudinal, circumferential orientation which gives it 
unique functional properties. The ECM of fibrous cartilage consists of approximately 60-
70% collagen, 8-13% non-collagenous proteins, and 1% PGs in dry weight. The water 
content in native meniscal tissue is around 70-75%14.  
The third and most widespread cartilage in the human body is the hyaline type. As the 
name already implies, it appears as a white and slightly bluish tissue with a 
macroscopically smooth surface. Its resistance to compression or tensile forces is due to 
the net-like organized structure of the collagen type II fibers combined with a high 
concentration of PGs. Hyaline cartilage can be found in the nose, the trachea, bronchi, 
and most joints in synarthroidal as well as in diarthroidal joint15. In diarthroidal joints 
hyaline cartilage covers the contact zones of two interlocked bones and is called articular 
cartilage (Fig. 3). 
Articular cartilage is a unique type of connective tissue. Although appearing 
homogeneous, articular cartilage has a highly ordered structure. It is organized on two 
levels: the structure and composition of articular cartilage varies according to its distance 
from the surface and also in relation to the distance from the cells. Typically, articular 
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cartilage is divided into four zones: uperficial, middle (or transitional), deep (or radial), 
and the zone of calcified cartilage. Chondrocytes from the different zones differ in size, 
shape, and metabolic activity. The superficial zone is the thinnest, and forms the gliding 
surface of the joint. It is composed of thin collagen fibrils aligned parallel to the joint 
surface, with elongated, inactive chondrocytes directly subjacent. The middle zone is 
thicker than the superficial zone, with more spherical cells and with larger collagen fibrils 
that are not oriented in a parallel fashion. In the deep zone, the cells are spheroidal, 
arranged in a columnar orientation. The collagen fibers here are oriented in a parallel 
fashion, similar to the cells, vertical to the joint surface. In the zone of calcified cartilage, 
collagen fibrils insert into the calcified cartilage, providing both a mechanical transition 
from the cartilage to bone, as well as fixation between the two tissues16.  	  
 
 
Fig. 3. Articular cartilage 
 
1.3.4 Vertebral bone region 
The intervertebral discs lie between the vertebral bodies, linking them together (Fig. 4). 
They are the main joints of the spinal column and occupy one-third of its height. Their 
major role is mechanical, as they constantly transmit loads arising from body weight and 
muscle activity through the spinal column. They provide flexibility to this, allowing 
bending, flexion and torsion.  
Introduction 
 	  
 
10 
They are approximately 7-10 mm thick and 4 cm in diameter (anterior - posterior plane) 
in the lumbar region of the spine17. The intervertebral discs are complex structures that 
consist of a thick outer ring of fibrous cartilage termed the annulus fibrosus, which 
surrounds a more gelatinous core known as the nucleus pulposus; the nucleus pulposus is 
sandwiched inferiorly and superiorly by cartilage end-plates. The central nucleus pulposus 
contains collagen fibres, which are organised randomly, and elastin fibres (sometimes up 
to 150µm in length), which are arranged radially18; these fibres are embedded in a highly 
hydrated aggrecan-containing gel.  
The annulus is made up of a series of 15-25 concentric rings, or lamellae, with the 
collagen fibres lying parallel within each lamella. The fibres are orientated at 
approximately 60° to the vertical axis, alternating to the left and right of it in adjacent 
lamellae. Elastin fibres lie between the lamellae, possibly helping the disc to return to its 
original arrangement following bending, whether it be flexion or extension. They may 
also bind the lamellae together as elastin fibres pass radially from one lamella to the next. 
The cells of the annulus, particularly in the outer region, tend to be fibroblast-like, 
elongated, thin and aligned parallel to the collagen fibres. Toward the inner annulus the 
cells can be more oval. Cells of the disc, both in the annulus and nucleus, can have 
several long, thin cytoplasmic projections, which may be more than 30µm long. Such 
features are not seen in cells of articular cartilage19. Their function in disc is unknown but 
it has been suggested that they may act as sensors and communicators of mechanical 
strain within the tissue.  
 
 
Chapter 1 
 
 
 
11 
 
 
Fig. 4. A schematic view of a spinal segment and the intervertebral disc. The figure shows the organization 
of the disc with the nucleus pulposus (NP) surrounded by the lamellae of the annulus fibrosus (AF) and 
separated from the vertebral bodies (VB) by the cartilaginous end-plate (CEP). The figure also shows the 
relationship between the intervertebral disc and the spinal cord (SC), the nerve root (NR), and the 
apophyseal joints (AJ). 
 
The third morphologically distinct region is the cartilage end-plate, a thin horizontal 
layer, usually less than 1mm thick, of hyaline cartilage. This interfaces the disc and the 
vertebral body. The collagen fibres within it run horizontal and parallel to the vertebral 
bodies, with the fibres continuing into the disc. The healthy adult disc has few (if any) 
blood vessels, but it has some nerves, mainly restricted to the outer lamellae, some of 
which terminate in proprioceptors. The cartilaginous end-plate, like other hyaline 
cartilages, is normally totally avascular and aneural in the healthy adult. Blood vessels 
present in the longitudinal ligaments adjacent to the disc and in young cartilage end-plates 
(less than about 12 months old) are branches of the spinal artery. Nerves in the disc have 
been demonstrated, often accompanying these vessels, but they can also occur 
independently, being branches of the sinuvertebral nerve or derived from the ventral rami 
or grey rami communicantes. Some of the nerves in discs also have glial support cells, or 
Schwann cells, alongside them20.  
 
1.3.5 Degeneration of bone tissue 
Deseases of articular bone region 
Traumas, inflammatory and degenerative diseases can induce significant damages to the 
Introduction 
 	  
 
12 
articular cartilage which, in a non negligible percentage, can evolve in chronic arthrosis 
disease. The cartilaginous tissue subjected to a damage, in particular to a deep damage, 
has a poor self-reparative ability considering the poorly vascularized anatomic region and 
the limited replication ability of the chondrocyte cells. The result of the self-reparative 
process of the cartilage is often a formation of fibrous tissue which certainly can not be 
compared, in terms of mechanical performances and physiological features, to a normal 
hyaline cartilage. Accordingly, the alteration of the viscoelastic and mechanical balance 
can lead to considerable pathological consequences with a following compromission of 
the articular function and with a pain occurrence, although the cartilaginous degeneration 
process in most of cases is an asymptomatic phenomenon. 
The situation evolves in a more complex way in case of lesions involving the sub-
chondral bone structure, when the complete demolition of the cartilaginous layer directly 
exposes the bone to the mechanical stress of the joint. 
In conclusion, between the pathological conditions which can induce nearly always 
irreversible degenerative processes there may be listed, by mere way of example: the bad 
alignments (varus and valgoid conditions), the avascular necrosis, the osteoarthritis and 
the rheumatoid arthritis. The known surgical techniques currently utilized for the repair of 
the cartilaginous tissue are of course applied as a function of the dimensions and the depth 
of the defect. 
 
Deseases of vertebral bone region 
One of the major problems facing the elderly spine is the occurrence of vertebral 
fractures, which are associated with height loss, back pain, disability and even increased 
mortality rates. As these vertebral fractures are strongly correlated to low bone density, 
they are commonly attributed to osteoporosis.  
Disc degeneration begins with the nucleus becoming dehydrated and more fibrous, 
followed by a loss of distinction between the nucleus and annulus, disorganized fibers in 
the annulus and, finally, a decreased disc height. With disc pressure measurements it was 
found that healthy discs show an area of constant pressure under the nucleus and the inner 
annulus. For degenerated discs the area of constant pressure was much smaller and the 
pressure within it was lower. Such a change in pressure in the disc and on the endplates 
would lead to bone adaptation in the adjacent vertebrae. Indeed, disc degeneration has 
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been found to be correlated to a changed bone density distribution within the vertebra21.  
 
1.3.6 Bio-mineralization processes: the basis of bone formation  
The formation of bone tissue takes place through different events22 that comprise the 
synthesis and modification of specific polypeptide chains inside osteoblast cells, which 
are then extruded into the extracellular space. Here, the collagen microfibrils, with a mean 
diameter of 1.5 nm, start to assemble into fibres. During the self-assembly of collagen 
fibres, a quarter-staggered arrangement of parallel molecules of tropocollagen (a triple 
helical-shaped molecule, precursor of collagen) is established, leaving a regular array of 
40 nm gaps within each periodic unit. These areas are known as hole zones (40 nm in 
length and 5 nm in width) and as reported23 are the preferential sites for the nucleation of 
the mineral phase (Fig. 5). 
The nucleation of mineral nanocrystals takes place in specific loci corresponding to non-
collagenous acidic macromolecules; many of which are highly charged from carboxylate 
groups that can bind Ca2+ ions. Following the chemical binding of Ca2+, the 
supersaturation of physiological fluids in phosphate ions and other minor species (e.g. 
Na+ and K+) provokes the precipitation and nucleation of the mineral phase as nano-sized, 
plate-shaped particles, which are initially confined to the hole zones, and progressively 
extend along the collagen fibrils. The organic template transfers information to the 
mineral phase at the molecular level: (i) the chemical interaction of hydroxyapatite (HA, 
Ca5(PO4)3OH) with collagen prevents the crystallization of the mineral phase, which is 
almost amorphous but is characterized by an apatite-like lattice; (ii) the size and shape of 
the nuclei are constrained by the activation of structural and morphological control 
mechanisms during the bio-mineralization process; (iii) the growth of nuclei is limited to 
very thin lamellae, which are spatially confined and have a specific crystal orientation; 
and (iv) lamellae organize through different hierarchical levels up to the macroscopic 
bone. 
Introduction 
 	  
 
14 
 
Fig. 5. Schematic illustration of nucleation of bone mineral crystals during the self-assembling of collagen 
fibres. 
 
The crystal state of the substrate induces the nucleation and growth of the apatite 
nanocrystals along a specific crystallographic direction (Fig. 6). Crystal growth is limited 
to very few unit cells of the apatite lattice, with values ranging from 30-50 nm long, 15-30 
nm wide, and 2-10 nm thick24. The apatite platelets develop along the long axis of 
collagen, so that the apatite crystals grow preferentially along the c axis of the hexagonal 
apatite lattice. 
 
 
Fig. 6. Schematic illustration: (a) an arrangement of mineralized collagen fibrils aligned both with respect 
to crystal layers and fibril axes; (b) arrangement of mineralized collagen fibrils with only the fibril axes 
aligned.  
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1.3.7 Biological bone mineral phase 
Bone mineral has the structure of a calcium-deficient apatite, with a Ca:P ratio <1.67, 
which is the theoretical value for pure HA25. Bone is a living tissue that is continuously 
undergoing remodelling and repair, therefore, the small size and/or non-stoichiometry of 
the crystals presumably endows the mineral phase with the solubility needed for 
resorption of the bone by osteoclasts (bone-resorbing cells). In fact, synthetic 
stoichiometric HA, although bioactive (stimulatory for bone formation), is rather slow to 
resorb because of the low solubility of HA under physiological conditions26. Besides the 
very small crystallite size, the low crystallinity of bone mineral (in relation to synthetic 
HA) is also caused by incorporation of ions into its lattice, such as CO32–, Na+, Mg2+, 
SiO44– or HPO42–, which are present in the physiological environment and extremely 
important for the biochemistry of bone remodelling (see Chapter 4)27. 
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CHAPTER 2 
 
BIOMATERIALS FOR REGENERATIVE 
MEDICINE: TREATMENT OF 
MUSCOLOSKELETAL DISEASES 
 
Regenerative medicine is a critical frontier in biomedical and clinical research. It is the 
process of creating living, functional tissues to repair or replace tissue or organ function 
lost due to age, disease, damage, or congenital defects. This field holds the promise of 
regenerating damaged tissues and organs in the body by stimulating previously 
irreparable organs to heal themselves1. 
Regenerative medicine applies the principles of engineering and life sciences to enhance 
the comprehension of the fundamental biological mechanisms underlying the structure 
function relationships in physiologic and pathologic tissues and to accomplish alternative 
strategies for developing in vitro biological substitutes which are able to restore, maintain, 
or improve tissue, and organ function2. 
Musculoskeletal tissue damage is an increasing problem with a growing aging population. 
Regenerative medicine aims to repair and replace lost or damaged tissues by initiating the 
natural regeneration process. Most approaches currently pursued or contemplated within 
the framework of regenerative medicine, including cell-based therapies and living tissue 
engineering, rely greatly on the ability to synthesize or otherwise generate novel 
biomaterials, to fabricate or assemble biomaterials into appropriate two-dimensional (2D) 
and three-dimensional (3D) forms, and to tailor physical, chemical, structural and 
biological properties to achieve desired clinical efficacy.  
In a regeneration strategy, biomaterials promote new tissue formation by providing 
adequate space (porosity) and appropriate surface to foster and direct cellular attachment, 
migration, proliferation, desired differentiation of specific cell phenotypes throughout the 
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scaffold where new tissue formation is needed3,4. 
Consequently, the 3D architecture plays a pivotal role. It refers to the way in which a bulk 
material is distributed in space from the macro, micro to nano scales (corresponding to 
tissue, cellular and molecular scales in a specific tissue, respectively)5. Such hierarchical 
porous architectures not only define the mechanical properties of the scaffold, but also the 
initial void space that is available for regenerating cells to form new tissues (including 
new blood vessels) as well as the pathways for mass transport via diffusion and/or 
convection. While interconnected macroporosity of a biomaterial is important to provide 
sufficient space for cellular activity6-9 interactions between cells and biomaterials occur at 
the interface, i.e. the entire internal pore walls of a 3D scaffold. The surface morphology 
or topography directly and significantly affects cell-scaffold interactions and ultimately 
tissue formation and function10. 
 
2.1 Rigeneration of bone and osteo-cartilaginous tissue: problems and solutions 
Regeneration of bone tissue 
The bone loss can occur in various situations such as trauma, tumors, atrophy and in 
different areas of bone tissue such as long, flat or short bones presenting a peculiar 
organization. The regeneration of bone tissue is a complex process that is known to be 
regulated by multiple factors and which occurs spontaneously under normal conditions. 
Nevertheless, the regeneration of bone does not occur in a complete way and this often 
leads to the formation of a fibrous tissue. In fact, the bone regeneration requires the 
formation of new bone tissue and blood vessels that mediate the transport of osteogenic 
precursors, of secretory molecules that act as activators for osteoblasts, transporters of 
nutrients and oxygen.  
There are various therapeutic strategies for promoting the regeneration of bone tissue; 
some are based on the use of autologous bone tissue other on the use of biomaterials 
alone or associated with osteo-progenitor cells and/or growth factors.  
Autografts have primarily been the material of choice to replace lost bone, although the 
use of autografts comes with some disadvantages such as the limited quantity available 
and its use also requires additional surgical procedures, and therefore, longer surgical 
time and possible complications of the wound of the donor site such as bleeding, pain and 
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infection among others. Allografts and xenografts have the potential of transferring 
pathogens. To avoid the biological risk, these materials are subjected to exhaustive 
procedures which have dramatic effects primarily on their osteogenic and osteoinductive 
properties and these procedures can also reduce their structural integrity leading to graft 
fracture11.  
An alternative is allogeneic bone grafting, obtained from human cadavers or living 
donors, which bypasses the problems associated with harvesting and quantity of graft 
material. Allogeneic bone is available in many preparations, including demineralised 
bone matrix (DBM), morcellised and cancellous chips, corticocancellous and cortical 
grafts, and osteochondral and whole-bone segments, depending on the recipient site 
requirements. Their biological properties vary, but overall, they possess reduced 
osteoinductive properties and no cellular component, because donor grafts are devitalised 
via irradiation or freeze-drying processing. There are issues of immunogenicity and 
rejection reactions, possibility of infection transmission, and cost.  
Bone-graft substitutes have also been developed as alternatives to autologous or 
allogeneic bone grafts. They consist of scaffolds made of synthetic or natural biomaterials 
that promote the migration, proliferation and differentiation of bone cells for bone 
regeneration. A wide range of biomaterials and synthetic bone substitutes are currently 
used as scaffolds, including collagen, hydroxyapatite (HA), β-tricalcium phosphate (β-
TCP) and calcium-phosphate cements, and glass ceramics, and the research into this field 
is ongoing12.  
The use of biomaterials as scaffolds for bone regeneration requires that scaffold is able to 
exchange chemical and biochemical signals with the surrounding physiological 
environment, in order to address the activity of progenitor cells towards selective 
differentiation. The proper cell behaviour also depends on physical signals imparted by 
the scaffold morphology and structure, which determine the cell conductivity and 
colonization of the inner part of the scaffold. Likewise, the establishment of an efficient 
vascular network is crucial for the process of tissue regeneration; in fact, biologic 
structures are organized on a basis of minimum energy expenditure, so the vascular 
system in living tissues is organized to exchange the fluids necessary for the organ 
activity with the highest efficiency. 
Therefore, the design and development of three-dimensional (3D) mineralized scaffolds 
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reproducing the structure and the hierarchically organized morphology of long bones is 
still a challenge, due to limitations in the current manufacturing technologies. In this 
view, the new trends in materials science research are looking at the peerless 
characteristics and properties of natural structures as new sources of inspiration to obtain 
innovative and smart biomorphic devices13.  
 
Regeneration of osteo-cartilagineouse tissue 
Currently available treatments depend upon the size of the osteo-chondral defect and the 
condition of the overlying cartilage. Using reparative surgery, cartilage treatments include 
arthroscopic debridement, abrasion arthroplasty, and microfracture. These procedures 
stimulate the body to heal the injury, mainly resulting in the formation of fibrocartilage. 
Fibrocartilage is a scar tissue presenting diminished resilience, reduced stiffness, and poor 
wear characteristics when compared to hyaline cartilage. Thus, fibrocartilage is unlikely 
to withstand physiological loading and cannot guarantee to function successfully in long 
term. Nevertheless, other options are available with restorative surgery, namely, 
autografts recurring to mosai-coplasty procedures, allografts14,15 and biologic replaement 
using cultured autologous chondrocytes. The biggest challenge with autografts is to 
achieve a final round shape that mimics the surface of the articular joints. Allograft 
procedure is similar to autografts and mostly used after other surgeries have failed. It is 
not recommended for patients with OA, and the limited supply of donor tissue is a major 
problem of this practice. Autologous chondrocyte transplantation/implantation16 has also 
been described to help restoring the structural make-up of the articular cartilage. The 
intermediate and long-term functional and clinical results are promising, especially 
regarding the durability of the repair in human patients follow-up17.  
Despite the availability of procedures, all current treatment options inflict further tissue 
destruction before any therapeutic effect can be achieved.  
The implantation of cells in the afflicted area could be a direct approach in osteo-chondral 
strategies, but the request for a support material to promote regeneration, especially in 
large sized defects, is to be critically considered. This idea is inspired in nature itself as, in 
the body, the majority of cells subsist in a 3D world, anchored onto a network of 
extracellular matrix (ECM), which scaffolding design proposes to recreate. 
Scaffold characteristics will greatly influence cells and should mimic the complex and 
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demanding environment to which cells are exposed to. Besides the tissue structural 
support and stimulation, either chemically or mechanically, the optimal scaffold should 
assist tissue functionality promoting the easy diffusion of nutrients, growth factors and 
cellular waste products. Additionally, the ideal scaffold should be biocompatible and its 
biodegradability adjustable to the time required for tissue regeneration18. 
 
2.2 The most important musculoskeletal diseases: osteoporosis (OP) and 
osteoarthritis (OA) 
Osteoarthritis (OA) and osteoporosis (OP) are among the most disabling degenerative 
diseases that affect millions of people each year, resulting in a strong negative socio-
economic impact, particularly related to the progressive aging of the population's 
increased of life. In severe cases, these conditions may lead to severe complications 
affecting the neuromuscular system and may significantly impair quality of life of 
patients and their longevity. 
Osteoporosis is the most prevalent skeletal disorder characterised by decreased bone 
mass and bone mineral density. Osteoporosis is characterized by a reduction of bone in 
the skeleton that results in skeletal fragility and an increased risk of fracture after minimal 
trauma. The three major osteoporotic fractures occur in the forearm, vertebral body, and 
hip, although fractures of the humerus, tibia, pelvis, and ribs are also common19.  
Osteoporotic fractures are a major cause of morbidity, mortality, and health and social 
service expenditures in both sexes. More than half of all patients with hip fracture have 
pain at the fracture site 6 months after surgery, and only one third regain their former 
mobility. Osteoporotic patients with vertebral crush fractures complain not only of back 
pain, loss of height, and kyphosis, but also have substantially less energy, poorer sleep, 
more emotional problems, immobility, and social isolation20.  
Overall mortality is increased by about 17% after both femoral and vertebral fractures, 
but in the case of vertebral fracture, this may be due to coexisting conditions rather than 
to fracture itself 21.  
In OP the bone micro-architecture is distrupted, and the amount and variety of non-
collagenous proteins in bone is altered. Furthermore, fractures are significantly 
exacerbated and healing is often impaired in osteoporotic patients. Post-menopausal OP is 
the most common and significant form of OP in which oestrogen deficiency gives rise to 
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a high turnover rate in bone metabolism. Accelerated bone resorption by osteoclasts has 
been established as a principal mechanism in OP, although the imbalance in bone 
remodelling as occurs in OP can be in part due also to inappropriate apoptosis of 
osteoblasts/osteocytes22-23.  
Osteoarthritis is a chronic disease in which articular cartilage undergoes degeneration 
with age or after focal injury24. OA is characterised by the progressive deterioration and 
sclerosis of articular cartilage and sub-chondral bone and changes in the synovial 
membrane as a result of mechanical and biological processes that modify cartilage 
homeostasis 25,26. 
Two major retrogressive changes occur during the onset and progression of osteoarthritis. 
The first is calcification, which decreases the diffusion of nutrients and oxygen to the 
chondrocytes. Chondrocytes of the calcified matrix die, and the matrix is resorbed. The 
second change is termed cartilage fibrillation, and involves a splitting of the matrix of the 
articular surface along the direction of orientation of the collagen fibers to expose these 
fibers, giving the surface a fuzzy appearance. This occurs at first in patches, which then 
enlarge. As the condition progresses, there is variable loss of cartilage by apoptosis and 
autophagy and exposure of underlying bone, accompanied by increasing pain27,28. 
 
2.3 Current clinical treatments for OA and OP  
Although OA and OP have completely different etiology and course, their degenerative 
effects lead to severe and almost similar symptoms. Currently (i) pharmacological 
treatments and ultimately (ii) tissue replacement and augmentation by implants are the 
main clinical interventions. However, both drug administration and implants suffer from 
significant limitations and they are not able to restore completely the patient’s mobility 
and quality of life. 
(i) The currently available pharmacological treatments are mainly designed to 
reduce inflammation and pain, to increase calcium uptake and to modify the 
equilibrium among bone formation and resorption, favouring the bone 
apposition on the trabecular surfaces. However, the efficiency of such drugs is 
limited, in some cases controversial and often they are poorly tolerated and 
elicit side-effects following systemic administration. Alternative non-surgical 
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interventions including injectable visco-supplements are also used for the 
treatment of early osteoarthritis, but patients with severe OA tend not to 
respond to such treatments. 
(ii) Tissue replacement and augmentation by implants is adopted in cases 
where pharmacologic treatment proves ineffective and OA and OP conditions 
cause persistent pain and disability. In particular, implants such as artificial 
knee prostheses and vertebroplasty and/or kyphoplasty are adopted when the 
tissue structure and functionality is irreversibly compromised. However, the 
prosthetic solution is generally reserved for older patients, due to the fact that 
the life span of prosthetic materials is limited to 10-15 years. For that reason 
the treatment of early arthritis in relatively young and active patients is even 
more problematic as it leads to revision surgery. In recent years, innovative 
bioengineering approaches have been proposed for the early treatment of 
arthritis. However, despite the emergence of encouraging laboratory data, the 
clinical application of tissue engineering products have not produced the 
expected clinical benefits.  
 
2.3.1 Main problems in the treatment of OA  
The main challenge in the treatment of OA by regenerative medicine approaches is 
represented by the need to regenerate two different and adjacent tissues: the cartilage and 
the underlying trabecular bone. These two tissues are closely connected within the osteo-
chondral unit despite their distinct physical, chemical and biological characteristics and 
different healing potential. Thus, aided regeneration of the osteo-chondral compartment 
by biomaterials or tissue engineering constructs requires tailored technological solutions 
able to fulfil the different histological and physiological features of both the tissue types.  
Several therapeutic strategies used are employed to limit the pain associated with the 
disease including simple analgesics, non steroidal anti-inflammatory drugs (NSAIDS), 
intra-articular injection of glucocorticoids, hyaluronic acid preparations, and COX-2 
specific inhibitors, rendered in combination with non-pharmacological therapy, such as 
patient education and physical/occupational therapy. However no medical intervention 
has been shown to halt disease progression or reverse joint damage in humans. Moreover, 
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many of these drugs are beset with serious side effects. Mesenchymal stem cells (MSCs) 
are now receiving enormous attention in numerous biomedical fields, including 
regenerative medicine, tissue protection, graft enhancement and immune-modulation. 
MSCs operate through a variety of effects or mechanisms on key cells of the innate and 
adaptive immune systems, mostly through manipulation of the cell cycle or inducing 
maturation arrest without apoptosis.  
In recent decades a variety of biomaterials have been developed and launched on the 
market in order to face the increasing need for bone substitutes29-31. 
Solutions ranging from autografts and allografts, synthetic polymers (e.g. PLA, PGA) and 
coral-derived materials up to the more advanced bioceramics or bioceramic-polymers 
composites have been proposed. These biomaterials are mainly used as bone fillers and in 
cartilage mosaicplasty, but they are not suitable for supporting the regeneration of 
complex anatomical regions the biochemical requirements of which have been affected by 
pathologies. Despite the improvements of the clinical outcomes delivered by these 
biomaterials, ideal tissue regeneration has not yet been achieved. Furthermore, source 
limitations and production costs reduce the clinical potential of these biomaterials. 
 
2.3.2 Main problems in the treatment of OP 
To date, drug therapy is indicated both for the prevention and for the treatment of 
osteoporosis. There are several classes of drugs, whose main action is to inhibit bone 
resorption by stabilizing or increasing the amount of bone mass. The most effective drugs 
for the recovery of bone mineral density and especially to reduce the risk of pathologic 
fractures are bisphosphonates (alendronate, risendronate, pamidronate, clodronate), 
strontium ranelate, raloxifene and parathyroid hormone peptides. All these interventions 
have been shown to reduce the risk of vertebral fracture when given with calcium and 
vitamin D supplements32. Bisphosphonates for example are widely used to ameliorate the 
effects of osteoporosis by inhibiting osteoclast functions. These drugs also act to inhibit 
apoptosis of both osteocytes and osteoblasts and to increase the bone forming potential of 
osteoblasts. Despite their potential, bisphosphonates appear to lead to excessive reduction 
in bone turnover thus causing increase of micro-damages33. Furthermore, experimental 
evidence supports the view that bone gained after anabolic treatment will be lost after the 
treatment is discontinued. Thus, it is vital to identify a treatment regimen that creates a 
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permanent reduction in fracture risk even after the therapy is discontinued. This might be 
achieved with a combination of biomaterials and drugs or with an entirely new approach. 
The surgical treatment of OP by vertebroplasty is performed to relieve pain related to 
pressure on the spinal nerves caused by the deformation and/or fracture of the vertebral 
bodies (VCF). Vertebroplasty and balloon kyphoplasty (injection of acrylic bone cement 
into a fractured vertebra) are widely used for this purpose, but they can only reduce the 
pain and do not provide tissue regeneration.  
However, for OP and OA both the administration of the drug, both plants suffer from 
significant limitations and are not able to completely restore the patient's mobility and 
quality of life. In this clinical picture is strongly desired a tissue regeneration based on a 
minimally invasive surgical approach in order to allow early treatment and repeated tissue 
still bearing and with good biomechanical properties. The development of such treatments 
is considered by the clinical sector as a highly innovative solution in the treatment of 
these debilitating conditions, as it will overcome the limitations associated with current 
treatments. 
2.3.3 Newly conceived biomaterials as scaffolds for the treatments of OA and OP 
Although the systemic nature of OP and OA will always require a degree of 
pharmaceutical treatment, new biomimetic, minimally invasive biodegradable 
biomaterials and tissue engineering constructs, will provide a jump-start for bone 
regeneration and will enhance the chance of successful clinical outcome.  
These new regenerative materials will eliminate the need for more radical surgical 
intervention and offer the accurate control of cell functions in the different histological 
compartments (i.e. bone and cartilage) through the simultaneous regulation of 
biochemical and chemical processes. 
The repairing of the osteochondral defect, which often represents a pathological condition 
of a difficult solution for the surgeon, particularly when the subject is a young patient, 
results more complex. In these conditions, besides the restoration of the cartilaginous 
layer, it is important the reconstruction of the sub-chondral bone structure.  
An emerging trend in the field of biomaterials research is the production of layered 
osteochondral scaffolds for the simultaneous treatment of compromised cartilage and 
subchondral bone in articular joint defects. These scaffolds seek to treat articular cartilage 
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lesions by augmenting marrow stimulation techniques, in which controlled damage is 
imparted to the subchondral bone plate to induce bleeding from the marrow cavity and 
allow marrow-derived stem cells to enter the lesion. By providing a scaffold to support 
and guide the reparative capacity of these cells, layered osteochondral scaffolds aim to 
induce the simultaneous regeneration of articular cartilage and the subchondral bone to 
which it is attached.  
Therefore, nano-structured bio-hybrid composites as matrices for multifunctional 
anatomical regions, with chemical, topotactic and morphological features of the osteo-
chondral tissue could be rappresent valid substitutes for the treatment of OA.  
Many different types of biomaterials, both synthetic and natural, are being developed, 
modified, and evaluated. These biomaterials can be made bioactive by incorporation of 
growth factors or gene vectors to improve cell ingrowth, cell proliferation, or matrix 
production. Even anti-inflammatory factors can be incorporated to inhibit inflammatory 
processes, which are known to have negative effects on cartilage repair. Controlled 
release of these factors in time and may be even sequential release of a number of factors 
will be necessary for optimal control of the tissue repair process. 
The major limitations of the scaffolds for bone and cartilage regeneration nowadays 
available on the market are related to the difficulties in controlling cell differentiation and 
angiogenesis processes and obtaining stable scaffold implantation in the pathological site. 
The in vivo provision of the scaffold with stem cells or/and growth factors in order to 
drive the tissue differentiation process and ensuing angiogenesis represents a most 
challenging request34. During the regeneration, the restoration of the mechanical 
resistance to physiological stresses should be accompanied by a parallel advance of the 
angiogenic process, leading to a complete morphological and biological maturation of the 
tissue. This is only achieved if angiogenesis is permanently stimulated by the presence, 
close to the scaffold, of various angiogenic proteins (growth factors)35,36. Mimicking 
endogenous growth factor production and delivery is still to be solved with conventional 
scaffolds37-39. Recently the idea of utilizing magnetic scaffolds for an additional control of 
the angiogenesis process in vivo was proposed40. This approach is expected to enable the 
scaffolds with such an advantageous property as long term operation, via the continuous 
interaction and material exchange of the scaffold with the magnetic external supplier. In 
addition such scaffolds are expected to feature multiple use and possibly multipurpose 
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delivery capable of repairing large bone defects and sub-chondral lesions in the articular 
surface of the skeletal system. 
For the treatment of OP injectable bone cements could be rappresent valid solution. 
Althought several injectable bone cement have been developed41-44 no ideal formulation 
has been already identified. The most important features of such formulations should be: 
easy injectability, high radio-opacity, appropriate setting time and resorption rates and 
mechanical properties similar to bone. PMMA cements are the most frequently used, due 
to their relatively high mechanical performance. Nevertheless, they have very important 
limitations including the exothermic polymerization reaction that leads to necrosis of all 
the contact tissues. In addition, the compact, bio-inert and non-degradable nature of the 
cement prevents the formation of new bone within the defect. It has also been reported 
that excessive cement rigidity reduces the endplate bulge of the augmented vertebra, 
thereby reducing the local spinal joint flexibility. As a consequence of the reduced joint 
flexibility there is an increase in the pressure on the intervertebral disc leading to an 
abnormal mechanical load transfer on the adjacent vertebral body with increased risk of 
fracture. It is also generally believed that the relatively hard bone cement leaks out from 
the vertebral body into the intervertebral disc resulting in new fractures as a consequence 
of the excessive stimulation of the adjacent endplate. Unlike PMMA-based materials, 
calcium/phosphate-based cements exhibit relatively lower mechanical properties, longer 
setting times, lack of radio-opacity, and can be tailored to improve most of their 
limitations and emphasise their intrinsic bioresorbability/ bioactivity. Recent studies have 
combined CaP-based cements with biodegradable polymers to create an open pore 
structure within the cement bulk over time. The gradual formation of pores upon 
degradation of the polymer phase opens a route for cell colonization thus favouring bone 
in-growth and, later, bone remodelling. However, research is still required to obtain 
tuneable rates of pore formation and cement resorption. 
Various cell-based therapies have been developed over the past years and could find their 
implementation into a wide range of clinical application. It is now recognised that bone 
marrow mesenchymal stem cells (BMMSCs)/osteoblast lineage cells may actively 
participate in the recovery of OP. In addition, various growth factors are known to 
influence the recruitment and differentiation of osteoblasts. Among these, transforming 
growth factors (TGF), fibroblast growth factors (FGF), insulin-like growth factors (IGF), 
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platelet derived growth factors (PDGF), and bone morphogenetic proteins (BMP) can be 
found in bone matrix and have been extensively studied regarding the influence on bone 
cells and their precursors both in vitro and in vivo. However, because of the lack of 
specificity and far-ranging side effects concerning cell proliferation and survival on 
various other cell types, systemic administration of growth factors is currently not 
feasible. On the other hand, transcriptional regulation of bone formation is a promising 
approach for future therapeutic strategies. In recent years, a number of transcription 
factors and cofactors that control osteogenesis and chondrogenesis have been identified, 
including runt-related transcription factor 2 (Runx2) for osteoblastic differentiation, the 
distal-less homeobox 5 (DIx5), msh homeobox homologue 2 (Msx2), the Fos-family 
transcription factors, and the zinc finger-containing protein Osterix (Osx), which acts 
downstream of Runx2. New anabolic therapeutic concepts have been suggested that can 
exploit the role of such transcription factors on the osteogenic cascade. These include new 
targets which are responsible for a high bone mass in humans such as low-density 
lipoprotein (LDL)-receptor-related protein 5 (LRP5)45,46. 
Recently, a new OP mechanism has been discovered involving T cells able to induce bone 
cell apoptosis via the Fas/Fas ligand pathway. In this case, a stem cell-based intervention 
led to a higher bone density47. This result suggests that new solutions in OP treatment can 
be obtained by harnessing the stem cells ability to balance the rate of bone remodelling 
through activation of osteoblasts and inhibition of osteoclasts.  
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CHAPTER 3 
 
MAGNETISM IN BIOMEDICAL 
APPLICATIONS: A NEW CONCEPT FOR 
TISSUE REGENERATION 
 
Magnetism, which is an intrinsic property of every atom, has a profound influence on 
living organisms. The use of materials in biological environment for implantation or for 
replacement of a part or a function of the body in a reliable and physiologically 
acceptable manner was a challenge for the last several decades. Of late the combination of 
fine particles and magnetism in the field of biology and biomaterials has been found 
useful in sophisticated bio-medical applications such as cell separation1-4, drug delivery5,  
and magnetic intracellular hyperthermia treatment of cancer6-8.  
The development of nano technology along with involvement of magnetism, opened new 
windows of sophisticated biomedical applications such as diagnostic, cancer therapy etc9.  
Most recent areas, where magnetic materials particularly when of nano size are used in 
biological applications, are following reported: 
•  Magnetic bioseparation  
•  Drug delivery 
•  MRI contrast agent  
•  Therapy – Hyperthermia treatment of cancer 
 
3.1 Biomedical applications 
3.1.1 Magnetic bioseparation 
Bioseparation is an important phenomenon for the success of several biological processes. 
Magnetic separation of cells and bio molecules is based on the contrast of magnetic 
susceptibility between separand (magnetic) and medium (containing other nonmagnetic) 
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materials. A few cells or biomolecules have intrinsic magnetic properties. 
The magnetic separation of cells or bio molecules is more effectively done by the super- 
paramagnetic materials, because it exhibits magnetic properties in presence of magnetic 
field only. In addition, ferromagnetic as well as superparamagnetic particles coated or 
encapsulated with polymers or liposome can be used for magnetic labelling. For this 
purpose, magnetite (Fe3O4) or haematite (γ-Fe2O3) have been extensively used as 
magnetic carriers.  
 
3.1.2 Drug delivery  
The activity of most pharmaceuticals or drugs against certain diseases or disease sites 
suffers from their inability to accumulate selectively in the pathological organ or cells. 
When the drug or pharmaceutical agent is introduced into the body intravenously, it gets 
distributed throughout the body. To reach the target site, the drug has to cross many 
biological barriers (organ, cells and its compartments), and hence there is a chance of its 
getting inactivated. Large quantities or doses have to be administered to get the required 
therapeutic concentration to a target site. As a result, many negative side effects may be 
caused by cytotoxic and/or antigenic drugs. The situation becomes particularly critical in 
case of drugs having very low therapeutic indices (e.g. most anti-cancer drug). However, 
the above problems may be solved by selectively and quantitatively accumulating the 
drug to the target site. Independent of the site and methods its administration, drug 
targeting at non-target sites should remain under certain minimum levels to avoid site 
reactions. 
There are many different approaches to targeted drug delivery, e.g. direct application of 
drug into the affected zone, use of reactor molecules having high affinity to the affected 
site and physical targeting10. Targeted drug delivery by external physical force (magnetic 
field) is an innovative new approach, capable of effective drug targeting. 	  
Mechanism:  
Magnetic drug transport technique is based on the fact that the drug can be either 
encapsulated in to a magnetic micro-sphere (or nano-sphere) or conjugated on the surface 
of the micro/nano sphere. When the magnetic carrier is intravenously administered, the 
accumulation can take place within the area to which the magnetic field is applied and 
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often augmented by magnetic agglomeration11.The accumulation of the carrier at the 
target site allows them to deliver the drug locally. Efficiency of accumulation of magnetic 
carrier depends on physiological parameters12 e.g. particle size, surface characteristics, 
field strength and blood flow rate etc. The magnetic field assists to extravasate the 
magnetic carrier into the targeted site. Though little is known about the process of 
extrusion, magnetic targeted carriers (MTC) are pulled through some kind of pore/ 
channel opened by the force of the magnet. It has been observed that immobilization of 
MTC occurs within the tumor area when magnetic field is removed13. 
Site-directed drug targeting is one way of local or regional antitumor treatment. The 
efficiency of chemotherapy treatment may be enhanced to a great extent by magnetically 
assisted delivery of cytotoxic agent to the specific site. There are a large number of 
magnetic carrier systems which demonstrates increasing drug concentration efficiency at 
the tumor site14,15. In case of brain tumours, the therapeutic ineffectiveness of 
chemotherapy is mainly due to the impervious nature of the blood-brain barrier (BBB), 
presence of drug resistance and lack of tumour selectivity.  
The aim of the specific cell targeting is to enhance the efficiency of drug delivery and at 
the same time to reduce the toxicity. An immense improvement of existing approaches to 
diagnosis and treatment of various diseases could be conveyed by targeted delivery of 
pharmaceuticals. The therapeutic applications of drug targeting are under investigation 
and some clinical trials are also under way. The numerous results16,17 show that the 
magnetic drug targeting is a promising area in the development of new and cost-effective 
clinical protocols in the near future. Further “magnetic drug delivery” will undoubtedly 
rise from its investigative origins, along with nano-biotechnology, to play an important 
role in improving human health. 
 
3.1.3 MRI contrast agents 
Magnetic resonance imaging is considered to be one of the most powerful techniques in 
diagnostic, clinical medicine and biomedical research. The magnetic resonance images 
are obtained by placing the area of interest within a powerful, highly uniform static 
magnetic field. Since hydrogen nucleus (single proton) is abundant in the body due to the 
high water content of the biological living carriers, the static magnetic field will make 
most of the protons to align with the field. These protons (nuclear spins) then move out of 
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their alignment by the application of an alternating magnetic filed, which in turn is 
produced by the radio frequency coil near the specimen (static magnetic field). The 
resonant frequency of the alternating magnetic field should be in the radio frequency 
range (15-60 MHz). The nuclei absorb energy from the oscillating magnetic field and 
undergo transition from the lower energy state to the higher energy state. When the 
alternating magnetic field is switched off, the nuclei that return to the equilibrium state 
thereby emitting energy at the same frequency as previously absorbed. Further, this 
induces a signal in the coil, which is the source of alternating magnetic field. This nuclear 
magnetization can be transformed to diagnostic images by a series of algorithms.  
MRI can provide information that differs from other imaging modalities. Its major 
technological advantage is that it can characterize and discriminate among living carriers 
using their physical and biochemical properties. The ability of MRI techniques to get 
images in multiple planes offers special advantages for radiation or surgical treatment. 	  
3.1.4 Hyperthermia for the treatment of cancer 
Heat treatment of organs, such that the temperature is increased to 42-46°C and the 
viability of cancerous cells reduces, is known as hyperthermia. It is based on the fact that 
tumour cells are more sensitive to temperature than normal cells18-20. In hyperthermia it is 
essential to establish a heat delivery system, such that the tumour cells are heated up or 
inactivated while the surrounding normal living tissue are unaffected. Though different 
hyperthermia techniques depend upon the heating methods used, each one has certain 
limitations. Boundary effects limit microwave, ultrasound, and magnetic hyperthermia.  
Magnetic hyperthermia can be induced by two different methods. In the first method, 
known for several decades, finite size magnetic implants are surgically placed within the 
tumour site, which absorbs energy from externally applied magnetic field and dissipates it 
in the form of heat to the surrounding tumour sites. These tumour sites can be destroyed, 
if the temperature rises above 42°C. It is however difficult to get homogenous heat 
distribution through this method. In such a method it is expected that temperature rise will 
be observed close to the implanted material and there will be non-uniformity in the 
temperature distribution in the tumour region. A major drawback of this procedure (using 
bulk materials) is that it is an invasive method and required surgical removal after 
hyperthermia treatment. Therefore, repeated surgery may be required which could be 
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traumatic. 
The alternative approach is to use fine particles as heat mediators instead of needles or 
rods such that hyperthermia becomes non-invasive. When fluids containing sub-micron 
sized magnetic particles (typically 1-100 nm)21 are injected, these particles are easily 
incorporated into the cells, since their diameters are in the nanometer range. These 
magnetic particles selectively heat up living tissue by coupling magnetic field to targeted 
magnetic nano particles. As a result, the whole tumour can be heated up uniformly. This 
is called intracellular hyperthermia. It has been shown that malignant cells take up nine 
times more magnetic nano particles than normal cells. Therefore the heat generated in 
malignant cells is more than in normal cells22. Also, as blood supply in the cancerous 
living tissue is not normal, the heat dissipation is much slower. Hence, the temperature 
rise in the region of tumour is higher than in the surrounding normal living tissue. It is 
therefore expected that this therapy is much more concentrated and localized. 
To make the hyperthermia as a potential therapy, selective destruction of cancerous cells 
is important. Though the hyperthermia is based on the fact that the tumour cells are very 
much sensitive to heat in the range of 42-46 °C18-20, it can assist the therapy to a high 
degree of selective destruction of cancerous cells. This is possible if targeted delivery of 
potential magnetic particles to the cancerous cells is made so that it will be much more 
effective to heat than the normal living tissue. For this, optimization of magnetic 
parameters of particles is essential, which includes synthesizing particles having high 
value of specific absorption rate23,24. 
 
3.1.5 Magnetic therapy for the treatment of bone disease 
Magnetic therapy has been considered a promising alternative in disease treatments in 
health care, especially in the treatments of bone diseases. Research has indicated that 
magnetic fields may stimulate the proliferation and differentiation of osteoblasts, promote 
the expression of growth factors such as bone morphological protein, increase 
osteointegration, and accelerate new bone formation25-28. Magnetic fields were also found 
to be beneficial in promoting the integration of bone and implants, increasing bone 
density and calcium content, and accelerating the healing of bone fractures29-32. 
Singh P. et al.33 reports the stimulating effect of static magnetic field (SMF) on 
microstructure and mineralization process of bone repair. A unilateral transverse fracture 
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of mid-shaft of metacarpal was surgically created in healthy goats under thiopental 
sedation and xylocaine analgesia. Two bar magnets (approximately 800 gauss/cm2 field 
strength) were placed across the fracture line at opposite pole alignment immobilized in 
Plaster of Paris (POP) splint bandage for static magnetic field stimulation. Radiographs 
were taken at weekly intervals up to 45 days. Results show that formation of extra-
cellular matrix and its microstructure can be influenced by non-invasive physical stimulus 
(magnetic field) for achieving an enhanced osteogenesis, leading to quicker regeneration 
of bone tissue in goats. 
Kotani H. et al.34 investigate the effects of a strong SMF (8 T) on bone formation in both 
in vivo and in vitro systems. After 60h of exposure to the SMF, cultured mouse 
osteoblastic MC3T3-E1 cells were transformed to rodlike shapes and were orientated in 
the direction parallel to the magnetic field. Although this strong SMF exposure does not 
affect cell proliferation, it up-regulate cell differentiation and matrix synthesis. The SMF 
also stimulate ectopic bone formation in and around subcutaneously implanted bone 
morphogenetic protein (BMP) 2-containing pellets in mice, in which the orientation of 
bone formation is parallel to the magnetic field. It is concluded that a strong SMF has the 
potency not only to stimulate bone formation, but also to regulate its orientation in both in 
vitro and in vivo models. In conclusion the combination of a strong SMF and a potent 
osteogenic agent such as BMP possibly may lead to an effective treatment of bone 
fractures and defects. 
Yamamoto et al.35 study the effects of SMF on osteoblastic differentiation, proliferation, 
and bone nodule formation using a rat calvaria cell culture. During a 20-day culture, the 
values of the total area and the number and average size of bone nodules showed high 
levels in the presence of SMF. In the matrix development and mineralization stages, the 
calcium content in the matrix and two markers of osteoblastic phenotype (alkaline 
phosphatase and osteocalcin) also showed a significant increase. Accordingly, these 
findings suggest that SMF stimulates bone formation by promoting osteoblastic 
differentiation and/or activation. 
Effects of a static magnetic field were also studied on bone formation using an ischemic 
rat femur model36. Metal rods were prepared from magnetized and unmagnetized 
samariun cobalt to have tapered structure, both with the same geometrical dimension, and 
were implanted transcortically into the middle diaphysis of 88 rat femurs. Both sides of 
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the rat femoral artery were ligated to create an ischemic bone model, followed by 
implantation of the tapered rod to the femur. The bone mineral density (BMD) and weight 
of the femurs were measured at 1st and 3rd week after implantation. The result at the 3rd 
week post-implantation revealed that the BMD and weight of the ischemic bone model 
rats were significantly reduced, compared with that of non-operated femur. It was also 
found that the magnetized group had significantly higher bone weights than the 
unmagnetized (p<0.05). The BMD of the rats implanted with the magnetized rods were 
similar to those of the non-operated (p>0.05). This enhancement of the femoral bone 
formation of the ischemic rat model by the static magnetic field seems to be due to the 
improved blood circulation of the femur. 
Taking into account the actually scientific evidence it is possible to assert that the 
application of static magnetic fields for the therapy of the bone tissue promotes the 
differentiation and activation of osteoblasts generating an increase of bone mineral 
density. 
 
3.2 Magnetic materials 
Magnetism is known to all of us from childhood as the phenomenon by which some 
materials attract or repel other materials from a distance; examples of such materials 
include iron, lodestone and some steels. Broadly, magnetic forces are generated by 
moving charged particles, leading to magnetic fields37.   
Consider a material placed in an external magnetic field. The atoms in this material 
possess an atomic moment which responds to this external field. It is useful to think of 
magnetic dipoles existing in magnetic materials; these dipoles can be considered to be 
small bar magnets with north and south poles. The dipoles possess a magnetic dipole 
moment which can respond to the external magnetic field. Some field vectors are needed 
to understand this response: the external magnetic field strength is denoted by H (units 
A/m), the magnetic induction in the material is denoted by B (units tesla) and the 
magnetization by M (units A/m). B, H and M are related by 
 
B = µ0 (H + M) 
 
where µ0 is the permeability of free space (its magnitude is 1.257 × 10−6 H/m) and M is 
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the magnetic moment m per unit volume of the material. The value of M depends on the 
type of material and the temperature and can be related to the field H through the 
volumetric magnetic susceptibility χ by the relation 
 
M = χH 	  
The magnetic response of bulk material results in materials being classified as either 
diamagnetic, paramagnetic or ferromagnetic.  
Diamagnetism is very weak and not permanent; it persists only as long as the external 
field is present. It occurs due to a change in the orbital motion of electrons due to the 
external field, the direction of the induced magnetic moment is opposite to the field. In an 
in homogenous field, such materials are attracted towards regions where the field is weak. 
In paramagnetism, each atom has a permanent dipole moment because of incomplete 
cancellation of its electron magnetic moments. When a field is applied these atomic 
dipoles individually tend to align with the field, much as a compass needle aligns with the 
earth’s magnetic field. 
Diamagnetic and paramagnetic materials exhibit magnetization only in the presence of an 
external field; the low values of susceptibility χ imply that the magnetic induction in such 
materials is very weak.  
Feromagnetism is the most familiar type of magnetism. It occurs, for example, in body 
centred cubic (b.c.c.) iron, cobalt, nickel, and in many alloy compositions based on Fe, Co 
and Ni. Ferromagnetic materials, unlike dia- and para- magnetic materials, show 
permanent magnetic moments even in the absence of an external field. The susceptibility 
values are very high compared to those of para- and dia- magnetic materials, reaching up 
to 106. The magnetic moments in such materials arise mainly from atomic spin magnetic 
moments. More importantly, interactions between atoms cause spin magnetic moments to 
align with one another in a cooperative fashion. Thus, large regions in a crystal can have 
atoms with their spins aligned with one another. When all the magnetic dipoles are 
aligned the magnetization reaches its saturation value (Ms). 
As mentioned earlier, ferromagnetism results from a cooperative parallel alignment of 
spins. In other materials, e.g., MnO, the magnetic moment coupling between atoms (or 
ions) results in the spin moments of neighboring atoms being aligned in opposite 
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directions. Such materials are antiferromagnetic. In the case of MnO, the moments of 
adjacent Mn2+ ions are antiparallel, thus the material has no net magnetic moment. 
Some materials include the magnetic biomaterial, magnetite (Fe3O4). Hexagonal ferrites 
and garnets are other ceramic materials that fall in this category. Cubic ferrites, such as 
magnetite, can be represented as MFe2O4, where M is a metal. In the case of Fe3O4, Fe 
ions exist in both the +2 and +3 valence states. The magnetic moments of the two types of 
Fe ions differs; in this case, there is a net magnetic moment because for the solid as a 
whole the spin moments are not completely cancelled; although the spin moments of the 
Fe3+ ions cancel one another, the magnetization arises from the parallel alignment of the 
moments of the Fe2+ ions (Fig. 1).  
 
 
 
Fig. 1. Schematic depicting the spin magnetic moments for Fe3+ and Fe2+ in Fe3O4 	  
 
3.2.1 The influence of Temperature 
It can be expected that temperature will play an important role in determining magnetic 
properties, since entropy effects will be more dominant at high temperatures. The 
magnetic properties of both ferri- and ferro-magnets depend on the coupling forces 
between neighboring atoms; at higher temperatures, entropy effects favour a random 
arrangement of spins, resulting in a reduction in saturation magnetization. The saturation 
magnetization decreases with increasing temperature; at the Curie temperature Tc it 
becomes zero and the material becomes paramagnetic above this temperature. Thus a 
given material can change its magnetic behaviour depending on the temperature; its use as 
a magnetic biomaterial will consequently depend on the relative values of the service 
temperature and the Curie temperature. The ferromagnetic to paramagnetic phase 
transformation described above has been used to act as an on-off switch in hyperthermia 
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applications; the magnetic material is designed to have a Curie temperature equal to the 
temperature required for hyperthermia. 
 
3.2.2 Factors affecting magnetic properties 
Since size plays an important part in many magnetic biomaterials applications the effect 
of particle size on magnetic properties is discussed (Fig. 2)38. In large particles (greater 
than about 1 µm) there are many magnetic domains; this leads to a narrow hysteresis loop. 
Such particles are useful in immunomagnetic separation of pathogenic microorganisms in 
microbiology. For smaller particle sizes (less than about 1µm) it is energetically more 
favourable for only one domain to exist.  
The response of such particles to a magnetic field is qualitatively different, resulting in a 
broader hysteresis loop.  
 
 
Fig. 2. Magnetic properties are affected by the particle size (DM = diamagnetic, PM = paramagnetic, SPM 
= superparamagnetic, FM = ferromagnetic) 
 
If the particle size is reduced further to about 20 nm (the exact size depends on the 
composition of the material), the material becomes superparamagnetic, which means 
that the magnetic moment of the particle fluctuates because of the thermal energy (kT); at 
the atomic level the individual atomic moments continue to be ordered relative to each 
other. Importantly, the remanence is zero, the result is a B-H curve showing no hysteresis; 
this property is important for reducing the tendency of the particles to agglomerate. The 
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physical basis for the fluctuation of the magnetic moments can be understood as a battle 
between ∆E, the energy barrier to moment reversal and the thermal energy (kT). In the 
simplest approximation the energy barrier is the product of the anisotropy energy density 
K and the volume V. When the particle size is small (small V), the KV term is small and 
comparable to the thermal energy; this leads to flipping of the magnetic moment. The 
“blocking” temperature TB can be regarded as the temperature above which the material 
becomes superparamagnetic.  
 
3.2.3 Intelligent magnetic nanobiomaterial for Tissue Engineering 
Development of functional engineered materials possessing intelligence has been one of 
the most challenging tasks in research over the past decade. The term “intelligent 
material” refers to materials that posses three main functions, including sensing changes 
in environmental condition, processing the sensed information and finally actuated by 
external stimuli. 
The recent convergence of biomaterials and nanotechnology has enabled the development 
of intelligent nanobiomaterials, such as nanoparticle-encapsulating hydrogels for 
applications in tissue engineering and regenerative medicine 39-41. These nanobiomaterials 
provide unique properties to address challenges in biology, medicine, and materials 
science41-43, e.g., modifiable mechanical and interfacial properties of a nanoscaffold to 
mimic native extracellular matrix (ECM)44.  
Among the magnetic materials usually used in the biomedical field, magnetic 
nanoparticles (MNPs) have drawn great interest owing to their unique magnetic 
properties, including the fact that they become superparamagnetic at diameters of < 20 
nm39. Coupled with their excellent biocompatibility, MNPs have been widely used in 
biomedical applications such as drug delivery, magnetic resonance imaging reagents, 
bioseparation, enzyme immobilization and magnetic hyperthermia45-48, but their 
application in tissue regeneration, especially in bone repair, has seldom been considered. 
As mentioned, at a size of < 20 nm, the MNPs become nonmagnetic on a macroscopic 
scale and behave like common materials in the absence of an exterior magnetic field. 
However, each particle could be considered a single magnetic domain, providing a 
magnetic field at a nano-scale, which makes it possible for magnetic scaffolds to provide 
an intrinsic magnetic therapy. Meanwhile, once exposed under an exterior magnetic field, 
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MNPs will be rapidly magnetized to saturation and respond to the exterior magnetic field 
to provide enhanced magnetic therapy49-52.  
The greatest therapeutic potential in the use of MNPs is probably associated with 
applications involving ‘intelligent’ particles with a magnetic core (to direct the particles 
to the vicinity of the target and also for hyperthermia or for temperature-enhanced release 
of the drug), a recognition layer (to which suitable receptors are attached), and a 
therapeutic load (adsorbed inside the pores or hosted within internal cavities of the 
particles). The challenges are formidable, especially those related to the development of 
suitable recognition layers. Not only must useful recognition moieties be identified and 
attached to the particles, but they must be loaded to a high density while maintaining their 
desired characteristics. For example, MNPs can be coupled to bioactive molecules such as 
tissue grow factors (Gfs) and guided, under an external magnetic field, through a 
magnetic scaffold. Under an external magnetic field, the magnetic moment of the 
magnetic scaffolds can be continuously controlled. This allows reloading of the scaffold 
from an external supervising center so that the scaffolds will work like a fixed ‘‘station’’ 
providing the opportunity to regulate tissue formation to the personal needs of the 
patient53.  
The potential of drug delivery systems based on the use of nano- and microparticles stems 
from significant advantages such as: (i) the ability to target specific locations in the body; 
(ii) the reduction of the drug quantity needed to attain a particular concentration in the 
vicinity of the target; and (iii) the reduction of the concentration of the drug at non target 
sites minimizing severe side effects54. 
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CHAPTER 4 
 
BIOMIMETIC MATERIALS 
 
4.1 Calcium phosphates in biologic systems 
The wide application in the last decades of calcium phosphates as biomaterials is mainly 
due to the biological properties of these materials, whose composition is very close to the 
one of bone mineral, which represents about 70% of the mass of dry bone tissue1-3. The 
first study dates back to the 1920, reporting an accelerated bone healing in surgically 
created defects in rabbits4. Anyway, specific interest in calcium phosphates for 
biomedical applications, and specifically in apatites, raised up in the 1960s and initial 
studies principally involved the synthesis and analysis of hydroxyl apatites in an attempt 
to better understand the physico-chemical and biological behaviour of natural apatites, 
which constitute the mineral part of human bones and teeth3,5,6. Following these studies, 
calcium phosphate-based bioceramics have been in use in medicine and dentistry for the 
last 40 years. Different phases of calcium phosphate ceramics are selected depending 
upon whether a resorbable or bioactive material is desired. These materials constituted a 
wide variety of biomaterials like coatings of metal orthopaedic (hip and knee joints) and 
dental implants, cements, injectable cements, composite materials, and drug carriers 
(antibiotics, anticancerous drugs, growth factors), three-dimensional dense and porous 
scaffolds for bone reconstruction or replacement, applied especially in small bones and 
middle ear bones, powder granulates for the repair of bone defect in maxillofacial 
surgery, alveolar ridge augmentation, otolaryngology. The stable phases of calcium 
phosphate ceramics depend considerably upon temperature and the presence of water, 
either during processing or in the use environment. At body temperature, only two 
calcium phosphates are stable in contact with aqueous media, such as body fluids: at pH < 
4.2, the stable phase is CaHPO4*2H2O (dicalcium phosphate, brushite, DCPD), whereas, 
at pH > 4.2, the stable phase is Ca10(PO4)6(OH)2 (Hydroxyapatite, HA). At higher 
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temperatures, other phases, such as Ca3(PO4)2 (β-tricalcium phosphate, TCP), and 
Ca4(PO4)2O (tetracalcium phosphate, TeCP) are present. The unhydrated, high 
temperature calcium phosphate phases interact with water, or body fluids, at 37 °C to 
form HA. Thus, the solubility of TCP surface approaches the solubility of HA and 
decreases the pH of the solution, which further increases the solubility of TCP and 
enhances resorption. 
Other calcium phosphates have been identified with or without association with apatite; 
they include: Ca8H2(PO4)6*5H2O (octacalcium phosphate, OCP); Ca2P2O7 (calcium 
pyrophosphate dehydrate in mono- and triclinic forms, CPP); amorphous calcium 
phosphate, ACP. 
Apatites in normal calcified tissues of teeth and bone have been postulated to form either 
directly or indirectly by way of precursor calcium phosphates such as ACP, DCPD, OCP 
or TCP.  
 
4.2 Tricalcium phosphate (TCP) 
Tricalcium phosphate exists under two crystallographic forms: β and α-TCP. The α- form 
is unstable at low temperature and is obtained by quenching the β-form heated above 
1125 °C (transition temperature). The β-form may however be stabilized by several ionic 
impurities, such as Mg2+ ions, frequently associated with Ca salts. α-tricalcium phosphate 
is more soluble and more reactive than β-TCP, and it can be rapidly hydrolyzed into 
apatite in aqueous media. Both varieties can be used in Ca-P cement preparations.  
α-TCP is highly reactive in aqueous systems and can be easily hydrolyzed to a mixture of 
other calcium phosphates. α-TCP crystallizes in a monoclinic structure, space group 
P21/a and unit cell a = 12.887(2) Å, b = 27.280(4) Å, c =15.219(2) Å and β =126.20(1)°, 
with 24 formula units per unit cell7. There is an approximate subcell with a b-axis 
parameter of b/3 (9.09 Å) that contains 8 formula units, which corresponds to the unit cell 
reported8. 
The structure of α-TCP is constituted of columns of Ca2+ and PO43- ions which run 
parallel to the c-axis; the section of the structure of α-TCP corresponds to a unit cell of 
apatite. The correspondence can also be seen from a consideration of the dimensions of 
the unit cell of α-TCP with those of apatite: the α-TCP approximate subcell b-axis 
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parameter of 9.09 Å corresponds to the a-axis apatite parameter, whilst half the c-axis 
parameter of α-TCP (7.6 Å) corresponds to the c-axis parameter of apatite.  
The β-form makes an excellent resorbable biomaterial. However, it is not found in 
biological systems and it cannot be obtained by precipitation. Biological TCP is always 
partially magnesium-substituted, giving rise to whitlockite (Ca,Mg)9(PO4,HPO4)6. It is not 
detected as constituents of normal tissue calcifications but their presence in several 
pathological tissue calcifications, in abnormally calcified cartilage and in human dental 
carious lesions has been reported9-10. β-TCP is more soluble than apatite and can be 
hydrolyzed into apatitic phases; whitlockite on the contrary seems less soluble and has 
never been shown to convert into apatite11-12. The presence of Mg in β-TCP is thus an 
important parameter affecting its biological properties, especially its ability to be 
resorbed.  
 
4.3 Bioactivity of calcium phosphate 
Synthetic bioactive Ca-P materials are not in equilibrium with biological fluids. Thus, 
several reactions occur on the mineral surface. For apatites, very first reaction is the 
hydrolysis of the surface PO43- groups into HPO42- and the uptake of carbonate and 
sodium ions. Generally the hydrolysis of surface phosphate groups is associated with a 
decrease of the calcium concentration at the surface13. These reactions correspond simply 
to exchanges between the solution and the first atomic layers of the apatite surface. The 
extent of these reactions may vary according to the composition of the mineral and how it 
was produced. Inflammatory cells in close proximity to the material, may also create an 
acidic environment. Poorly crystalline apatites with many defects are particularly 
sensitive to these changes. 
As biological fluids are generally supersaturated with respect to apatite, the Ca-P 
materials also serve as a template for the formation of carbonate-apatite crystals. This 
event has been shown to be the major factor behind the osteoconductivity of all 
biomaterials and has been evidenced in different classes of bioactive orthopaedic implants 
(polymers and bioactive glasses). The crystals formed are very much like bone mineral 
crystals. They are carbonated apatites and exhibit non-apatitic environments. 
The precipitation of the neo-formed crystals can also be boosted by release of calcium, 
phosphate ions or rise in the pH that may locally increase the supersaturation ratio in the 
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vicinity of the implant surface. This phenomenon can be favoured by hydrolysis reactions 
of the material constituents. Enlarging the surface area is another way to increase the 
amount of reactive, neo-formed crystals. 
The ability of a biomaterial to generate this layer has been considered as a measure of its 
biological activity, although such a relationship has not yet been established on a 
quantitative basis. Despite the analogy of the crystals formed with bone mineral crystals, 
the processes of formation and organization appear to be rather different. Bone mineral 
crystals are always formed in an organic collagen matrix with which they are closely 
associated. Although the layer formed on bioactive biomaterials frequently incorporates 
bone proteins, there is no organization like that of bone. It appears more like an 
uncontrolled mineralization. 
The functions of the neo-formed layer have not yet been clearly established. This layer 
creates a very reactive surface with a high specific surface area, which is able to attach 
bone specific proteins, especially osteopontin and osteocalcin14. The neo-formed layer 
appears, as a support, and the adsorption of proteins to it is necessary to accommodate 
osteoblast cell attachment and favour their multiplication. Although such proteins might 
bind directly to the HA surface, the adsorption affinity could be quite different depending 
on the apatitic substrate. Thus, synthetic apatites rich in labile non-apatitic environments 
exhibit a high surface reactivity and have a higher affinity for some proteins than 
stoichiometric HA. Depending on the apatitic substrate and the rate of formation of the 
layer, the presence of labile non-apatitic environments and the reactivity of the neo-
formed layer may vary. 
 
4.4 Apatites 
4.4.1 Hydroxyapatite: structure and chemistry 
Apatites are an industrially important group of materials with applications in catalysis, 
environmental remediation, bone replacement and ceramic membranes amongst others, 
and constitute a large class of materials with general formula15 [M(1)2][M(2)3](XO4)3Z, 
where: M represents a bivalent cation; XO4 represents a trivalent anion; Z represents a 
monovalent anion. Among all the apatites, calcium hydroxyapatite is the most relevant in 
biological systems, as it is the major component of bones and teeth; its formula is defined 
as: Ca5(PO4)3OH or, more often, Ca10(PO4)6(OH)2. M/X ratio commonly defines the 
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stoichiometry of an apatite, in case of HA it corresponds to Ca/P = 1.667. In ideal HA, 
calcium, phosphorus and hydroxyl ion are present in the following weight percentage: 
Ca2+ = 39.84%; PO43- = 56.77%; OH- = 3.39%. The apatite prototype Ca5(PO4)3F 
structure was first determined by Naray-Szabo in 193016 and was confirmed to adopt 
P63/m symmetry (Fig. 1.). 
 
 
Fig. 1. Crystal structure of Hydroxyapatite. 
 
The 10 Ca2+ ions occupy two crystallographically different symmetry sites, 4f and 6h. 
Four Ca2+ ions (4f ) are located in columns along the three-fold axes at 1/3, 2/3, 0 and 2/3, 
1/3, 0 separated by approximately one half of the c-axis. These are commonly referred to 
as Ca1 (or column Ca). Ca1 is coordinated to nine O atoms, with six shorter bonds that 
define an approximate trigonal prism and three longer bonds capping the prism faces. The 
Ca-O9 polyhedra share the trigonal faces to form chains parallel to the c-axis. The 
remaining six Ca2+ ions (6h sites, referred to as Ca2 or triangular Ca) form two triangular 
sets at z = 1/4 and 3/4 on the mirror planes. The Ca2 ions are seven-coordinated, with six 
O atoms and one OH- ion. The six XO4 tethraedra are PO43- groups in a 6h site. OH- 
anions occupy the special position 4e at z/c=0.202, that has multiplicity of 4. As in the 
hexagonal structure the presence of the mirror plane at 1/4 and 3/4 make hydroxyls ions 
in this position reflected too close to themselves, an occupation factor of 1 would result in 
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an incorrect stoichiometry. Thus, the occupation of the site must be 0.5, and in this case 
the orientation of the OH- groups in the lattice cannot be known. A full description of OH- 
sites in stoichiometric HA can be achieved by reducing the symmetry of the crystal to the 
subgroup P21/b17. As the cell contains twice the atoms of the hexagonal one, the correct 
stoichiometry is retained and the sticking of the hydroxyls is prevented; the resulting unit 
cell parameters are a = 9.421 Å, b = 18.843 Å, c = 6.881 Å, γ= 120.0°.  
Thus, HA can be described in terms of two interpenetrating lattices: an overall P63/m 
structure, with a local P21/b in correspondence of the hydroxyls columns. For this reason 
and for sake of simplicity, we will always refer to the hexagonal description of HA, as the 
monoclinic description is required only for explaining the statistical occupation of OH- 
ions and is not influent on the chemico-physical properties of HA related to the biologic 
behaviour. 
 
4.4.2 Biological Apatites 
Although the above-described structure of synthetic HA has been used as a model for the 
apatite present in the human hard tissues for many years, many differences in composition 
and in other properties make the biological apatites different from pure calcium 
hydroxyapatite and from each other and should be more appropriately referred to as 
calcium-deficient, multi-substituted hydroxyapatite. The apatite lattice is very tolerant of 
substitutions, vacancies and solid solutions, for example, X can be replaced by ½CO3 or 
½O; Ca by Sr, Ba, Pb, Na or vacancies18; and PO4 by HPO4, AsO4, VO4, SiO4 or CO3. 
Owing to this ability, biological apatites are capable of variable composition and therefore 
to be heterogeneous even within each category and even within each calcified tissue 
(enamel, dentine, bone). Non-stoichiometry (Ca/P of biological apatites ranges from 1.54 
to 1.73 compared to 1.67 for pure HA), the presence structural or surface-bound of 
foreign ions and the co-existence or pre-existence of possible precursors such as DCPD, 
octacalcium phosphate (OCP), TCP, ACP make an accurate crystallochemical analysis 
and definition a difficult, if not an impossible undertaking. 
Because of these difficulties, many studies on biological apatites have been made 
indirectly by studying apatites prepared from aqueous and non-aqueous systems. 
Notwithstanding, the chemico-physical behaviour of the synthetic apatites cannot always 
be directly extrapolated to biological apatites. The biological apatites are uniquely similar 
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in that they all contain carbonate in varying amounts as a substitute for phosphate in the 
apatite structure19,20. They differ in crystallite sizes, shapes and other physico-chemical 
properties such as chemical (susceptibility to acid dissolution) and thermal stabilities21,22. 
Based on observations from in vitro systems19,21,23-25, some of these foreign ions affect the 
crystallinity (reflecting crystallite size and/or strain), morphology, lattice parameters of 
the biological apatites and as a consequence, impart stability or instability to the tissues 
involved. Some of these impurities are associated with the susceptibility or resistance of 
human tooth enamel to acid dissolution (caries) and of bone resorption processes26,27. 
Biological apatite is not a stable material, as it is involved in the complex bone 
metabolism and thus subject to a continuous structural remodelling, due also to its very 
poor crystallinity degree. One important characteristics of biologic HA is for example, the 
increase of its crystallinity in the ageing and the increase of Ca/P ratio. This phenomenon 
reflects in a progressive decrease of the capacity of biologic HA to remodel itself, as the 
stability and solubility of HA strongly decreases when it approaches to the stoichiometry 
(Ca/P =1.667). 
 
4.4.3 Effect of Carbonate 
The presence of carbonate ions in the biological apatites strongly contributes to the 
variation of Ca/P ratio. As higher its content as higher is the metabolic activity of the 
tissue: for example, enamel, which is a nearly inert tissue, contains very few carbonate, 
compared to bone and dentin, which are very active tissues. Carbonate ions are either 
adsorbed on the surface or incorporated into the HA structure, into two different 
crystallographic sites, hydroxyl (A-type carbonation) or phosphate (B-type carbonation). 
The B-type is the preferential carbonate substitution found in the human bone, in the 
range 2-8 wt%, depending on the age of individual28, with the A/B type ratio in the range 
0.7-0.9. A higher value of the A/B ratio was observed in old tissue, compared to young 
tissue29. It has been observed by in vivo tests that the decrease of crystallinity in B-
carbonated HA yields an increase of solubility30. B-type carbonation is related to a higher 
affinity of apatite for osteoblast cells, compared to A-type carbonation, as it does not alter 
the surface polarity of HA. This reflects in a higher cellular adhesion and an increase 
production of collagen31,32. 
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4.4.4 Effect of Magnesium 
Among substituting cations, magnesium is widely studied due to its biological relevance. 
It has been verified that in calcified tissues, the amount of magnesium associated with the 
apatite phase is higher (about 5% at.) at the first stages of the bone remodelling process 
and decreases with increasing calcification and with the ageing of individual33. The 
presence of magnesium increases the nucleation kinetic of HA contemporary retarding 
that of its crystallization; for this reason magnesium concentration is higher in the 
cartilage and in young bone and there is growing evidence that it may be an important 
factor in the qualitative changes of the bone matrix that determines bone fragility. 
Magnesium depletion adversely affects all stages of skeletal metabolism, causing 
cessation of bone growth, decrease of osteoblastic and osteoclastic activities and 
osteopenia. 
 
4.4.5 Effect of Strontium 
Among the bivalent cations that can replace calcium in CaHA, strontium has attracted a 
remarkable interest for its possible biological role. 
Strontium is one of the alkaline earth metals. It never occurs free in nature, because 
metallic Sr oxidises easily forming strontium oxide, which has a yellowish colour. The 
elements of group 2 of the periodic system, to which Sr belongs along with Ca and Mg, 
form divalent cations in biological fluids, and have varying degrees of protein binding in 
biological fluids like serum or plasma. 
Radioactive Sr isotopes are dealt with only when they are used for physiological or 
diagnostic purposes. Some of the Sr radioisotopes can be used in medicine. They have 
been used as excellent tools for kinetic studies, substituting for Ca in kinetic 
investigations because the two metals behave very much alike in the human body, both 
having strong bone-seeking properties. 
However, biological differences between the two elements exist, explicable in part by the 
larger size of the Sr molecule. 
Toxic symptoms due to overdosing of Sr have not been reported in man. However, 
intravenous administration of high doses of Sr induces hypocalcaemia due to increased 
renal excretion of Ca. 
The only stable Sr-containing chemical that is considered to be harmful to humans in 
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small amounts is strontium chromate, the toxicity being caused by the chromium which is 
a genotoxic carcinogen. 
The amount of Sr in the skeleton is only 0.035 of its Ca content. Radiostrontium is 
cleared from the blood almost immediately after injection34. 
It is present in the mineral phase of the bone, especially at the regions of high metabolic 
turn-over, and its beneficial effect in the treatment of osteoporosis is well known. In vitro, 
strontium increases the number of osteoblasts and decreases the number and the activity 
of osteoclasts, whereas strontium administration reduces bone resorption and stimulates 
bone formation. Strontium can replace calcium in the HA structure in the whole range of 
composition. The solid solutions, which have been obtained by hydrothermal methods or 
by treatment at high temperatures, display a linear variation in the lattice parameters with 
composition, whereas different data are reported on the preferential substitution site of Sr 
for Ca in CaHA. A better understanding of the interaction of Sr with hydroxyapatite 
structure could provide useful information also for clarifying the biological role of Sr in 
the process of biomineralization of bone and related pathologies35 even though the role of 
strontium in human pathology had attracted less attention than the other two important 
divalent metals, calcium and magnesium. However, there has been an increasing 
awareness of the biological role of strontium since the development of the drug strontium 
ranelate, which has recently been shown to reduce incidence of fractures in osteoporotic 
patients. In fact, strontium is a trace element that is found in calcareous rocks and ocean 
water; it is also a natural component of food and beverages but there is growing evidence 
that strontium has a beneficial effect on bone because of its ability to enhance bone 
volume and prevent bone loss. In line with its chemical analogy to calcium, strontium is a 
one seeking element and 98% of the total body Sr content can be found in the skeleton. Sr 
has become increasingly popular in the prevention and treatment of osteoporosis as a 
ranelate compound. Sr has been associated with improving postmenopausal osteoporosis 
by reducing bone resorption and increasing bone formation with an eventual effect of 
decreasing the risk of fractures. The currently available data indicate that strontium 
administration at low dose reduces bone resorption and increases bone formation, 
resulting in increased bone mass in normal orovariectomized animals. In vitro studies 
revealed that strontium ranelate (SR) has an anabolic and antiresorptive activity which 
leads to an increase in both the collagen and non-collagen protein synthesis, an 
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enhancement in pre-osteoblast differentiation, an inhibition in osteoclast differentiation, 
and a reduction in osteoclast function36,37. 
 
4.5 Non-stoichiometric and substituted HA 
As pH values decrease, a calcium deficient HA is more likely to be formed38,39. During 
aqueous precipitation, other species may be substituted in the structure or adsorbed onto 
the surface. Non-stoichiometric apatites are quite easy to synthesize, as they can be 
obtained by any precipitation method over a wide range of pH, temperature and 
concentration. Their composition and crystal characteristics are however more difficult to 
control. The most interesting of these apatites are HPO42- and CO32- containing apatites 
which are close to bone mineral. Although bone mineral has a variable composition, 
diverse apatites mimicking the evolution of bone mineral in young and old animals can be 
prepared. These apatites also show similar crystal shape and dimensions and their 
composition can be represented by a chemical formula analogous to that of bone mineral. 
Addition of more than one substitute element group can lead to a combination of an 
expansion and contraction of the unit cell24. For example, carbonate causes a decrease in 
the a-axis40 that could be counteracted by an increase from an acid phosphate group41. 
This reaction sequence is complicated by the ability of carbonate to substitute phosphate 
or hydroxide, the former being the more common. The addition of many of these 
chemical groups decreases the growth rate at low concentrations. Full substitution of 
fluoride for the hydroxyl ion removes lattice distortion, produces a more stable apatite 
and, thus, is able to drive precipitation to completion more easily42. Carbonate replaces 
phosphate in reactions containing fluoride and at high pH43. All ionic sites of the apatite 
structure accept substitutes. It is generally the size of the ionic substitute that determines 
its incorporation in a given lattice. For Ca-P apatites, the monovalent anionic site 
substitution of OH- by F-, Cl-, Br- are known but I- is not. These sites may also be 
occupied by carbonate ions, as in enamel and bone. The trivalent anionic phosphate sites 
may be occupied by bivalent or tetravalent ions like carbonate, HPO42-, or silicate SiO44- 
and many other trivalent ions such as vanadate or arsenate. These sites cannot accept 
vacancies, probably because the trivalent anions are quite large and vacancies would 
destabilize the lattice. Cationic sites can also be occupied by other divalent cations like 
Pb2+, Mg2+, Zn2+, Cu2+, Mn2+, and by monovalent ions such as Na+ and K+ or trivalent 
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ions like La3+. The cationic site can also accept vacancies: up to maximum of 2 sites out 
of the 10 existing in stoichiometric apatites. This property of the apatite structure allows 
the adaptation of its physical and chemical properties to many different calcified tissues, 
such as enamel, bone, dentine, and fish scales. However, in the preparation of pure HA, 
this property is a drawback because many ions from the solution can be incorporated, 
including toxic ions, or mineral ions with a positive biological activity. Thus the 
preparation of pure apatite has to take these properties into account. 
The pH is an important factor in the precipitation of apatites as it determines the HPO42- 
content of the final product. Stoichiometric apatites are generally obtained at alkaline pH 
and in boiling solutions. Anyway, stoichiometric hydroxyapatite does not form 
spontaneously in solution; their formation in highly supersaturated solutions is preceded 
by the precipitation of an amorphous phase possessing a Ca/P ratio much lower than that 
of apatite. This first precipitate then transforms into an apatite phase whose Ca/P ratio 
tends progressively towards that of HA. 
Surface properties also play a role in the preparation of apatites. Generally, precipitated 
apatites have a very high specific surface area (between 50 and 90 m2/g) that may adsorb 
many ions or constituents. In fact, adsorbed ions may eventually be incorporated into the 
lattice during growth or maturation of the crystals. Surface constituents generally slow 
down the maturation process and the evolution towards stoichiometry. The surface CO32- 
and HPO42- ions play a special role as they may alter the global stoichiometry of the solid. 
Precipitation has been performed in various conditions. The preparation of HA seems to 
be better achieved in Ca-rich solutions than in phosphate-rich solutions. 
Following, the effect of the most relevant ionic substitutes on the chemico-physical 
properties of synthetic HA are described in more detail. 
 
Carbonate (CO32-) 
A key target of biomaterials research is the preparation of a synthetic carbonate 
containing hydroxyapatite (CHA) bone-substitute ceramic, that mimics the chemical 
composition of the natural hard tissue. The carbonate group can substitute both the 
hydroxyl and the phosphate ions, giving rise to the A-type and B-type carbonation 
respectively, so that a CHA substituted in both sites can be described as 
Ca10−x/2[(PO4)6−x(CO3)x][(OH)2−2y(CO3)y]. The charge unbalance occurring when (CO3)2− 
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ions replace (PO4)3− (B-type CHA) groups is primarily compensated by vacancies in Ca1 
sites42. The exact position of the carbonate ions in the lattice of the HA has been 
elucidated only recently42,44. By using full Rietveld refinement of the crystal structure of 
the synthetic calcium-deficient carbonated apatite two orientations of CO3 triangles, 
sharing one of their edges, were found. They occupy randomly the adjacent faces of a PO4 
tetrahedron that are parallel to the c axis.  
Carbonate substitution in type B carbonate apatites causes the following effects: a) 
decrease in a axis and increase in c-axis dimensions compared to CO3- free apatites; b) 
decrease in crystal size as shown by the broadening of the diffraction peaks in the XRD 
patterns and in TEM; c) increase in crystal strain as shown by the loss of resolution of the 
PO4 absorption bands in the IR spectra; d) change in crystal morphology; e) greater 
solubility. As carbonation in B site increases the biomimetism of the synthetic apatite, it 
is advisable to orient the synthesis techniques for the incorporation of suitable amounts of 
carbonate ions, substituting the phosphate. 	  
Magnesium (Mg2+) 
As Mg2+ is smaller than Ca2+ (0.86 Å vs. 1.14 Å), the incorporation of magnesium affects 
the crystal structure of HA and the substitution cannot occur over the full concentration 
range. Progressive increase of the amount of incorporated magnesium, in fact, slightly 
reduces the cell parameters of the crystal and the average crystal radius; above a 
concentration limit of ~ 0.15 Mg2+/Ca2+ the apatite structure likely collapses and the 
formation of other phases (typically TCP or amorphous calcium magnesium phosphates), 
that act as segregating phases for this ion, is observed3. The incorporation of Mg in 
synthetic apatites is very limited (maximum of about 4 wt% Mg) unless carbonate or 
fluoride ions are simultaneously incorporated with Mg. The amount of Mg incorporated 
in the apatite is proportional to the Mg concentration in the solution. The incorporation of 
Mg increased by the simultaneous incorporation of F- or CO32-. The limited incorporation 
of Mg is also observed in apatites prepared at high temperatures (above 900 °C) by solid 
state reaction. The presence of Mg in the apatite causes the following effects on its 
properties: a) decrease in a-axis dimension; b) decrease in crystallinity as shown in XRD 
patterns and IR spectra; c) increase in HPO42- incorporation as shown by the higher β-
TCP/HA ratio in sintered Mg-containing HA and d) increase in extent of dissolution. As 
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for B-carbonation, the incorporation of magnesium in synthetic HA is of great interest for 
the design of biomimetic bone substitutes45,46. 
 
Strontium (Sr2+) 
Sr (ionic radius 0.12 nm) can replace Ca (ionic radius 0.099 nm) in the structure of HA 
over the whole range of composition, causing a linear expansion of the lattice constants. 
A detailed structural and morphological investigation carried out on HAs precipitated 
from aqueous solutions at different Sr concentrations demonstrated that relatively low Sr 
replacement of Ca induces a decrease in the coherent length of the perfect crystalline 
domains and disturbs the shape of the crystals, whereas the crystallinity, as well as the 
mean dimensions of the crystals, significantly increase at relatively high Sr content47. 
Moreover, the results of the structural refinements indicate that Sr exhibits a slight 
preference for the M(II) site, as expected on the basis of its greater ionic radius than that 
of Ca, for most of the composition range, but at very low content it displays a modest 
preference for the smaller M(I) site. Destabilization of crystal structure by the larger Sr 
atom has been invoked to justify the significant increase in solubility with Sr content. 
 
Iron (Fe2+/Fe3+) 
The concentration of iron within hard tissue is low, indicating that iron can be present 
within the body without disturbing the apatite structure and hence the function of bone. 
Exposure of teeth to externally applied solutions containing iron leads to easier 
incorporation of iron. Though iron is one of the most essential elements in the human 
metabolism, its effect on the properties of DCPD and HAP has not been reported in the 
literature so far. Ming Jung et al.48 investigated the local geometry of Fe2+/Fe3+ in Fe-
doped hydroxyapatite and they find that the Ca(2) site is energetically favoured over 
Ca(1) sites for Fe2+ substitution and that sixfold coordination is most stable. However for 
nonstoichiometric Fe3+ substitution, the fourfold case is most stable at the Ca(1) site. 
 
4.6 Natural polymer  
While many polymers have been studied for medical applications, they share certain 
properties that are fundamental to their use as biomaterials. Their application in tissue 
engineering requires them to be biocompatible, nontoxic, and noninflammatory, which is 
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particularly important when designing degradable polymers as the degradation products 
too must meet these criteria. David Williams proposed the following definition: “The 
biocompatibility of a scaffold or matrix for a tissue engineering product refers to the 
ability to perform as a substrate that will support the appropriate cellular activity, 
including the facilitation of molecular and mechanical signalling systems, in order to 
optimise tissue regeneration, without eliciting any undesirable local or systemic 
responses in the eventual host”49. 
The use of degradable polymers is desirable because the need for surgical removal is 
obviated; however, care must be taken to ensure the compatibility of both intermediate 
and final degradation products, the timing of the degradation process, and how each of 
these affects the regenerative process.  
Naturally derived degradable polymers, such as collagen, alginate or gelatin, have also 
been explored clinically because they are biocompatible, easily modified, and easily 
processed into various structures50. 
Starting from the consideration that natural bone consisting of an organic and an 
inorganic phase interacting among themselves, natural polymer has been added to 
ceramic phase in order to improve the biomimetic properties of the materials.  
 
4.6.1 Collagen 
Collagen, the most abundant protein in animals, is the major component of connective 
tissue; represents the major protein of tendons, ligaments, and the cornea; and forms the 
matrix of bones and teeth51.    
The collagen molecule consists of three polypeptide chains, in each of which one has the 
repeating unit tri-peptide Gly-XY, where X and Y positions are frequently occupied by 
proline and hydroxyproline, two amino acids that locally affect the configuration of the 
chain because of the rigidity of their structures (Primary Structure). Each single chain, 
wrapped in a helix-clockwise (Secondary Structure), consists of a series of amino acid 
residues linked together by means of peptide bonds (Fig. 2) originated from the reaction 
between the amine function of an amino acid and the carboxylic function of the next. 
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Fig. 2. Peptide bond 
 
The partial double bond character of the peptide bond determines a limited freedom of 
rotation around it which, associated with the formation of interchain hydrogen bonds (a 
hydrogen bond every three amino acid residues, between the NH of glycine and the OR of 
the group C = O of the triplet close) and the complementary interactions between residues 
(R), make stable the structure of the α-helix typical of the collagen.  
The three chains are wrapped in a right-handed super helix to form the characteristic 
coiled-coil structure (tropocollagen) (tertiary structure), stabilized by intra-and 
intermolecular interactions as well as the water of hydration; two molecules of water 
every three residues amino acid, arranged in a bridge to form H-bonds between the C=O 
of Gly-NH2 and the residues X or Y.  
In collagen type I, two of the three polypeptide chains, have identical amino acid 
composition, consisting of 1056 amino acid residues, while the third, has a different 
composition and comprises 1038 residues. The triple helix structure, involves 1014  
residues for each of the three chains; the remaining residues, with a non-helical 
configuration, are called telopeptides. 
The quaternary structure, characterized by the repetition of the structural unit in triple 
helix, packed to form a defined pattern representative of the basic element of the solid 
state, the microfibrilla (Fig. 3). 
The collagen molecules are assembled into an almost-hexagonal geometry with a 
Biomimetics materials 
 	  
	  
66 
 
interchain distance of about 1.3 nm which is considerably lowers when the microfibrilla is 
dehydrated. 
 
	  
Fig. 3. Steps of collagen fibers assembling 	  	  
The particular three-dimensional structure, makes the collagen a protein not soluble in 
water. 
The amino acids present in the amino acid sequences of collagen contain amino (-NH2), 
carboxyl (-COOH) and hydroxyl (-OH) groups which, together with the peptide bond of 
the main chain, represent the possible sites of chemical interaction of collagen molecule. 
By the amino acid composition of the collagen protein depends its isoelectric point (pI) 
that is the value of pH where a particular molecule or surface carries no net electrical 
charge. For the collagen, this pH value is equal to 5.552. 
 
4.6.2 Alginate 
Alginates is a natural polymer belonging to the family of carbohydrates that is extracted 
from brown algae (diatoms family). Alginate is a linear copolymer composed by the 
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repetition of two monomeric units that are (Fig. 4): 
• D- mannuronic acid (M) 
• L-guluronic acid (G) 
linked by means of β-1.4 and 1.4 α-glycosidic bounds. 
Alginates formed by binding with monovalent ions are generally water soluble, while 
salts with bivalent cations like Ca2+ form insoluble hydrogels, through an “egg box” 
model (Fig. 5); in the case of partial binding with bivalent ions, solubility in water is 
partially retained.  
 
	  	  
Fig. 4. Structural unit of Alginate 	  
Calcium cross-linked alginate hydro-gels have been used in many biomedical 
applications, including cell transplantation and drug delivery53. 
	  	  
Fig. 5. “Egg box” model 
 
There are various types of alginate that differ as a function of the ratio G/M and the length 
of the polymer chains.  
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Algined used in this work for the production of composite materials described is 
characterized by G/M ratio equal to 65-70/35-30.  
This ratio it is important since alginate shows its ability to bind divalent ions, whereby it 
forms insoluble salts, in correspondence of the monomers of L-guluronic acid (G), 
according to the scheme of Fig. 654. 	  
 
Fig. 6. Scheme of the bound between calcium ion and L-guluronic acid monomer 
 
 
4.6.3 Gelatin 
Gelatine is the product of thermal denaturation or disintegration of insoluble collagen 
with various molecular weights (MWs) and isoionic points (IEPs) depending on the 
source of collagen and the method of its manufacturing process of recovery from 
collagen55. Gelatine is divided into two main types: Type A, which is derived from 
collagen of pig skin by acid pre-treatment with IEP of 7-9, and Type B, which is derived 
from collagen of beef hides or bones by liming (alkaline process) with IEP of 4.6-5.4. 
Type A gelatine (dry and ash free) contains 18.5 % nitrogen, but due to the loss of amide 
groups, Type B gelatine contains only about 18% nitrogen. Amino acid analysis of 
gelatine (Fig. 7) is variable, particularly for the minor constituents, depending on the raw 
material and process used, but proximate values by weight are: Gly 21%, Pro 12%, Hyp 
12%, Glu 10 %, alanine (Ala) 9%, Arg 8%, Asp 6%, Lys 4%, serine (Ser) 4%, leucine 
(Leu) 3%, valine (Val) 2%, phenylalanine (Phe) 2%, threonine (Thr) 2%, isoleucine (Ile) 
1%, hydroxylysine (Hyl) 1%, methionine (Met), His < 1% and Tyr < 0.5%.  
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Fig. 7. Gelatin structure 
 
Gelatine forms physical gels in hydrogen-bond friendly solvents above a concentration 
larger than the chain overlap concentration (~ 2 % w/v). The gelatine sol undergoes a first 
order thermo-reversible gelation transition at temperatures lower then Tg with is ~30°C, 
during which gelatine molecules undergo an association-mediated conformational 
transition from random coil to triple helix. The sol has polydisperse random coils of 
gelatine molecules and aggregates, whereas in gel state there is propensity of triple 
helices stabilized through intermolecular hydrogen bonding, during which, three 
dimensional (3D) interconnected network connecting large fractions of the gelatine chains 
is formed56. Hydrogel formation, accompanied by a disorder-order rearrangement in 
which gelatine chains partially recover the triple helix collagen structure, leads to forming 
of renaturated gelatine with amorphous main regions of randomly-coiled gelatine chains 
interconnected with domains of spatially-ordered microcrystallites, stabilized by 
hydrogen bonds between N-H of Gly and C=O from Pro57.  
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CHAPTER 5 
 
ANALYTICAL TECNIQUE 
 
5.1 X-Ray Diffraction (XRD) 
X-ray diffraction is a non-destructive analytical technique which reveals information 
about the crystallographic structure, crystallite size, and preferred orientation in 
polycrystalline or powdered solid samples. This technique is based on observing the 
scattered intensity of an x-ray beam hitting a sample as a function of incident and 
scattered angle, polarization, and wavelength or energy. 
Powder diffraction is commonly used to identify unknown substances, by comparing 
diffraction data against a database of Powder Diffraction Files (PDF) maintained by the 
International Centre for Diffraction Data (ICDD). It may also be used to characterize 
heterogeneous solid mixtures to determine relative abundance of crystalline compounds 
and, when coupled with lattice refinement techniques, such as Rietveld refinement, can 
provide structural information on unknown materials. Powder diffraction is also a 
common method for determining strains in crystalline materials. 
The great advantages of the technique are: 
 simplicity of sample preparation  
 rapidity of measurement  
 the ability to analyze mixed phases 
 
When X-rays hit an atom, they make the electronic cloud move as does any 
electromagnetic wave. The movement of these charges reradiates waves with the same 
frequency (blurred slightly due to a variety of effects); this phenomenon is known as the 
Rayleigh scattering (or elastic scattering). The scattered waves can themselves be 
scattered but this secondary scattering is assumed to be negligible. A similar process 
occurs upon scattering neutron waves from the nuclei or by a coherent spin interaction 
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with an unpaired electron. These re-emitted wave fields interfere with each other either 
constructively or destructively (overlapping waves either add together to produce stronger 
peaks or subtract from each other to some degree), producing a diffraction pattern on a 
detector or film (Fig. 1). 
The resulting wave interference pattern is the basis of diffraction analysis. X-ray 
wavelength is comparable with interatomic distances (~150 pm) and thus is an excellent 
probe for this length scale.  
 
	  
Fig. 1. Constructive and destructive interference in Rayleigh scattering of X rays 
 
The interference is constructive when the phase shift is a multiple to 2d; this condition 
can be expressed by Bragg’s law: 
nλ = 2d· sin θ 
 where: 
• n is an integer determined by the order of diffraction,  
• λ is the wavelength of x-rays,  
• d is the spacing between the planes in the atomic lattice, 
•  θ is the angle between the incident ray and the scattering planes. 
 
Powder diffraction data are usually presented as a diffractogram in which the diffracted 
intensity I is shown as function either of the scattering angle 2θ.  
The most widespread use of powder diffraction is in the identification and 
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characterisation of crystalline solids, each of which produces a distinctive diffraction 
pattern. Both the positions (corresponding to lattice spacings) and the relative intensity of 
the lines are indicative of a particular phase and material, providing a "fingerprint" for 
comparison multi-phase mixture will show more than one pattern superposed, allowing 
for determination of relative concentration.  	  
Crystal structure 
The crystal structure of a material or the arrangement of atoms in a crystal can be 
described in terms of its unit cell. The unit cell is a tiny box containing the spatial 
arrangement of atoms. The units cells stacked in three-dimensional space describe the 
bulk arrangement of atoms of the crystal. The unit cell is given by its lattice parameters, 
the length of the cell edges and the angles between them, while the positions of the atoms 
inside the unit cell are described by the set of atomic positions (xi,yi,zi) measured from a 
lattice point. The symmetry properties of the crystal are embodied in its space group. 
Crystal structure and symmetry play a role in determining many of its properties, such as 
cleavage, electronic band structure, and optical properties.  
Although there are an infinite number of ways to specify a unit cell, for each crystal 
structure there is a conventional unit cell, which is chosen to display the full symmetry of 
the crystal. However, the conventional unit cell is not always the smallest possible choice. 
A primitive unit cell of a particular crystal structure is the smallest possible volume one 
can construct with the arrangement of atoms in the crystal such that, when stacked, 
completely fills the space. This primitive unit cell does not always display all the 
symmetries inherent in the crystal. In a unit cell each atom has an identical environment 
when stacked in 3 dimensional space. In a primitive cell, each atom may not have the 
same environment. The crystal structure consists of the same group of atoms, the basis, 
positioned around each and every lattice point. This group of atoms therefore repeats 
indefinitely in three dimensions according to the arrangement of one of the 14 Bravais 
lattices (Table 1).  
The possible lattice centrings are: 
 P: Primitive centring, lattice points on the cell corners only;  
 I: Body centred, one additional lattice point at the center of the cell;  
 F: Face centred, one additional lattice point at centre of each of the faces of the 
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cell;  
 A, C: Centred on a single face, one additional lattice point at the centre of one of 
the cell faces 
	  
Table 1. Bravais lattice in three-dimension 
 
There are only seven possible crystal systems that atoms can pack together to produce an 
infinite 3D space lattice in such a way that each lattice point has an identical environment 
to that around every other lattice point. The simplest and most symmetric, the cubic (or 
isometric) system, has the symmetry of a cube. The other six systems, in order of 
decreasing symmetry, are hexagonal, tetragonal, rhombohedral (also known as trigonal), 
orthorhombic, monoclinic and triclinic. 
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When the crystal systems are combined with the various possible lattice centrings, we 
arrive at the Bravais lattices. They describe the geometric arrangement of the lattice 
points, and thereby the translational symmetry of the crystal. In three dimensions, there 
are 14 unique Bravais lattices which are distinct from one another in the translational 
symmetry they contain. 
 
Miller indices 
Miller indices are an useful tool to describe the lattice plans, specifying their orientation 
with respect to the three axis of the unit cell. To calculate the Miller indices of a plane one 
has to determine the reciprocal of its intersections with the three axes in terms of fractions 
or multiples of the unit cells edges; these numbers are indicated in brackets, e.g. (hkl), 
which indicates an infinite number of equidistant parallel planes, so that the following 
expression is satisfied:  
h(x/a) + k(y/b) + l(z/c) = n 
where n indicates the plane position with respect to the origin.  
In Fig. 2 some examples of the use of Miller indices are illustrated. 
 
 
Fig. 2. Some examples of Miller planes 
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Crystallinity 
In contrast to a crystalline pattern consisting of a series of sharp peaks, amorphous 
materials (liquids, glasses etc.) produce a broad background signal. Many polymers, 
organic molecules or inorganic glasses usually exhibit this kind of pattern, but often also 
inorganic nanostructured crystalline phases can contain also an amorphous fraction. XRD 
can be used to determine the degree of crystallinity by comparing the integrated intensity 
of the background pattern to that of the sharp peaks. 
 
Size and Strain Broadening 
There are many factors that determine the width B of a diffraction peak. These include: 
1. instrumental factors  
2. the presence of defects to the perfect lattice  
3. differences in strain in different grains 
4. the size of the crystallites 
In powder samples, the strain can often be neglected, so that a simple formula can be 
applied to obtain the average size of the diffracting coherent domains, the Scherrer 
formula:	  	  
 
 
where:  
D is the crystallite average size; 
K is a form factor, usually taken as 0.9; 
λ is the wavelength of the incident radiation; 
B is the peak width corrected for the instrumental broadening; 
θ is the diffraction angle. 
 
5.1.1 Quantitative phase analysis: Reference Intensity Ratio (RIR) Method 
The Reference Intensity Ratio (RIR) is a method used for quantitative analysis by powder 
diffraction. The reference intensity ratio (RIR) for a phase i is defined as: 
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where Ii is the intensity of the 100% peak of phase i, and Is is the intensity of the 100% 
peak of a reference phase s, taken by convention to be α-Al2O3, corundum, in a 50:50 
mixture by weight. Even without the addition of a known amount of an internal standard 
to a sample it is possible to compute the ratio of the weight fractions of any two phases in 
a mixture, provided their RIRs are known and assuming that the sum of all phases is 100 
wt%. 
 
5.1.2 Rieteveld Method 
The Rietveld method for structural refinement of powder diffraction data has been 
developed over the last four decades and has proved indispensable in solving crystal 
structures. The process involves minimising the difference between a crystallographic 
model and experimental data, via a least squares refinement; such intricate modelling of 
the height, width and position of Bragg reflections in an X-ray diffraction pattern can 
yield a lot of information about the crystal structure of a material. 
 
5.2 Fourier-Transform Infrared Spectroscopy (FTIR) 
Infrared spectroscopy (IR spectroscopy) is the subset of spectroscopy that deals with the 
infrared region of the electromagnetic spectrum. The infrared portion of the 
electromagnetic spectrum is divided into three regions; the near-, mid- and far- infrared, 
named for their relation to the visible spectrum.  
The far- infrared, approximately 400-10 cm-1 (1000-30 µm), lying adjacent to the 
microwave region, has low energy and may be used for rotational spectroscopy. The mid-
infrared, approximately 4000-400 cm-1 (30-1.4 µm) may be used to study the fundamental 
vibrations and associated rotational-vibrational structure. The higher energy near-IR, 
approximately 14000-4000 cm-1 (1.4-0.8 µm) can excite overtone or harmonic vibrations. 
Infrared spectroscopy exploits the fact that molecules have specific frequencies at which 
they rotate or vibrate corresponding to discrete energy levels (Fig. 3). These resonant 
frequencies are determined by the shape of the molecular potential energy surfaces the 
masses of the atoms and, by the coupling of vibrational and electronic interactions in the 
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molecule. Thus, the resonant frequencies can be in a first approach related to the strength 
of the bond, and the mass of the atoms at either end of it. Thus, the frequency of the 
vibrations can be associated with a particular bond type and can be used for the 
characterization of very complex mixtures. 
The infrared spectra of a sample is collected by passing a beam of infrared light through 
the sample. Examination of the transmitted light reveals how much energy was absorbed 
at each wavelength. This can be done with a monochromatic beam, which changes in 
wavelength over time, or by using a Fourier transform instrument to measure all 
wavelengths at once. From this, a transmittance or absorbance spectrum can be produced, 
showing at which IR wavelengths the sample absorbs. Analysis of these absorption 
characteristics reveals details about the molecular structure of the sample. 
 
Fig. 3. Possible vibrations detected by infrared spectroscopy 	  
The method employed for sample preparation is to grind a quantity of the sample with 
potassium bromide finely (to remove scattering effects from large crystals), which is used 
also as a reference. This powder mixture is then crushed in a mechanical die press to form 
a translucent pellet through which the beam of the spectrometer can pass. A reference is 
used for two reasons: 
1. This prevents fluctuations in the output of the source affecting the data; 
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2. This allows the effects of the solvent to be cancelled out (the reference is usually 
pure solvent) 
 
The equipment employed in the present work was a Thermo Nicolet-Avatar 320 FT-IR 
 
5.3 Inductively Coupled Plasma Atomic Emission Spectroscopy (ICP- AES) 
ICP-AES, also referred to as Inductively Coupled Plasma Optical Emission Spectrometry 
(ICP-OES), is a type of emission spectroscopy that uses a plasma (e.g. inductively 
coupled plasma) to produce excited atoms that emit electromagnetic radiation at a 
wavelength characteristic of a particular element. The intensity of the radiation is 
proportional to the concentration of the element, which is obtained through a previous 
calibration obtained with opportune standard solutions. An inductively coupled plasma 
(ICP) for spectrometry is sustained in a torch that consists of three concentric tubes, 
usually made of quartz. The end of this torch is placed inside an induction coil supplied 
with a radio-frequency electric current. A flow of argon gas is introduced between the two 
outermost tubes of the torch and an electrical spark is applied for a short time to introduce 
free electrons into the gas stream. These electrons interact with the radio-frequency 
magnetic field of the induction coil and are accelerated first in one direction, then the 
other, as the field changes at high frequency. The accelerated electrons collide with argon 
atoms, and sometimes a collision causes an argon atom to part with one of its electrons. 
The released electron is in turn accelerated by the rapidly- changing magnetic field. The 
process continues until the rate of release of new electrons in collisions is balanced by the 
rate of recombination of electrons with argon ions (atoms that have lost an electron). This 
produces a ‘fireball’ that consists mostly of argon atoms with a rather small fraction of 
free electrons and argon ions. The samples to be analyzed are firstly solubilized and then 
introduced into the hot region through an atomizer. The temperature of the plasma is very 
high, of the order of 10.000 K, so that the atomization of the sample is nearly complete, 
improving the accuracy of the analysis. Moreover, the carrier gas is inert (usually argon), 
so preventing the formation of oxides. As a droplet of atomized sample enters the central 
channel of the ICP, it evaporates and any solids that were dissolved in the liquid vaporize 
and then break down into atoms. At the temperatures prevailing in the plasma a 
significant proportion of the atoms of many chemical elements are ionized, each atom 
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losing its most loosely-bound electron to form a singly charged ion. 
The equipment employed in the present work was a Liberty 200, Varian, Clayton South, 
Australia. 
 
5.4 Scanning Electron Microscopy (SEM) 
The scanning electron microscope (SEM) is a type of electron microscope that creates 
various images by focusing a high energy beam of electrons onto the surface of a sample 
and detecting signals from the interaction of the incident electrons with the sample's 
surface. The types of signals gathered in a SEM vary and can include secondary electrons, 
characteristic x-rays, and back scattered electrons (Fig. 4). In a SEM, these signals come 
not only from the primary beam impinging upon the sample, but from other interactions 
within the sample near the surface.  
The SEM is capable of producing high-resolution images of a sample surface in its 
primary use mode, secondary electron imaging. Due to the manner in which this image is 
created, SEM images have great depth of field yielding a characteristic three-dimensional 
appearance useful for understanding the surface structure of a sample. This great depth of 
field and the wide range of magnifications are the most familiar imaging mode for 
specimens in the SEM. 
 
 
 
Fig. 4. Signals produced by the interaction of the electron beam with the sample. 
 
Chapter 5 
 
 
 
85 
Characteristic X-rays are emitted when the primary beam causes the ejection of inner 
shell electrons from the sample and are used to tell the elemental composition of the 
sample. The back-scattered electrons emitted from the sample may be used alone to form 
an image or in conjunction with the characteristic X-rays as atomic number contrast clues 
to the elemental composition of the sample. 
In a typical SEM, thermo-ionic electrons are emitted from a tungsten cathode and are 
accelerated towards an anode (Fig. 5).  
Tungsten is used because it has the highest melting point and lowest vapour pressure of 
all metals, thereby allowing it to be heated for electron emission. The electron beam, 
which typically has an energy ranging from a few hundred eV to 100 keV, is focused by 
one or two condenser lenses into a beam with a very fine focal spot sized 0.4 nm to 5 nm. 
The beam passes through pairs of scanning coils or pairs of deflector plates in the electron 
optical column, typically in the objective lens, which deflect the beam horizontally and 
vertically so that it scans in a raster fashion over a rectangular area of the sample surface. 
When the primary electron beam interacts with the sample, the electrons lose energy by 
repeated scattering and absorption within a teardrop-shaped volume of the specimen 
known as the interaction volume, which extends from less than 100 nm to around 5 µm 
into the surface. The size of the interaction volume depends on the electrons’s landing 
energy, the atomic number of the specimen and the specimen's density. The energy 
exchange between the electron beam and the sample results in the emission of electrons 
and electromagnetic radiation, which can be detected to produce an image, as described 
below. 
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Fig. 5. Scheme of a Scanning Electron Microscope. 
 
Detection of secondary electrons 
The most common imaging mode monitors low energy (< 50 eV) secondary electrons. 
Due to their low energy, these electrons originate within a few nanometers from the 
surface. The electrons are detected by a scintillator-photomultiplier device and the 
resulting signal is rendered into a two-dimensional intensity distribution that can be 
viewed and saved as a digital image. This process relies on a raster-scanned primary 
beam. The brightness of the signal depends on the number of secondary electrons 
reaching the detector. If the beam enters the sample perpendicular to the surface, then the 
activated region is uniform about the axis of the beam and a certain number of electrons 
"escape" from within the sample. As the angle of incidence increases, the "escape" 
distance of one side of the beam will decrease, and more secondary electrons will be 
emitted. Thus steep surfaces and edges tend to be brighter than flat surfaces, which results 
in images with a well-defined, three-dimensional appearance. Using this technique, 
resolutions less than 100 nm are possible. 
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Resolution of the SEM 
The spatial resolution of the SEM depends on the size of the electron spot, which in turn 
depends on both the wavelength of the electrons and the magnetic electron-optical system 
which produces the scanning beam. The resolution is also limited by the size of the 
interaction volume, or the extent to which the material interacts with the electron beam. 
The spot size and the interaction volume both might be large compared to the distances 
between atoms, so the resolution of the SEM is not high enough to image individual 
atoms, as is possible in the shorter wavelength (i.e. higher energy) transmission electron 
microscope (TEM). The SEM has compensating advantages, though, including the ability 
to image a comparatively large area of the specimen; the ability to image bulk materials 
(not just thin films or foils); and the variety of analytical modes available for measuring 
the composition and nature of the specimen. 
The equipment employed in the present work was a Stereoscan 360, Leica, Cambridge, 
UK. 
 
Energy dispersive X-ray spectroscopy (EDS) 
EDS (or EDX) is an analytical technique, coupled with the SEM equipment, used 
predominantly for the elemental analysis or chemical characterization of a specimen. 
Being a type of spectroscopy, it relies on the investigation of a sample through 
interactions between electromagnetic radiation and matter, analyzing X-rays emitted by 
the matter in this particular case. Its characterization capabilities are due in large part to 
the fundamental principle that each element of the periodic table has a unique atomic 
structure allowing X-rays that are characteristic of an element's atomic structure to be 
uniquely distinguished from each other. To stimulate the emission of characteristic X-rays 
from a specimen, an high energy beam of charged particles such as electrons or protons, 
or a beam of X-rays, is focused into the sample to be characterized. At rest, an atom 
within the sample contains ground state (or unexcited) electrons situated in discrete 
energy levels or electron shells bound to the nucleus. The incident beam may excite an 
electron in an inner shell, prompting its ejection and resulting in the formation of an 
electron hole within the atom’s electronic structure. An electron from an outer, higher-
energy shell then fills the hole, and the difference in energy between the higher-energy 
shell and the lower energy shell is released in the form of an X-ray. The X-ray released by 
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the electron is then detected and analyzed by the energy dispersive spectrometer. These 
X-rays are characteristic of the difference in energy between the two shells, and of the 
atomic structure of the elements form which they were emitted. 
A detector is used to convert X-ray energy into voltage signals; this information is sent to 
a pulse processor, which measures the signals and passes them onto an analyzer for data 
display and analysis. The equipment employed in the present work was an INCA 300, 
Oxford Instruments, UK. 
 
5.5 Thermogravimetric and Thermoanalytical analyses (TG-DTA) 
Thermogravimetric Analysis or TGA is a type of testing that is performed on samples to 
determine changes in weight in relation to change in temperature. Such analysis relies on 
a high degree of precision in three measurements: weight, temperature, and temperature 
change. As many weight loss curves look similar, the weight loss curve may require 
transformation before results may be interpreted. A derivative weight loss curve can be 
used to tell the point at which weight loss is most apparent. The analyzer usually consists 
of a high-precision balance with a pan loaded with the sample. The sample is placed in a 
small electrically heated oven with a thermocouple to accurately measure the temperature. 
The atmosphere may be purged with an inert gas to prevent oxidation or other undesired 
reactions. A computer is used to control the instrument. Analysis is carried out by raising 
the temperature gradually and plotting weight against temperature. After the data is 
obtained, curve smoothing and other operations may be done such as to find the exact 
points of inflection. 
 
Differential thermal analysis (or DTA) is a thermoanalytic technique. In DTA, the 
material under study and an inert reference (Al2O3 in our case) are heated (or cooled) 
under identical conditions, while recording any temperature difference between sample 
and reference. This differential temperature is then plotted against time, or against 
temperature (DTA curve or thermogram). Changes in the sample, either exothermic or 
endothermic, can be detected relative to the inert reference. Thus, a DTA curve provides 
data on the transformations that have occurred, such as phase transitions, glass transitions, 
crystallization, melting and sublimation. The area under a DTA peak can be to the 
enthalpy change and it is not affected by the heat capacity of the sample. A DTA 
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apparatus consists of a sample holder comprising thermocouples, sample containers and a 
ceramic or metallic block; a furnace; a temperature programmer; and a recording system. 
The key feature is the existence of two thermocouples connected to a voltmeter. One 
thermocouple is placed in the inert reference material, while the other is placed in a 
sample of the material under study. As the temperature is increased, there will be a brief 
deflection of the voltmeter if the sample is undergoing a phase transition. This occurs 
because the input of heat will raise the temperature of the inert substance, but be 
incorporated as latent heat in the material changing phase. 
The equipment employed in the present work was a Netzsch Gerätebau Jupiter STA 
(Simultaneous Thermal Analysis) 449C, Selb, Germany. 
 
5.6 Powder Analysis 
5.6.1 Specific surface area  
Specific surface area is a material property of solids which measures the total surface area 
per unit of mass, solid or bulk volume, or cross-sectional area. It is a derived scientific 
value that can be used to determine the type and properties of a material (e.g. soil). It is 
defined either by surface area divided by mass (with units of m2/kg), or surface area 
divided by the volume (units of m2/m3 or m-1). The SSA can be measured by adsorption 
using the BET isotherm. This has the advantage of measuring the surface of fine 
structures and deep texture on the particles. BET theory is a well-known rule for the 
physical adsorption of gas molecules on a solid surface, that is basis for an important 
analysis technique for the measurement of the specific surface area of a material. In 1938, 
Stephen Brunauer, Paul Hugh Emmett, and Edward Teller published an article about the 
BET theory in a journal for the first time; “BET” consists of the first initials of their 
family names. The concept of the theory is an extension of the Langmuir theory, which is 
a theory for monolayer molecular adsorption, to multilayer adsorption with the following 
hypotheses: (a) gas molecules physically adsorb on a solid in layers infinitely; (b) there is 
no interaction between each adsorption layer; and (c) the Langmuir theory can be applied 
to each layer. The resulting BET equation is expressed by (1): 
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P and P0 are the equilibrium and the saturation pressure of adsorbates at the temperature 
of adsorption, v is the adsorbed gas quantity (for example, in volume units), and vm is the 
monolayer adsorbed gas quantity. c is the BET constant, which is expressed by (2): 
 
	  
 
E1 is the heat of adsorption for the first layer, and EL is that for the second and higher 
layers and is equal to the heat of liquefaction. Equation (1) is an adsorption isotherm and 
can be plotted as a straight line with 1 / v[(P0 / P) − 1] on the y-axis and φ = P / P0 on the 
x-axis according to experimental results. This plot is called a BET plot. The linear 
relationship of this equation is maintained only in the range of 0.05 < P/P0 < 0.35. The 
value of the slope A and the y-intercept I of the line are used to calculate the monolayer 
adsorbed gas quantity vm and the BET constant c.  
The following equations can be used: 
 
 
The BET method is widely used in surface science for the calculation of surface areas of 
solids by physical adsorption of gas molecules.  
A total surface area Stotal and a specific surface area S are evaluated by the following 
equations: 
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where N is Avogadro’s number, s is the adsorption cross section, V is the molar volume 
of adsorbent gas and a is the molar weight of adsorbed species. The equipment adopted in 
the present work was a Sorpty 1750, Carlo Erba, Milano, Italy. 
 
5.6.2 Granulometric Analysis 
The behaviour of particles which, subjected to gravity force, drop and sediment when 
immersed in a liquid medium (generally water), is a very common method to determine 
particles dimensions. It is a versatile method because it is efficient for a huge range of 
materials and because it permits to analyze dimensions lower than microns. 
The most simple case occurs when spherical particles sediment with laminar motion with 
a constant speed.  
The relationship between drop speed and particles dimensions is defined by the Stoke’s 
law: 
D2 = 18 νη/(ρ - ρ0) g 
 
Where:  
D = diameter of spherical particles (cm)  
ν = drop speed (cm/sec)  
η = viscosity of the fluid (g cm-1 sec-1)  
ρ = density of the sedimenting material (g/cm3)  
ρ0 = density of the fluid (g/cm3)  
g = acceleration of gravity (= 981 cm/sec2) 
 
The analysis is based on the Stoke’s law with the hypotheses that the particles are 
spherical and that the drop speed is in function only of their dimensions. The suspension 
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is stirred by a magnetic stirrer and poured in the cell of analysis through a peristaltic 
pump, providing for a continuous refill of the cell with the suspension. The refill stops 
when the sedimentation begins. The apparatus uses an X-ray beam to test the 
transparency of the suspension. 
So, as soon as the analysis begins, the beam measures the transparency in the lowest part 
of the cell, and then the cell is moved upward, in order to reduce the sedimentation speed 
of the finest particles (slow sedimentation). This kind of analysis is easy for the 
instrument employed, but the suspension need to be very carefully prepared, because the 
powder needs to be disaggregated and the suspension stable. The equipment adopted is a 
Sedigraph 5100, Micromeritics, Norcross, GA. 
 
5.7 Mechanical properties 
Compressive strength is the capacity of a material or structure to withstand axially 
directed pushing forces. It provides data (or a plot) of force vs deformation for the 
conditions of the test method. When the limit of compressive strength is reached, brittle 
materials are crushed. By definition, the compressive strength of a material is that value 
of uniaxial compressive strech reached when the material fails completely.  
The easier-to-handle transverse test is used to determine the compressive strength of 
ceramics materials. The specimen is loaded up to failure.  
For ceramic specimens the test is performed on cylindrical porous specimens, 12 mm x 18 
mm (diameter x height), with a crosshead speed of 2 mm/min. To avoid stress 
concentration, a thin paper foil was inserted between each end of the specimen and the 
loading plates of the machine.  
The compressive strength was calculated from the maximum load registered during the 
test (Pmax) divided by the original area (A). 
 
σc = Pmax /A 
 
The maximum stress at fracture is commonly referred to as fracture strength. Five 
specimens were tested for each batch.  
Apparatus for ceramics specimens: Zwich/Roell Z050 machine (ULM, Germany). 
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Young’s Modulus 
Young’s Modulus of Elasticity is defined as the ratio of stress (force per unit area) to 
corresponding strain (deformation) in a material under tension or compression. 
Elastic modulus is sometimes called Young's modulus after Thomas Young who 
published the concept back in 1807. An elastic modulus (E) can be determined for any 
solid material and represents a constant ratio of stress and strain (a stiffness): 
 
E  =  σ/ε  	  
where σ = stress and ε = strain. 
 
A material is elastic if it is able to return to its original shape or size immediately after 
being stretched or squeezed. Almost all materials are elastic to some degree as long as the 
applied load does not cause it to deform permanently. Thus, the "flexibility" of any object 
or structure depends on its elastic modulus and geometric shape. A static method to test 
Young’s modulus of a material basically consists in measuring the slope of its stress-
strain plot within the elastic range (as shown in Fig. 6). 
 
 
 
Fig. 6. Stress-Strain Plot Showing the Elastic Range 
 
The initial straight-line portion of the curve is the elastic range. If the material is loaded to 
any value of stress in this part of the curve, it will return to its original shape. Thus, the 
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modulus of elasticity is the slope of this part of the curve. It is important to remember that 
a measure of a material's modulus of elasticity is not a measure of strength.  
Strength is the stress needed to break or rupture a material (as illustrated in Fig. 6), 
whereas elasticity is a measure of how well a material returns to its original shape and 
size. 
 
5.8 Magnetic measurement 
5.8.1 Magnetic Susceptibility 
Based on their magnetic properties, all substances can be classified into one of three 
groups, those attracted by a strong magnetic field, known as paramagnetic, those 
repelled, designated diamagnetic, and, finally, the most recognised class, ferromagnetic, 
unique in their ability to retain their own magnetic field. Ferromagnets are able to retain a 
permanent magnetic field since their free electrons are in close proximity and remain 
aligned even after the external magnetic field is removed. Unlike the ferromagnets, the 
magnetic properties of the diamagnetic or paramagnetic materials could only be observed 
and measured when these samples are held within a magnetic field applied externally. 
In electromagnetism the magnetic susceptibility χ is defined as the ratio of the intensity of 
magnetism induced in a substance to the magnetising force or intensity of field to which it 
is subject.  
The volume susceptibility χv is defined by: 	  
χv = I/H 
 
Where: 
I = Intensity of magnetism produced in a substance 
H= Intensity of magnetic field applied externally 
The Mass Susceptibility (χg) is defined by: 	  
χg = χv/ d 
Where: 
d = Density of substances 
The nature of the electrons within a sample determines the magnetic properties. The 
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magnetic forces that are generated are more less neutralised when two electrons become 
paired. Free unpaired electrons give rise to magnetic forces which are attracted to a strong 
magnetic field, and the strength of these attractive forces are in direct proportion to the 
number of free electrons. The presence of free electrons results in materials being 
classified as paramagnetic and the lack of them results in a compounds being 
diamagnetic. Crystallinity, chemical reactions, oxidation states, and virtually anything 
that can alter the electronic configuration of a compound, may also change the magnetic 
properties. Analogous to spectral measurements, magnetic susceptibility measurements 
are both qualitative and quantitative in nature. 
Magnetic Susceptibility values of the powders at low field was measured at 34 x 10-4 N 
A-1 m-1 via a YSZ 01C/02C Susceptometer (Sartorius Mechatronics, Italy) 
In this procedure, the interaction between a permanent magnet and the weight being 
tested is determined as a weight using a high-resolution mass comparator. Taking into 
account the known properties of the test magnet, the distance of the weight from the test 
magnet and the weight geometry, the desired magnetic quantities of the weight can be 
calculated. At the core of the susceptometer is a Sartorius mass comparator with a 
resolution of 10µg or 1µg. This is securely mounted on a stable base plate and surrounded 
by a housing that is resistant to air and temperature changes and holds the loading 
platform onto which samples are placed.  
Susceptometer is used to determine both the magnetic susceptibility and the permanent 
magnetization of weakly-magnetized weights through measurement of the force exerted 
on a mass standard in the magnetic field gradient of a strong permanent magnet. The 
direction that magnetic field moves indicates whether the sample is paramagnetic or 
diamagnetic which is shown by a plus or minus indication on the display balance.  
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CHAPTER 6 
 
MAGNETIC Fe2+/Fe3+ DOPED 
HYDROXYAPATITE (FeHA) 
 
The first step in the development of a bone-like biomaterial concerns the synthesis of a 
powder having chemical and physical properties as much as possible corresponding to the 
ones of the inorganic component of bone tissue. Thus, the above-mentioned powder 
should be biomimetic and suitable for the production of devices able to integrate with 
living tissues and, simultaneously, stimulate new bone growth. 
A synthesis of a magnetic biomimetic apatitic powder has been optimized in order to 
introduce iron ions into the cell structure, rising higher bioactivity and bioreabsorbibility 
in comparison to stoichiometric hydroxyapatite. 
Numerous stoichiometric HA synthesis techniques have been developed1. The most 
commonly used are the wet method in aqueous solution by precipitation2,3, or the 
technique of hydrolysis of acid calcium phosphate salts4,5. The former is a wet 
neutralization reaction that allows to precipitate pure apatites with controlled crystallinity 
degree in function of nucleation temperature and ripening.  
To prepare a stoichiometric hydroxyapatite calcium hydroxide and phosphoric acid was 
used as reagents in suitable stoichiometric ratio according to the following reaction: 
 
10Ca(OH)2 + 6H3PO4 → Ca10(PO4)6(OH)2 ↓ + 18H2O 
 
The synthesis process above described was also used to develop magnetic FeHA powder. 
For this purpose both iron species (Fe2+ and Fe3+) were introduced in form of soluble iron 
salts in the synthesis process; in this way the substitution of specific Ca crystallographic 
sites with a specific coordination6 by iron ions generates in the apatitic lattice two 
different sublattices whose interaction induce superparamagnetic behaviour7.  
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With this aim a synthetic procedure to obtain a magnetic (Fe2+/Fe3+)-lattice substituted 
HA has been developed and optimized, minimizing the formation of magnetite as 
secondary phase. 
 
6.1 Synthesis of FeHA powder 
The synthesis of magnetic FeHA powders was carried out by employing calcium 
hydroxide (Ca(OH)2, 95wt% pure) and phosphoric acid (H3PO4, 85wt% pure), with the 
addition of iron(III) chloride hexahydrate (FeCl3·6H2O, 97wt% pure) and iron(II) chloride 
tetrahydrate (FeCl2·4H2O, ≥ 99wt% pure), as sources of Fe3+ and Fe2+ ions respectively, 
in aqueous solution; all reactants were provided by Sigma-Aldrich (S. Louis, MO, USA). 
The amount of reactants was set up in order to keep the calcium/phosphorus ratio equal to 
1.667, so that a competition between Ca2+, PO43- and the substituting ions (Fe3+ and Fe2+) 
could be established. The total amounts of Fe ions with respect to Ca ions were adjusted 
so as to obtain Fe/Ca=20 mol%.  
In details a phosphoric acid (44.40 g in 300 ml H2O) solution was added dropwise into a 
basic suspension of calcium hydroxide (50 g in 400 ml H2O) containing Fe ions, over a 
period of 2 h, under constant heating and stirring. To study the relationship between the 
synthesis parameters and physicochemical properties of the powders, the process was 
carried out in the temperature range 25-60 °C and pH decreased from 12 to 5 during 
neutralization.	   
 
 
Fig. 1. Equipment for the synthesis of FeHA powder 
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During synthesis, a brownish precipitate formed; after the dripping of the phosphate 
solution was completed, the precipitate was left to ripen and decant in the mother liquor 
for 24 hours (Fig. 1), then the supernatant was eliminated and the cake-like product was 
washed three times in 1 litre of distilled water and centrifuged. The product was freeze-
dried and sieved under 150 µm. 
To obtain a magnetic iron doped hydroxyapatite, three synthesis methods based on the Fe 
source added to calcium hydroxide suspension have been developed and investigated 
starting by the synthesis method above described.   
 
Method 1: reductive process 
FeCl3·6H2O (35.72 g in 150 ml H2O) was used as a source of Fe3+ ions to substitute Ca2+ 
during the nucleation of HA, carried out at 40 °C. A reductive process was subsequently 
applied on the freeze-dried and sieved material to convert some of the Fe3+ into Fe2+ ions 
and to maintain both species in the HA lattice. The process was performed at 300 °C in a 
closed autoclave (Parr, Alloy C276) for 1 h under continuous stirring. A gas mixture 
Ar/H2 (96:4) was used as a reductive atmosphere at different pressures: 0.1 Mpa (sample 
A), 1.9 MPa (sample B) and 2.8 MPa (sample C). The features of the obtained samples 
are reported in Table I (p. 104) 
 
Method 2: oxidative process 
FeCl2·4H2O (25.48 g in 150 ml H2O) was used as a source of Fe2+ ions and HA was 
synthesized, exploiting the spontaneous oxidation of Fe2+ ions, due to the reaction 
environment. Different synthesis temperatures were tested: 25, 40 and 60 °C; the 
respective products were coded D, E and F (see Table II p.104).  
 
Method 3: simultaneous addition 
FeCl2·4H2O (12.74 g in 75 ml H2O) and FeCl3·6H2O (17.86 g in 75 ml H2O) were added 
together to calcium hydroxide suspension as sources of Fe2+ and Fe3+ ions during the 
neutralization process. Different synthesis temperatures were investigated (25, 40 and 60 
°C) and and the synthesis products identified as samples G, H (Fig. 2) and K, respectively 
(Table III p.104).  
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  a)    b) 
Fig. 2. a) FeHA powder (sample H) obtained by synthesis method 3 at T= 40°C; b) FeHA powder (sample 
H) attracted by a magnet. 	  
6.2 Chemical, structural and magnetic characterizations of FeHA powder 
The as-prepared FeHA powders were characterized by several analytical techniques (see 
also Chapter 5). 
The phase composition was determined by X-ray powder diffraction (XRD), performed 
by a D8 Advance Diffractometer (Bruker, Karlsruhe, Germany) using CuKa radiation at 
40kV and 40mA. XRD spectra were recorded in the 2h range 10-60° or 15-120°, with a 
step size of 0.02 and a counting time of 1 second (corresponding to 185 seconds using a 
conventional detector). Quantitative evaluation of phase compositions and cell parameters 
was performed by full- profile Rietveld analysis of the XRD spectrum (TOPAS v. 4.2, 
Bruker AXS, Karlsruhe, Germany). Computer simulation of XRD patterns of FeHA 
powders based on structural models was carried out by the aid of the software Powder cell 
2.4 (W. Krause and G. Nolze, 2000). 
Quantitative inductively coupled plasma-atomic emission spectrometry (ICP-OES) 
analysis, using an (ICP-OES: Liberty 200, Varian, Clayton South, Australia), was applied 
to determine the overall content of Ca, P and Fe. The samples for ICP analysis were 
prepared dissolving 20 mg of powder in 2 ml of HNO3 (Aldrich, 65 wt.% pure) and the 
solution volume was increased up to 100 ml with deionized water. A reference solution 
was prepared by mixing standard solutions containing the investigated atoms at the 
expected concentrations. An equally diluted solution of nitric acid was also analysed and 
the corresponding spectrum subtracted by the experimental one. 
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The amount of Fe2+ present in the HA lattice was measured by a colorimetric method8 
based on the use of orthophenantroline (Merck 1,10-phenantroline, P99% pure): ferrous 
ions in the presence of orthophenantroline form a stable red-orange complex 
[(C12H8N2)3Fe]2+ in the pH range 4-5; this complex is detectable at 510 nm by UV-
Visible spectrophotometry (Lambda 35 UV/VIS Spectrometer; Perkin Elmer Instrument, 
USA). The samples for UV/VIS analysis were prepared dissolving 20 mg of powder in 
0.8 ml of H2SO4 (Aldrich, 96 wt.% pure) after having verified that sulfuric acid did not 
affect the concentration of the Fe2+-complexed compound, at least in the time required to 
make the analysis. 10 ml of sodium citrate (0.5 M) were added to the solution containing 
sulfuric acid to set the pH around 4-5, then orthophenantroline (0.1 M) was added to the 
solution to set the molar ratio Fe2+/orthophenantroline at 1/3. The volume of the final 
solution was increased up to 50 ml using deionized water. 
An estimation of the amount of Fe3+ was performed calculating the difference between 
the total amount of Fe (determined by ICP) and the total amount of Fe2+ (determined by 
UV-VIS). The concentration of Fe2+ and Fe3+ associated to HA was derived by 
subtracting the contribution of Fe2+ and Fe3+ forming magnetite (detected by XRD and 
quantified by Rietveld refinement) from the total amount of Fe2+ and Fe3+ determined by 
ICP and UV analysis. 
To gain information about the local chemical environment of Fe, X-ray absorption 
spectroscopy (XAS) at the Fe K-edge has been performed at the SUL-X beamline of the 
synchrotron radiation source ANKA (Karlsruhe Institute of Technology; Karlsruhe, Ger- 
many). SUL-X is a beamline with a wiggler as radiation source. A Si (111) crystal pair 
with a fixed beam exit was used as a monochromator. Higher harmonics have been 
suppressed by a silicon mirror behind the double-crystal monochromator. The beam was 
focused on the sample position by Kirkpatrick-Baez mirrors to about 100 x 100 µm. Fe 
K-edge XAS data were acquired in transmission (with ionization chambers as detectors) 
and fluorescence modes. The Fe concentration of the FeHA samples was sufficient to use 
the transmission data for evaluation. Energy was calibrated using a 3 µm thick Fe foil 
mounted between the second and third ionization chambers to the first inflection point of 
the Fe K-edge at 7112 eV. A typical scan ranges from 150 to 50 eV with a 5 eV energy 
step width and from 50 to 20 eV with a 2 eV step width prior to the edge. In the edge 
region between 7092 and 7142 eV the step width has been decreased to 0.3 eV and above 
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the edge, in the EX- AFS region, up to k = 16, a k step width of 0.5 has been chosen. The 
measurement time per scan was 1 s, increasing with k =0.5 above the edge. Two scans 
have been performed on two different sample positions for FeHA-F and at one sample 
position for FeHA-H. Spectra were pre-edge and post-edge background corrected, and 
normalized to an edge jump of 1 using the Athena programme of the IFFEFIT package9. 
Reference spectra of magnetite (Fe3O4) and maghemite (c-Fe2O3) have been taken from 
the SUL-X reference database and these were obtained with similar parameters. 
The analysis of powder morphology was carried out by scanning electron microscopy 
(SEM; Stereoscan 360, Leica, Cambridge, UK).  
High-resolution transmission electron microscopy (HRTEM) analyses was performed by 
a JEOL JEM 3010-UHR, operating at 300 kV. As apatite samples might evolve under the 
electron beam, potentially leading to further crystallization and/or to a loss of constitutive 
water10, observations were carried out under feeble illumination conditions (significantly 
lower than that indicated in the literature) to avoid any modifications of the materials 
during the analysis. 
Magnetization (M) of FeHA powders at low field was measured at 34 x 10-4 N A-1 m-1 via 
a YSZ 01C/02C Susceptometer (Sartorius Mechatronics, Italy). Magnetic measurements 
were also performed at higher field in a superconducting quantum interference device 
(SQUID) magnetometer from Quantum Design (San Diego, CA, USA), capable of 
operating from 1.8 to 350 K under a maximum applied magnetic field of H = 5 N A-1 m-1 . 
In this case, about 20 mg of powder were measured from 5 to 300 K at an applied 
magnetic field of H = 0.01 N A-1 m-1 in order to obtain the magnetization vs. temperature 
(M vs. T) curves, while the magnetization vs. magnetic field (M vs. H) curves were 
measured in a magnetic field cycle from 2 to -2 N A-1 m-1 at T = 300 K. Measurements of 
magnetically induced heating were performed by placing each sample in the center of a 
coil of a homemade device generating an alternating magnetic field of 0.03 N A-1 m-1 at a 
frequency m = 293 kHz. 
 
6.2.1 Phase analysis by XRD 
XRD spectra reveal a low-crystalline apatite (ICDD card no. 09-0432) with a crystallinity 
extent much lower than the non-substituted HA prepared at the same temperature (see 
Figs. 3-5), while the presence and amount of secondary phases can be related to the 
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synthesis methods and parameters. 
XRD structural analysis confirms the substitution of Fe ions into the HA lattice. 
Computer simulations clearly indicate that the Fe ions found in the HA lattice are not 
situated at cell interstitial positions but at Ca-substituting positions (with small differences 
be- tween the 4f and 6h positions). In fact, the substitution of one Ca2+ ion by Fe2+ or 
Fe3+, both in 4f and 6h positions, has little effect on the intensity of the diffracted X-ray 
lines. On the other hand, the introduction of one Fe2+ or Fe3+ ion into one of the possible 
interstitial positions (2b, 2c, 2d, 4a and 6g) heavily modifies the line intensities, always 
making the calculated pattern rather different from the observed one and significantly 
increasing the discrepancy factor. It can be observed that even if the Fe substitution into 
the HA lattice does not remarkably twist the structure, the presence of Fe and/or Fe–O 
species during HA nucleation hampers the crystallite organization.  
 
 
Fig. 3. XRD profiles of the HA synthesized at T=40 °C and samples obtained by a reductive 
process at different pressures applied to a FeHA powder synthesized by method 1 at 
T=40°C. 	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Fig. 4. XRD profiles of the HA synthesized at T= 40 °C and FeHA synthesized by method 2 
at different temperatures (D=25°C; E=40°C; F=60°C). The peaks identified by * correspond 
to magnetite 	  
 
 
Fig. 5. XRD profiles of the HA synthesized at T= 40 °C and FeHA synthesized by method 3 
at different temperatures (G = 25 °C; H = 40 °C; K = 60 °C). The peaks identified by * 
correspond to magnetite. 	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The XRD analysis (Fig. 3) of the powders prepared following method 1 reveals no 
secondary phases apart from HA whose crystallinity increases with synthesis temperature: 
the degree of crystallinity is ~8% at 40°C and ~30% at 60°C10. 
The powders prepared following synthesis method 2 have characteristics strictly 
dependent on the synthesis temperature: the formation of magnetite starts at T = 40 °C as 
also reported in a previous work11. It follows that magnetite is absent in sample D and the 
HA crystallinity is very low (see XRD profiles in Fig. 4)12. 
Increasing the temperature causes the kinetics of both magnetite formation and apatite 
crystallization to increase: XRD patterns of samples E and F (Fig. 4) show the peak of 
magnetite at 2θ ≈ 36° which strengthens when the synthesis temperature is increased.  
The simultaneous addition of both Fe species makes both Fe2+ and Fe3+ available 
simultaneously during the first stage of the HA nucleation (synthesis method 3). In 
sample G (Fig. 4) magnetite is absent as expected for a synthesis temperature of 25 °C11; 
the crystallization extent of HA is very low and the lack of organization of the HA lattice 
reflects also the poor coordination level of the Fe ions substituting calcium. At T= 40 °C 
(sample H) the formation of magnetite is minimized when compared with method 2 since 
both ions preferentially enter the newly formed HA (Fig. 5).  
A further increase of the synthesis temperature up to 60°C (sample K) results detrimental: 
the doping efficiency lowers and the formation of magnetite slightly increases (Fig. 5).  
 
6.2.2 Chemical analysis by ICP 
Table I-II-III shows the results of the chemical analysis of the iron-substituted HA 
powders examined in this work. The chemical analysis performed on FeHA confirms the 
presence of Fe in the powders at a level of 90% with respect to the one nominally 
introduced as reagent. For all the prepared FeHA samples, the molar ratio (Fe + Ca)/P 
ranges between 1.61 and 1.73, while Ca/P ratio is lower than the theoretical one: 1.31 < 
Ca/P < 1.51, confirming the replacement of Ca with Fe. 
The highest effectiveness of Fe2+ and Fe3+ substitution into the HA lattice is reached in 
sample H where it approaches a nominal doping of 20 mol.%. The (Fe + Ca)/P ratio is 
1.68 which corresponds to the theoretical Ca/P ratio for HA, and the content of magnetite 
is only 1.6 vol.% (Table III). 
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FeHA 
Sample 
code 
Fetot 
wt% Fe3+ 
wt % 
Fe2+ 
wt % 
Fe3+/Fe2+ 
wt % 
Fe/Ca  
% mol. 
Ca/P 
mol. 
(Fe+Ca)/P 
mol. 
M  
Am2Kg-1 
A 10.42 6.28 4.14 1.52 27.92 1.31 1.68 0.00 
B 10.42 3.10 7.32 0.42 27.92 1.31 1.68 0.00 
C 10.42 0.83 9.59 0.09 27.92 1.31 1.68 0.00 	  
Table 1. Characteristics of powders prepared by method 1 + reductive process 
 
Magnetite FeHA 
Sample 
code 
Fetot 
wt.% vol.% wt.% Fetot 
wt.% 
Fe3+ 
wt.% 
Fe2+ 
wt.% 
Fe3+/Fe2+ 
wt.% 
Fe/Ca  
%mol. 
Ca/P 
mol. 
(Fe+Ca)/P 
mol. 
M  
Am2Kg-1 
D 
T=25°C 
8.71 0.0 0.0 0.0 7.41 1.30 5.70 22.78 1.41 1.73 0.00 
E 
T=40°C 
8.80 3.0 4.8 3.5 4.26 1.04 4.10 13.51 1.51 1.72 0.34 
F 
T=60°C 
9.09 5.5 8.7 6.7 0.32 2.47 0.13 6.97 1.49 1.61 0.56 
	  
Table 2. Characteristics of powders prepared by method 2 
 
Magnetite FeHA 
Sample 
code 
Fetot 
wt.% vol.% wt.% Fetot 
wt.% 
Fe3+ 
wt.% 
Fe2+ 
wt.% 
Fe3+/Fe2+ 
wt.% 
Fe/Ca  
%mol. 
Ca/P 
mol. 
(Fe+Ca)/P 
mol. 
M  
Am2Kg-1 
G 
T=25°C 
9.26 0.0 0.0 0.0 8.39 0.87 9.64 26.63 1.31 1.66 0.15 
H 
T=40°C 
9.93 1.6 2.6 1.9 6.03 2.00 3.01 19.89 1.41 1.68 0.95 
K 
T=60°C 
9.61 2.0 3.2 2.3 5.26 2.05 2.56 17.99 1.44 1.69 1.20 
 
Table 3. Characteristics of powders prepared by method 3 
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6.2.3 Magnetic and microstructural investigation 
In the synthesis method 1 iron is present into HA only in its higher oxidation state and the 
powder does not show any magnetisation signal. After application of the reductive 
process no magnetite-like phase forms as detected by XRD (Fig. 3) and magnetisation 
signal results zero for samples A, B and C (Table I). It can be supposed that the reduction 
of Fe3+ trapped into HA lattice, which occurs at the heterogeneous gas-solid interface, is 
not homogeneous throughout the whole bulk and cannot assure a balanced distribution of 
Fe2+ and Fe3+ inside the structure13.  
Detailed magnetic and microstructural characterizations were performed on samples E 
and H: zero-field-cooled (ZFC) and field- cooled (FC) magnetization curves as function 
of temperature were acquired under a high magnetic field (Fig. 6). Each sample shows 
behavior typical of a system of interacting magnetic particles14. The average blocking 
temperature, TB, is found to be around 170 K for sample H, while for sample E it is 
beyond the measured temperature (300 K). TB is closely related to the particle size and 
dipolar interparticle interactions and gets higher as the dipolar interactions increase. As a 
consequence of the formation of aggregates, the local concentration of nanoparticles and 
hence the strength of dipolar interparticle interactions increases, changing the energy 
barrier for magnetization relaxation and determining the collective magnetic behavior of 
the sample15. The significantly higher value of TB for sample E suggests the presence of 
larger magnetic aggregates (ascribable to magnetite as secondary phase) in respect to 
sample H. This is in agreement with the XRD analysis which reports a higher 
concentration of magnetite in sample E vs. sample H. 
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Fig. 6. Magnetization curves at zero-field-cooled (ZFC) and field-cooled (FC) in function of temperature. 
ZFC-FC magnetic curves for sample E (square symbol) and H (circle symbol) at an applied magnetic field 
of 100 Oe. 
 
In agreement with magnetization measurements, TEM analysis of sample H shows very 
low concentration of dark spots (5-10 nm in size) corresponding to inclusions of iron rich 
phases (Fig. 7a). For samples E and H the micrograph in Fig. 7b shows calcium 
phosphate particles with needle-like morphology, rather heterogeneous in size, 5-20 nm in 
width and up to 50-80 nm in length. 
The magnetization curves as function of the applied magnetic field for samples E and H 
(Fig. 9) show the typical superparamagnetic (SPM) behaviour of single-domain magnetic 
nanoparticles. Contrary to what expected on the basis of the amount and aggregate size of 
magnetite, the magnetization of saturation (Ms) of sample H (4.0 - 4.2 emu/g) is higher 
than sample E (1.8 - 2.0 emu/g). The 1.6 vol% of magnetite as secondary phase in sample 
H is not sufficient to justify such a magnetization value, therefore a contribute of another 
magnetic phase must be claimed.  
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Fig. 7. TEM micrographs. (a) sample H; (b) image 
representing the typical FeHA morphology of 
sample H and E. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 8. High Resolution TEM micrograph of sample 
H observed from the [2,0,1] zone axis of HA. The 
black arrow indicates the orientation of the c-axis of 
the FeHA lattice retrieved from the Fourier 
Transform of the image (inset); the white arrow 
points toward an amorphous region of the particle 	  
As a support for this assumption, HRTEM analysis on sample H reveals that the material 
is made up of both amorphous and crystalline HA domains elongated in the direction of 
the c-axis, that can even coexist in the same particle (Fig. 8 and relative inset). By EDS 
analysis (carefully choosing the apatitic matrix and avoiding the few iron oxides clusters) 
no evidence of iron-rich phases is found by a series of punctual analyses on sample H. 
Iron appears homogeneously dispersed in the materials likely in form of single ions 
substituting Ca2+ into the HA lattice. The total Fe content as well as the Ca/P ratios of the 
calcium phosphate phase for both powders E and H has been measured by EDS (carefully 
choosing those regions where no iron oxides particles were detected) and the results are 
nicely consistent with those obtained by ICP and XRD analyses reported in Tables II and 
III.  
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Fig. 9. Magnetic curves in function of the applied magnetic field up to 2 Tesla for the sample H (continue 
line) and E (dotted line) at T = 300 K. 
 
Fig. 10A contains the XANES spectra of FeHA powders (i.e. samples E and H), in 
comparison with magnetite and maghemite, selected as reference materials. In this 
respect, FeHAs gave XANES spectra that differ from those of magnetite and maghemite, 
particularly concerning the different features at energies in the range 7126-7155 eV. 
Because of the magnetite content in the samples E and H, X-ray absorption spectra are a 
superposition of Fe in FeHA and Fe in magnetite, so that the shape of the pure Fe K-edge 
spectra of FeHA cannot be extracted easily. Nevertheless, the differences in shape 
indicate that part of the Fe does not belong to magnetite or maghemite and hence can be 
assigned to FeHA. A shift in the absorption edge (flank and white line) from magnetite 
(containing both Fe ions) to maghemite (containing only Fe3+) can be observed and it can 
be related to different Fe3+/Fe2+ ratios. Looking at the curves in the range between 0.5 and 
1 of the edge jump, it is possible to notice that the flank and the maximum position of the 
white line shift from magnetite (Fe3+/Fe2+ ratio=2) to sample H (Fe3+/Fe2+ ratio=3), 
sample E (Fe3+/Fe2+ ratio=4) and last to maghemite (Fe3+/Fe2+ ratio = ∞).  
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A) 
 
B) 
 
Fig. 10. Fe K-edge X-ray absorption near edge (XANES) spectra with edge region in the inset (A) and 
Fourier Transform of the EXAFS function (B), both k2 weighted for samples E and H and the magnetite 
and maghemite reference substances. 
 	  	  
	  
In Fig. 10B the Fourier Transform for 3.5<k<9 of the EXAFS function (inset) for samples 
E and H, magnetite and maghemite standards are reported. Samples E and H show a 
higher intensity of the peak related to the first coordination shell and a shift of the bond 
length to higher values for both the first and the second shell when compared to 
maghemite and magnetite. This is in agreement with the bond length contraction from 
2.43Å to 2.04Å reported by Jiang et al.6 for substitution of Ca(1) with Fe3+ and also 
reinforces the conclusion that part of the iron is entering in the hydroxyapatite lattice. 
 
6.2.4 Hyperthermia effect of FeHA powder 
The evolution of heat versus time of exposure to magnetic field (hyperthermia) is reported 
in Fig. 11. Sample H exhibits an increase of temperature of about 40°C in 60s; the 
hyperthermia curves B and C are relative to magnetite mixed with stoichiometric HA, in 
the amount of 5/95 wt% and 10/90 wt% respectively. Fig. 11 gives evidence to a much 
higher hyperthermia effect for the magnetic FeHA powder in comparison with the 
magnetite/HA mixtures which exhibit lower increases of temperature in longer time. 
Since the two magnetite/HA mixtures contain higher amounts of magnetite (5 and 10 
wt%) compared to sample H (magnetite = 1.6 vol%, i.e. ≈ 2.6 wt%), the intense 
Magnetic Fe2+/Fe3+ doped Hydroxyapatite (FeHA) 
 	  
	  
112 
 
hyperthermia is not justifiable by the sole presence of magnetite in sample H and a bulk 
effect due to the existence of a new magnetic HA phase must be called into question. 
	  
 
Fig. 11. Hyperthermia curves: (A) sample H, (B) mixture of magnetite/HA (95/5wt%) and (C) mixture of 
magnetite/HA 10/90wt%. 
 
6.3 Development of FeHA granulate 
FeHA powder was processed in order to obtain a more stable granulate (400-600 µm) 
(Fig. 12). In detail, the powder was hydrated with distilled water and agglomerated. 
Agglomerates were dried at 40°C for 48 h and sieved in the range 400-600 µm. 
For the in vitro and in vivo tests glass vials containing 0.5 g of granulates were prepared 
and sterilized with 25 kGγ γ-ray.  
 
Fig. 12. FeHA granulates 
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6.4 Biocompatibility tests 
 
6.4.1 In vitro evaluation of biocompatibility and cell morphology 
In vitro test were performed on FeHA powder to verify any toxic effects induced by the 
magnetic material compared to the HA, keeping in mind its future in vivo applications. At 
this purpose the in vitro evaluation of the effects of the FeHA powder on osteoblast-like 
cell culture was conducted. In detail, 24 hours after Saos-2 cells were plated, 4 different 
concentrations of FeHA and HA, in a range from 200 µg/ml up to 2000 µg/ml, were 
added to the culture medium.  
The cell culture was analysed for 7 days for cell viability, with the Live/Dead assay 
showing for both FeHA and HA groups a very high ratio of viable cells at each 
experimental time point with no significant differences among the two groups, with a 
range respectively between 98.0 ± 0.5% and 100% at day 1, 96.7 ± 0.4% and 99.1 ± 0.5% 
at day 3, 97.3 ± 0.5% and 99.7 ± 0.2% at day 7 (Fig.13).  
Furthermore, the presence of FeHA powder in the cell culture media positively influences 
cell proliferation compared to HA powder. In fact, analysing the DNA content, significant 
differences are observed at day 3 and day 7 for FeHA and HA groups (Fig.14). While at 
day 1 there are no statistic significant difference among the superparamagnetic and the 
control nanoparticles, there is a trend showing a higher number of cells in FeHA groups 
compared to the HA groups. These data are in agreement with several studies where 
different types of magnetic particles were used and they influence cell proliferation16-18. 
The obtained results demonstrate the good biocompatibility of the FeHA powder. In fact 
not only they do not reduce the cell viability, they also enhance cell proliferation 
compared to respective HA groups. 
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Fig. 13. Analysis of cell viability. Cell viability was analysed by the Live/Dead assay (n = 2). Calcein AM 
stains for live cells in green, EthD-1 stains for dead cells in red. A) HA 1000 µg/ml at day 3. B) FeHA 1000 
µg/ml at day 3. C) HA 200 µg/ml at day 7. D) FeHA 200 µg/ml at day 7. Scale bars: A,B) 200 µm. C,D) 
100 µm. 
 
Fig. 14. Cell proliferation assay. The Picogreen DNA content assay was performed on cultures of 
osteoblast-like cells seeded with 4 different concentrations of HA and FeHA nanoparticles at 1, 3 and 7 
days of culture (n = 5). n.s. = not significant; *** p ≤ 0.001 
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Looking in detail at the cell morphology, FeHA nanoparticles seems to be accumulated in 
the cytoplasm (Fig. 15A,B) and even when the cells show high MNP accumulation they 
remain firmly attached to the well surface. This fact suggests that the novel intrinsically 
magnetic FeHA powder is well tolerated by the cells in a similar way as the HA groups, 
where HA serves as the main component of several bone substitutes already used in 
clinical applications, and have also been shown to induce cell proliferation. 
 
Fig. 15. Analysis of cell morphology. Cells are spread with good morphology and firmly attach to the 
surface. Black spots are the MNPs that have been internalized by cells. A) FeHA 500 µg/ml at day 3, cells 
stained with Calcein AM in green and EthD-1 in red. B) FeHA 200 µg/ml at day 7, bright field image. Scale 
bars: 50 µm. 
 
6.4.2 Effect of the in vitro application of a static magnetic field 
After demonstrating the similar biocompatibility of FeHA and HA particles, the presence 
of an externally applied static magnetic field (SMF) was investigated in order to study 
how it could modulate the cell proliferative effects and bone regenerative capacity 
induced by this FeHA material. All the experiments were conducted with or without 
applying a 320 mT SMF on cells seeded with the 4 different concentrations of FeHA 
particles. 
In the literature, there have been far fewer studies on the cellular effects of static magnetic 
field at the cellular level, compared to those of extremely low frequency electromagnetic 
fields. While several studies showed that exposure to static magnetic fields alone has no 
or extremely small effects on cell growth and genetic toxicity regardless of the magnetic 
density, in combination with other external factors such as ionizing radiation and some 
chemicals, there is evidence to strongly suggest that a SMF modifies their effects19. The 
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results obtained are strongly in agreement with these data. In fact, after confirming that 
SMF on cells in culture by itself does not affect cell behaviour (data not shown), data with 
FeHA MNPs confirm a statistically significant increase in cell proliferation from day 1 to 
day 7 between FeHA groups with SMF application compared to groups without magnetic 
field application (Fig. 16). In detail, the 200 µg/ml FeHA powder concentration induce a 
higher cell proliferation compared to the 2000 µg/ml FeHA powder only with exposure to 
the SMF, suggesting that the lowest concentration of FeHA particles acts synergy with 
the magnetic field to stimulate cell proliferation (Fig. 16). 
 
 
Fig. 16. Cell proliferation assay in the presence of a static magnetic field. The Picogreen DNA content 
assay was performed on cultures of osteoblast-like cells seeded with 4 different concentrations of FeHA 
MNPs at 1, 3 and 7 days of culture, either in the presence or absence of a static magnetic field (SMF) (n = 
5). ** p ≤ 0.01; *** p ≤ 0.001. 
 
 
Furthermore, with respect to osteoblast activity on each condition, AP activity seems to 
be influenced by the synergic effect of FeHA and SMF, with a significant effect at day 3, 
indicating that there might be also a positive effect on osteoblast activity given by the 
presence of SMF (Fig. 17). 
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Fig. 17. Alkaline phosphatase activity assay in the presence of a static magnetic field. AP activity was 
measured with different concentrations of FeHA seeded with human osteoblast-like cells at 1, 3 and 7 days, 
either in the presence or absence of a static magnetic field (SMF) (n = 5). * p ≤ 0.05. 	  
6.4.3 In vivo pilot experimental and histological analysis 
In order to assess how well in vitro observations translate in vivo, the biocompatibility of 
FeHA materials in a pilot animal study of bone repair (a rabbit critical bone defect model) 
has been tested. For this purpose FeHA powder was processed in order to obtain a 
granulate (400-600 µm) more easily handled and similar to bone fillers already used in 
clinical applications (see paragraph 6.3). The FeHA granules were not stabilized with the 
same thermal treatment applied to the reference material to avoid chemico-physical 
modification of the nanostructure. 
The control group consist of a bone filler made of HA granulate of identical size (400- 
600 µm), already commercially available, and stabilized for one hour at 300°C 
(FinGranule, Finceramica Faenza Spa, Italy). 
The study was performed in accordance with EC guide-lines (EC Council Directive 
86/609, 1986) and the Italian legislation on animal experimentation (Decreto L.vo 
116/92). The research protocol on animals has been approved by the Ethical Committee 
of Rizzoli Orthopaedic Institute and by the responsible public authorities.  
Six male rabbits (Oryctolagus cuniculus, Charles River, Lecco,Italy), 2.4 ± 0.2 kg body 
weight, were housed at a controlled temperature of 22 ± 1°C and relative humidity of 55 ± 
5% in single boxes and fed a standard diet (Mucedola, Milano, Italy) with filtered tap 
water ad libitum. After quarantine of at least 10 days, the animals were fasted for 24 
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hours before surgery. The animals were subjected to surgery to implant the tested 
biomaterials at the distal femoral epiphysis under general anaesthesia and in aseptic 
conditions. After having shaved and disinfected the posterior legs, the animals underwent 
a lateral longitudinal incision of lateral femoral condyle. Femoral lateral condyle 
trabecular bone was cross-sectionally drilled at low speed and a profuse irrigation with 
cold sterile 0.9% NaCl solution was maintained throughout the process to prevent the risk 
of bone necrosis. A critical bone defect of 6.00 mm in diameter and 8.00 mm in depth 
was made in each lateral femoral condyle. Defects were filled with FeHA granules and 
with the HA granules in the contralateral condyle as a control group. For each defect, 
approximately 0.5 g granules, sterilized by 25 kGγ γ-ray radiation, were used. Finally, the 
skin was sutured. General anaesthesia was induced by an intramuscular injection of 44 
mg/kg ketamine (Imalgene 1000, Merial Italia S.p.A, Milan, Italy) and 3 mg/kg xylazine 
(Rompun, Bayer SpA, Milano). 
 
	  
A) 
	  
B) 
Fig. 18. Histological evaluation of the in vivo implanted HA and FeHA granules. Toluidine Blue, Acid 
Fucsin and Fast Green staining shows similar histocompatibility for both biomaterials 4 weeks after 
implantation (n = 6). A) HA control group, B) FeHA group. Scale bars: 1 mm. 	  
At 4 weeks post-implantation, macroscopic evaluation shows that the HA and FeHA 
biomaterials are in the proper position and there is no evidence of haematoma, edema, 
infection or tissue necrosis in either bone and peri-implant soft tissue associated with 
control or magnetic implants. Bone tissue is well visible around the biomaterials in both 
groups demonstrating a good bone integration of FeHA granules (Fig. 18). In detail, 
between the granules, the magnetic FeHA group shows more immature bone not yet 
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completely mineralized stained with Toluidine Blue respect to HA granulate control 
group (Fig. 18).  
This is probably due to the lower physical stability of the FeHA granules in comparison 
with the reference material, which has been subjected to the thermal treatment. This 
would result in a less compact material with a higher specific surface available for bone 
integration, possibly making FeHA more bioactive than control. In the long term these 
characteristics might positively influence tissue regeneration and stability and reduce 
biomaterial resorbability. 
 
6.5 Conclusion 
A neutralization method has been employed to synthesize HA nanopowders in which Ca 
is partially substituted by Fe2+ and Fe3+. The simultaneous addition of both Fe species 
under controlled synthesis conditions leads to FeHA with a (Fe + Ca)/P ratio very close to 
the theoretical one (Ca/P = 1.67) and a very small content of magnetite as secondary 
phase. XRD, ICP and TEM analysis confirm that both Fe2+ and Fe3+ ions enter the HA 
lattice. The new FeHA exhibits very low crystallinity and a structural coherence at the 
nanometer length scale together with very low thermal stability. Likewise, XANES and 
EXAFS spectra reveal additional contribution from the Fe K-edge, besides Fe in mag- 
netite, assignable to Fe in apatite. Powder H shows the superparamagnetic-like behaviour 
typical of single-domain magnetic nanoparticles: the signal largely exceeds the one 
expected for such a low content of magnetite. A relevant hyperthermia effect indicates a 
bulk phenomenon that even more clearly confirms the intrinsic magnetic behaviour of this 
FeHA phase. 
The occupation of the Ca(1) and Ca(2) crystallographic positions of the HA lattice by the 
two Fe species and their specific spatial distribution (which implies a specific Fe3+/Fe2+ 
ratio) rais the hypothesis of two distinct interacting structural domains or sublattices, 
whose nature deserves further investigation, as does as the mechanism underlying the 
superparamagnetic effect. 
Overall, the in vitro results show that the novel superparamagnetic FeHA powder not only 
does not reduce cell viability, but it enhance cell proliferation compared to HA particles 
controls already used in clinical application. Moreover, the positive effect of these 
nanoparticles is significantly increased when a SMF is applied. 
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The magnetic property of the FeHA phase together with its biocompatibility open the 
door of the regenerative medicine to a conceptually new family of biomimetic scaffolds 
able to be biologically manipulated or activated in situ by means of an external magnetic 
field. Additionally, the high hyperthermia of FeHA offers a true advantage with respect to 
the present solutions in anti-cancer therapies: the benefits foreseen are not only the more 
intense and rapid local effect, but most of all its biocompatibility/degradability, which 
overcome the side effects of long-term cytotoxicity. Injected MNPs can also increase the 
resolution, up to the cellular scale, of diagnostic techniques such as resonance. Hence, 
such FeHA nanoparticles could be effectively used in cancer prevention, allowing further 
development of the resonance technique that can be improved towards the early detection 
of even small tumoral cell aggregates. In conclusion, regenerative medicine and the wider 
field of theranostics may benefit from solutions represented by these completely 
biocompatible and biodegradable magnetic nanocarriers. 
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CHAPTER 7 
 
DEVELOPMENT OF MAGNETIC BIOHYBRID 
FeHA/COLL SCAFFOLDS 
 
Magnetic biohybrid scaffolds (FeHA/Coll) was developed following the bio-inspired 
mineralization process1,2: the reproduction of biomimetic conditions of bone synthesis 
allowed to obtain hybrid constructs where the mineral phase is nucleated upon guidance 
of the chemical features and physical confinement imposed by the polymeric matrix, so 
that the mineral phase has physical, chemical and ultra-structural similarity with the 
mineral bone3,4. In this way, the chemico-physical properties of the biohybrid scaffolds 
are highly affected not only by the chemical interactions between FeHA crystals and 
proteinic matrix but also by the structural organization of the matrix itself5. Taking into 
account the biomineralization concept2, not only the mineral phase was nucleated on the 
collagen fibres, creating a tissue conductive system that resembled the complex hierarchic 
structure of bone1, but also during the stage of mineral phase nucleation, both iron species 
(Fe2+ and Fe3+) were introduced into the apatitic lattice in different Ca crystallographic 
sites with a specific coordination6 generating in situ a magnetic mineral phase (FeHA) 
endowed with intrinsic superparamagnetism7. 
The nucleation method is based on the same acid-base reaction already discussed for the 
synthesis of the mineral phase (FeHA powder) (§ 6.1) but differs in the presence of 
collagen added during the process. 
 
7.1 Synthesis process of HA/Coll composite 
The synthesis of the non-magnetic composites HA/Coll was performed following the 
biologically inspired synthesis previously described8. In order to obtain scaffold that 
resembling the chemical composition of the bone tissue, the weight ratio percent between 
the mineral and organic phase was fixed to 70/30 wt%. 
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The organic component, working as matrix mediating the mineralization process, was 
Collagen (Coll) Type I extracted from equine tendon, telopeptides free and supplied as 
buffered acetic gel (an aqueous acetic buffer solution with pH=3.5 containing 1 wt% of 
pure type-I collagen) (Opocrin S.p.A., Italy).  
In detail, 250 ml of H3PO4 solution (0.083M, Sigma Aldrich 85 wt%), mixed with 150 g 
of 1 wt% collagen gel, were dropped in a basic suspension, containing 2.71 g of Ca(OH)2 
(Sigma Aldrich 95 wt% pure) in 500 ml of distilled water to yield a composite material 
HA/Coll in the ratio 70/30 wt%. The drop-wise addition procedure was performed under 
manual stirring, assuring a slow decrease of pH up to neutrality. During the nucleation of 
HA the synthesis temperature was kept at 25°C. 
 
7.2 Synthesis process of magnetic FeHA/Coll composite 
The nucleation of FeHA on the self assembling collagen fibres requires the preservation 
of both iron species so that they can enter the HA structure in two different coordination 
position and induce the superparamagnetism7: actually the oxidation condition of the 
acidic (by acetic acid) suspension of collagen would have oxidize Fe2+, therefore the 
procedure previously set up to prepare HA/Coll hybrid composite8 could not be applied.  
In particular, to avoid the oxidation of Fe2+ to Fe3+ due to the acetic acid present in the 
collagen gel suspension, 150 g of 1 wt% of collagen gel were precipitated with NaOH 
(0.1M) solution added up to pH 5.5 and washed three times with distilled water. Then, the 
precipitated collagen gel was mixed with 250 ml of H3PO4 (0.083 M) solution that was 
dropped in a basic calcium hydroxide suspension (g 2.71 of Ca(OH)2 in 500 ml of 
distilled water) previously enriched with FeCl2 × 4H2O (Aldrich, ≥ 99 wt% pure, 0.689 g 
in 25 ml of distilled water) and FeCl3 × 6H2O (Aldrich, ≥ 98 wt% pure, 0.956 g in 25ml of 
distilled water) to yield a composite FeHA/Coll material in the ratio 70/30 wt%. The total 
amount of iron chloride salts was calculated to obtain a molar ratio (Fe/Ca) = 0.20 mol in 
the mineral phase. The pH of the basic suspension after the addition of iron ions was 
unchanged (pH=12) and at the end of the synthesis the pH value of the aqueous medium 
was 8. 
For the realization of magnetic biohybrid FeHA/Coll scaffolds three different synthesis 
temperatures (25, 40 and 50 °C) were investigated and the respective synthesis products 
were coded FeHA/Coll25; FeHA/Coll40 and FeHA/Coll50.  
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After the synthesis, HA/Coll and FeHA/Coll materials were filtered and poured into 
plastic moulds. 
To obtain dried and porous samples, a freeze-drying process with a controlled freezing 
and heating ramp was performed from 25 °C to -25°C and from - 25°C to 25°C for 50 
min under vacuum conditions (P = 0.20 mbar). 
The samples after the freeze-drying process were treated with the cross-linking agent 1,4-
butanediol diglycidyl ether (BDDGE) through immersion for 24 h at 25°C in a BDDGE 
aqueous solution (2.5 mM), setting up a BDDGE/Collagen ratio equal to 1 wt%. After 
this cross-linking treatment, each sample was washed from the un-reacted BDDGE 
residual and freeze-dried again. 
 
7.3 Chemico-physical and magnetic characterization of FeHA/Coll magnetic 
composite 
Following the biomineralization process, (Fe2+/Fe3+) substituted bone-like hydroxyapatite 
nano-crystals were nucleated on self-assembling collagen fibres, exploiting the ability of 
the negatively charged carboxylate groups of collagen to bind the calcium ions of HA.  
 
7.3.1 X-ray diffraction analysis (XRD) 
The scaffold phase composition was determined by X-ray sample diffraction (XRD) 
performed by a D8 Advanced Diffractometer (Bruker, Karlsruhe, Germany) using Cu Kα 
radiation at 40 kV and 40 mA. XRD spectra were recorded in the 2θ range 10°- 60°, step 
width 0.02° and counting time 1 second. The samples were ground using a cryo-milling 
apparatus to obtain a relatively uniform particle size material.  
For FeHA/Coll composites XRD profiles (Fig. 1) displays patterns typical of a very low 
crystalline apatite indicating that the nucleation happens according to the natural process 
of bio-mineralization: the nano-size dimension of HA crystallites is responsible for the 
large broadening of reflections in the pattern, they are growing inside collagen fibres with 
their c-axis preferentially oriented parallel to the direction of orientation of the collagen 
fibres8. 
The resolution of the spectra are quite low, however it can be stated that no secondary 
phase is appreciated except for FeHA/Coll25 sample where Calcium Carbonate has been 
detected in traces (Fig. 1) as also confirmed by Tg-DTA analysis in Fig. 3 showing a peak 
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in the DTA curve at 400°C corresponding to the decomposition of calcium carbonate. 
In the Fig. 1 the peak at 2θ ≈ 36° relative to sample FeHA/Coll50 can be attributed to 
growing amount of magnetite as expected since the formation of magnetite is favoured at 
temperature above 40°C7. 
During the FeHA nucleation process, the morphology of FeHA crystallites is influenced 
by the synthesis temperature, as confirmed by XRD analysis: for samples synthesized at 
higher temperatures (FeHA/Coll40 and FeHA/Coll50) a more crystalline FeHA phase is 
detected (Fig. 1) compared to the FeHA/Coll25 composite. 
 
 
Fig. 1. XRD spectrum of FeHA/Coll25, FeHA/Coll40 and FeHA/Coll50. The peak identified by * 
corresponds to magnetite while peaks identified by ° correspond to calcium carbonate. 
 
7.3.2 Thermogravimetric analysis (TG-DTG) 
Thermogravimetric investigations (STA 449 Jupiter Netzsch Gerätebau, Selb, Germany) 
were carried out on dried samples using an alumina crucible in air and a heating ramp rate 
of 10 °C/min, from 20 to 1200 °C to estimate the amount of mineral phase bound to 
collagen phase. 
The thermal decomposition profile of collagen used as starting material in the production 
of composite materials (Fig. 2) shows three distinct weight losses, attributable to three 
processes activated by the temperature increase during the analysis, according to the 
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thermal cycle ramp performed from 20 °C to 800 °C. The first weight loss was observed 
in the range temperature 50-150 °C and it was due to the loss of water, the second weight 
loss occurred between 200 and 450 °C and it was attributed to depolymerization and 
decomposition of collagen molecules into gelatin fragments, followed by a third final loss 
of weight  in the range 500-650 °C due to the combustion of the organic residue 
composite9. 
 
Fig. 2. Thermal decomposition profile (TG-DTG) of freeze-dried pure collagen 
 
The TG-DTG curves relative to the composite FeHA/Col prepared at three different 
temperatures using the weight ratio 70:30 are shown in Fig. 3: the plot appear modified if 
compared with those of pure freeze-dried collagen, demonstrating the interaction of 
inorganic phase with collagen fibers.  
The overall loss of weight undergone by the samples (Fig. 3), derived from the sum of the 
effects of processes of dehydration and thermal decomposition of collagen over that of 
dehydration and decarbonation of hydroxyapatite. From consideration of the overall 
losses suffered, the reaction yield of FeHA synthesis, turns out to be rather high. 
In the case of the profile of thermal decomposition of the composite FeHA/Coll (70/30), 
there are still three distinct weight losses in three temperature ranges.  
In the range of 50-100 ° C, there is a reduction in weight by about 10%, due to the loss of 
water adsorbed on the surface of the particles of HA and that of hydration of the collagen 
molecules. At about 200 °C starts the subsequent weight loss, as a result of a first 
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degradation and decomposition of collagen. The processes of thermal decomposition are 
completed in the neighborhood of 550 °C, about 100 °C before compared to pure 
collagen, with an overall decrease of about 40% of the total weight. 
Thermal analysis (Fig. 3) performed on FeHA/Coll25, FeHA/Coll40 and FeHA/Coll50 
composites showed the same extent of mineralization for all the composites: a loss of 
collagen of about 40 wt% with respect to the total mass of the sample was detected, so 
that the final weight ratio was fixed to 60/40 wt/wt instead of 70/30 wt/wt of the one 
nominally set up. 
 
 
 
Fig. 3. TG–DTG curves of freeze-dried (A) FeHA/Coll25; (B) FeHA/Coll40 and (C) FeHA/Coll50  
 
7.3.3 Infrared spectroscopy analysis (FTIR) 
Infrared spectroscopy analysis (FTIR) were performed by using a Thermo Nicolet Avatar 
320 FT-IR Spectrometer on pellets (13 mm Ø) prepared by mixing 2 mg of ground 
sample with 100 mg of KBr in a mortar and pressing. The analysis was used to determine 
the typical bands relative to functional groups present in apatite and collagen and also to 
study the probable interaction between organic and inorganic phases in the composites. 
Fig. 4 compares FeHA spectrum with spectra relative to FeHA/Collmix composite 
obtained by simply mixing of FeHA nanopowder and collagen and FeHA/Collnucl 
composite obtained by nucleation of FeHA on collagen fibres. 
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In table 1 are reported wave number signals characteristic of collagen and hydroxyapatite. 
 
	  
 
Fig. 4. FTIR analysis of FeHA/Coll 70/30 composite compared with FeHA, HA/Coll and the composite 
(FeHA/Coll(70/30)mix) obtained by mixing of the mineral phase with the collagen. 
 
Functional group Wave number (cm-1) Vibrational motion 
Carboxylic Acid 
 -COOH 
1000-1300  
1340  
1600-1700  
3000 
bending C-O  
Asymmetric stretching (COO)  
stretching (C=O) 
 (O-H) 
Secondary amide 
-CONHR 
1550  
1680  
3300 
bending (C-N)  
stretching (C=O)  
stretching (N-H) 
-CO3 
850-880  
1410-1545  
2350 
bending  
stretching  
stretching 
-PO4 
560-600  
1630  
980-1100 
bending (O-P-O)  
stretching (HPO4)  
stretching (P-O) 
-OH 
600  
1640  
3000-3600 
bending (O-H)  
 stretching 
 
Table 1. Intervals of wave numbers (cm-1) characteristic of collagen and hydroxyapatite 
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A proof of the chemical interaction between FeHA and collagen fibres comes from the 
study of the FTIR spectra (Fig. 4), in which a shift from 1340 to 1338 cm-1
 
of the band 
corresponding to the stretching of –COO group of collagen was observed. This shift is 
absent in the composite material obtained by simply mixing of FeHA nanopowder and 
collagen (FeHA/Coll (70/30) mix) (Fig. 4). The band at 873 cm-1
 
is stronger for the 
nucleated FeHA/Coll scaffolds with respect to the pure FeHA, indicating that the 
nucleation of FeHA into collagen implies carbonation of the inorganic phase. Moreover 
the carbonation can be assigned only to the B position as confirmed by the absence of the 
band at 880 cm-1. 	  
	  
Fig. 5. FTIR analysis of FeHA and FeHA/Coll composites synthesized at 25; 40 and 50°C.  
 
In Fig. 5 a comparison between spectra of FeHA/Coll composites synthesized at different 
temperatures is reported: normally the low site symmetry of the PO43- tetrahedron of 
crystalline HA splits the ν4 PO43- contour into three components which fall near 630, 600, 
and 550 cm-1.10,11 The triplets, according to the synthesis temperature, tend to merge in 
two and one broad band, respectively for the composite FeHA/Coll50, FeHA/Coll40 and 
FeHA/Coll25. All these features indicate that the mineral phase nucleated on collagen 
fibres is non-stoichiometric and that decreasing the synthesis temperature results in an 
increase in the amorphous character of the apatite resembling that of newly formed bone. 
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7.3.4 Morphological analysis by scanning electron microscope (SEM) and by 
transmission electron microscope (TEM) 
Scaffolds morphology determination was carried out by scanning electron microscopy 
(SEM; Stereoscan 360, Leica, Cambridge, UK). SEM analysis shows, for all the 
composites, assembled collagen fibres completely covered by the mineral phase (Fig. 6F, 
I, L). The morphology of the sample FeHA/Coll25 (Fig. 6F) appeares very similar to that 
of natural bone: nano-globular apatite crystals cover completely the collagen fibres giving 
to the material a porous architecture with a network of micro-macro porosity (Fig. 6D) to 
allow cell adhesion and proliferation.  
 
 
Fig. 6. A,D,G,J) Detailed analysis of morphology of bio hybrid scaffolds B,E,H,K) Detailed analysis of cell 
morphology of cell-seeded scaffolds at day 1. C,F,I,L) Details of morphological features of the mineral 
phase. A,B,C) HA/Coll. D,E,F) FeHA/Coll25. G,H,I) FeHA/Coll40. J,K,L) FeHA/Coll50. Scale bars: 
A,D,G,J) 100 µm. B,E,H,K) 10 µm. C,F,I,L) 5 µm. 
 
Development of magnetic biohybrid FeHA/Coll scaffolds 
 	  
	  
132 
 
For samples FeHA/Coll40 (Fig. 6I) and FeHA/Coll50 (Fig. 6L) composites, the higher 
synthesis temperature causes the growing of bigger apatitic crystals with a plate-like 
morphology that, thickening the collagen fibres, reduce the porosity of the samples (Fig. 6 
G,J). 
Morphological investigations on the apatitic nuclei and on their interaction with the 
collagen fibres are augmented by TEM observations of samples FeHA/Coll40 and 
FeHA/Coll50. Low magnification images provide evidence of the close assembly of the 
apatitic nuclei on the surface of collagen fibres (Fig. 7, left). In several cases, overlayers 
are observed, anyway resulting from the stacking of FeHA nano-particles on a “primary 
layer” in close contact with the surface of the collagen matrix (Fig. 7, inset).  
 
Fig. 7. (Left) TEM images of the external border of the assemblies of apatite particles around collagen 
fibres. Panel A: FeHA/Coll40; Panel B: FeHA/Coll50. Insets: view, at higher magnification, of the interface 
between collagen and the mineral phase. 
(Right) TEM images representative of the assembly of apatite particles around collagen fibres. Panel A: 
FeHA/Coll40; Panel B: FeHA/Coll50.  
 
Noticeably, the morphology of the apatitic nano-particles appears different in dependence 
on the synthesis temperature. As better observed in the images at higher magnification of 
the external border of FeHA assemblies on the collagen fibres, many of the particles of 
FeHA/Coll40 projected on the image plane a rectangular shape, 150-200 nm long and 25-
50 nm width (Fig. 7A, right). Differently, the particles of FeHA/Coll50 produce two 
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different projections on the image plane, one resulting in tabular shapes ca. 100-150 nm 
(length) x 75-100 nm (width) in size, characterized by a weak contrast, and the other in 
needle-like shapes ca. 100-150 nm (length) x 5-10 nm (width), appearing significantly 
darker. On the base of the mass-thickness contrast mechanism12 they might then 
correspond to “side view” of the particles with tabular morphology. It is worth to notice 
that for both materials no particles with significant different morphology, likely due to 
separated iron oxide phases have been observed.  
 
7.3.5 Chemical analysis by ICP 
ICP-OES quantitative analysis, using an inductively-coupled plasma-atomic emission 
spectrometrer, (ICP-OES: Liberty 200, Varian, Claython South, Australia), was applied to 
determine the content of the chemical elements (Fe, Ca and P) constituting the mineral 
phase of biohybrid materials. 
 	   (Ca+Fe)P (mol) Ca/P (mol) Fe/Ca (mol) Fe (wt%) 
HA/Coll - 1.544 - - 
FeHA/Coll25 1.940 1.708 0.136 2.968 
FeHA/Coll40 1.691 1.426 0.186 3.833 
FeHA/Coll50 1.699 1.380 0.231 4.432 
 
Table 2. ICP features of HA/Coll and FeHA/Coll composites synthesized at 25, 40 and 50°C. 
 
For FeHA/Coll40 and FeHA/Coll50 composites the Ca/P molar ratio is lower with respect 
to the HA/Coll reference while the (Ca+Fe)/P molar ratio is very close to the theoretical 
one (1.68), confirming the effective replacement of Ca ions with Fe ions (Table 2). 
Moreover, for these two samples the highest substitution of iron ions in the HA lattice is 
reached since the amount of iron ions detected by ICP resembled the nominal one fixed 
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for the synthesis with an experimental mistake of about 15%, indicating that the higher 
temperature favours the replacement of Fe ions instead of Ca in agreement with the 
results previously published for the synthesis of the pure FeHA7. 
In the case of FeHA/Coll25 sample, the Ca/P molar ratio and (Ca+Fe)/P molar ratio are 
higher than the ones of the reference (HA/Coll) (Table 2) due to the presence of Calcium 
Carbonate; at the same time the formation of Calcium Carbonate during the synthesis 
causes a depletion of Calcium ions available for the formation of the apatitic phase, so 
that the amount of iron ions entered in the HA lattice results lower (Fe/Ca = 0.136 mol) 
than the nominal one fixed for the synthesis of FeHA (Fe/Ca = 0.20 mol). 
 
7.3.6 Magnetic properties of FeHA/Coll composite 
The magnetic properties (Fig. 8) of the FeHA/Coll samples are affected by the 
substitution of iron ion in the HA lattice and hence by the synthesis temperature, as 
reported in a previously work7. The magnetic curves measured (black curves) can be 
decomposed into two components: one background component (blue curves) that 
increases linearly with field, typical for paramagnetism far away from saturation, 
probably assigned to collagen, and one following a Brillouin function (red curves) that is 
due to the superparamagnetism of FeHA. The paramagnetic background is of comparable 
magnitude for all the samples investigated here, with a trend towards stronger background 
for those samples that were synthesized at higher temperatures. For the sample 
FeHA/Coll25 (Fig. 8A), the low crystallization and the scarce organization of the HA 
lattice cause a poor coordination level of the iron ions inside the crystalline structure, 
reflecting in a low magnetization in the sample (0.091 emu/g at 7T). Higher 
magnetization values are measured for samples synthesized at higher temperatures, 
indicating that temperature influences the substitution and the coordination of the iron 
ions in the HA lattice, as confirmed also by ICP analysis. FeHA/Coll40 has a value of 
magnetization (0.182 emu/g at 7T; Fig. 8B) quite low for the disturbing effect of collagen 
on the measure and much lower than the one of FeHA/Coll50 (1.103 emu/g at 7T; Fig. 
8C) in agreement with the presence of magnetite in sample prepared at the highest 
temperature, that even if in very low concentration (as can be argued by the presence of a 
feeble peak in XRD patter in spite of the high scattering power of magnetite) contribute 
consistently to the increase of magnetization. 
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Fig. 8A. Magnetic measurements of  FeHA/Coll25. Black: measured curves. Blue and red: non-saturating 
and saturating paramagnetic contributions, respectively. Non-saturating contributions are roughly equal for 
all three samples.  
 
 
 
Fig. 8B. Magnetic measurements of  FeHA/Coll40. Black: measured curves. Blue and red: non-saturating 
and saturating paramagnetic contributions, respectively. Insets: small hysteresis indicates the 
superparamagnetic nature of the samples. 
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Fig. 8C. Magnetic measurements of  FeHA/Coll50. Black: measured curves. Blue and red: non-saturating 
and saturating paramagnetic contributions, respectively. Insets: small hysteresis indicates the 
superparamagnetic nature of the samples 
 
7.4 In vitro evaluation of FeHA/Coll scaffolds  
MG-63 human osteoblast-like cells were cultured within the biohybrid FeHA/Coll 
scaffolds for 1, 3 and 7 days. Non magnetic HA/Coll, already tested in several in vitro and 
in vivo studies was used as control13. 
Live/Dead assay was performed for each time point without magnetic field application in 
order to evaluate the cell viability of the novel magnetic FeHA/Coll scaffolds. All groups 
demonstrate high cell viability representing good biocompatibility, with FeHA/Coll25 
presenting a better performance than FeHA/Coll40 and FeHA/Coll50 (Fig. 9A-C). 
Moreover the cell morphology, visualized with Live/Dead Calcein staining, shows that 
cells seeded on FeHA/Coll25 have more widespread morphology, respect to the other 
groups (Fig. 9A-C).  
This could also be seen with immunofluorescence staining against actin, where already at 
day 3 FeHA/Coll25 group shows better cell adhesion and distribution, exhibiting more 
characteristic osteoblast morphology throughout the scaffold (Fig. 9D).  
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Fig. 9. Analysis of cell viability and morphology. Cell viability was analysed by the Live/Dead assay 
(Calcein acetoxymethyl stains live cells in green, Ethidium homodimer-1 stains dead cells in red). A,B,C) 
FeHA/Coll25, FeHA/Coll40, FeHA/Coll50 respectively at day 3. D) FeHA/Coll25 at day 7, cell 
morphology was analysed by actin staining (actin is shown in green, DAPI in blue). Scale bars: A-C) 500 
µm, D) 100 µm 
 
For a detailed analysis of cell morphology within these composite scaffolds, SEM 
characterization has been performed and it reveals very high cell integration within the 
nanostructure of the scaffold for all groups. The complex HA/collagen fibre mesh and 
how cells exploit such a matrix can be observed, illustrating high biocompatibility and 
osteoinductivity performances of such scaffolds (Fig. 6B, E, H, K). 
From the above viability and morphological characterization, it results that the cell 
behavior on FeHA/Coll40 and FeHA/Coll50 scaffolds is very similar. Considering the 
higher magnetization of FeHA/Coll50 sample, a detailed cell proliferation assay was done 
comparing FeHA/Coll25 and FeHA/Coll50 to the control scaffold. 
Cell proliferation was quantified by the MTT assay and results were plotted on graph 
(Fig. 10). As it is possible to observe in Fig. 10A, the magnetic material groups present a 
high rate of cell proliferation, equal or even higher than control group without static 
magnetic field application (SMF). FeHA/Coll25 presents better performance than 
FeHA/Coll50 scaffold, with a statistically significant difference seen at day 3 (p≤0.001). 
FeHA/Coll25 scaffold has therefore the potential to strongly enhance cell proliferation at 
an early stage, and focusing on tissue regeneration application this fact could be 
extremely important to shorten the regeneration timing. Even though, at day 7 no 
significant difference was seen between the magnetic scaffold groups and the control 
group, already used in clinic application. 
Overall, both novel magnetic FeHA/Coll composites show high biocompatibility. The in 
vitro performance of the magnetic biohybrid composites seems to be affected more by 
their chemical and morphological features than by their magnetic properties. In fact, the 
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best in vitro performance of FeHA/Coll25 can be assigned, as previously described, to its 
more open porosity that resembles that of the natural bone, respect to FeHA/Coll50 
composite, which allow increased cell adhesion and proliferation. 
In order to address magnetic properties contribution to in vitro performance, the MTT 
experiment was performed also with the application of a 320 mT static magnetic field 
(SMF). An overall increase in cell proliferation due to the SMF application is observed. 
In particular, a statistical significant difference is seen at day 3 (p≤0.01) and at day 7 
(p≤0.05) (Fig. 10B). Looking in detail to the behavior of cells seeded into scaffolds under 
SMF application it possible to observe that, again, FeHA/Coll25 shows the best 
performance, with a trend comparable to the results obtained without SMF application 
(Fig. 10C). 
FeHA/Coll25 shows a significantly higher cell proliferation compared to the control 
group for every time point (day 1 p≤0.05, day 3 and day 7 p≤0.001), demonstrating that 
the SMF enhances cell proliferation, in fact this difference between FeHA/Coll25 does 
not seen at day 7 without SMF application (Fig. 10A). Also the FeHA/Coll50 scaffold 
shows a significant increase in cell proliferation at day 7 compared to the control group 
(p≤0.01). These results underline how the superparamagnetic properties of the novel 
scaffolds which are emphasized by the application of an external static magnetic field 
enhancing cell proliferation. 
Gene expression analysis shows an increase in Collagen type I, alpha 1 (Col1A1) and 
Runt-related transcription factor 2 (RUNX2) in cells cultured in the magnetic scaffolds 
respect to control (1.53-fold and 1.13-fold, respectively). Moreover, the application of 
SMF increases this difference even further (2.91-fold Col1A1, and 2.12-fold RUNX2). 
The above results show that not only the novel magnetic scaffolds are biocompatible, but 
moreover if they are subjected to a SMF application, their performance in cell 
proliferation is even improved respect to the control scaffold already used in clinic. 
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Fig.10. Cell proliferation assay. MTT assay was performed 1, 3 and 7 days after MG63 human osteoblast-
like cells seeding (n=3), either without (A,B) or with (B,C) the application of a static magnetic field. A) 
Cell proliferation is higher for FeHA/Coll25 composite at day 1 and day 3, B) Application of a static 
magnetic field (SMF) results in an overall increase in cell proliferation, C) Magnetic scaffold have the best 
performance under the application of a SMF. * p≤0.05, ** p≤0.01, *** p≤0.001. 	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7.5 Development of a three-layer magnetic scaffold 
Taking into consideration the good results coming from the pre-clinical and clinical 
application of Maioregen® as one of the most effective scaffold14,15 in the current 
innovative orthopaedic practise, a three-layered structure resembling the sub-chondral 
bone, the tide-mark and the cartilagineous layer as been designed and developed 
following the same paradigm8 but nucleating FeHA instead HA as the mineral component 
of the composite. 
To realize the scaffold with different grade of mineralization, mimicking the complexity 
of the osteochondral region and having an associated magnetization gradient (Fig. 10a), 
three different layers were prepared following the nucleation method described (§ 7.2) 
and assembled: (a) the upper one, mimicking the cartilagineous layer, and composed of 
pure collagen; (b) the intermediate one, mimicking the tidemark, and composed of 
FeHA/Coll (40/60 wt%) composite; (c) the lower one, mimicking the sub-chondral bone, 
and composed of FeHA/Coll (70/30 wt%) composite. 
 
a) 
	  	  	  	  	  
b) 
Fig. 10a. Picture of tree-layer scaffold: the upper 
layer was constituted of FeHA/Coll (70/30wt%), 
the intermediate of FeHA/Coll (60/40 wt%) and the 
lower one of pure collagen. 
Fig. 10b. Picture of tree-layer scaffold attracted by 
a magnet 
	  
The nucleation of the superparamagnetic phase in different concentration from 0% (in the 
layer charged for cartilage regeneration) up to 70% (in the layer charged for sub-condral 
bone regeneration) generated also a magnetic gradient, as schematically described in Fig. 
11. 
This design has been conceived to exploit the simple activation that the magnetized 
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scaffold can exert on osteblast cells, as previously demonstrated16,17 and in addition to 
attract growth factors or other important biomolecules linked to magnetic nanoparticles. 
In fact FeHA in form of nanoparticles could be injected as magnetic carriers, and, 
exploiting the magnetic guiding process, recalled from the fisiological environment 
towards the three-layered scaffold up to the scaffold/sub-chondral bone interface. Tuning 
the intensity of the external static magnetic field it can be also envisage to direct the 
carriers specifically into one of the scaffold layer on demand following a particular 
regenerative need. A simple horizontal assemblage of two plastic tubes, having the 
scaffold in the middle, was realized and by means of XRD and ICP analysis was proved 
that FeHA nano-carriers contained in a suspension inside one of the plastic tube can be 
recalled towards the highly mineralized and magnetized layer of the scaffold (in contact 
with the second plastic tube) under the action of an external static magnetic field of 320 
mT. 
 
Fig. 11. Development of a 3-layer magnetic scaffold. A) Photo of the three-layer magnetic scaffold. B) 
ESEM micrograph of scaffold morphology: three different layers are distinguishable due to the different 
content of mineral phase that increases moving from the upper (cartilagineous: collagenic only) to the 
intermediate (tidemark: FeHA/Coll 40/60 wt% composite), and to the lower layer (bone layer: FeHA/Coll 
70/30 wt% composite). C) Scheme of the activation that the magnetized scaffold can exert on osteblast cells 
or to recall growth factors. 
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Additionally the magnetically graded scaffold allows the positional/mechanical 
stabilization of the scaffold into the osteochondral defect thanks to the merging of a small 
magnet into the sub-chondral bone18. Such a tool prevents the occurring of micro-
movements at the regenerative interface and opens a completely new area of investigation 
related to a morphological control in the newly formed tissue. In fact the strength lines of 
the magnetic field induce a specific anisotropic imprinting, favouring the growth of a 
lamellar mechanically competent new bone tissue as recently demonstrated.  
 
7.6 Conclusion 
FeHA/Coll magnetic biohybrid composites were prepared through a biologically inspired 
mineralization process. The introduction of the iron ions into the apatitic lattice during the 
stage of HA nucleation induces in the final composite (FeHA/Coll) those chemico-
physical, structural and morphological features typical of newly formed bone along with 
superparamagnetic properties. The synthesis temperatures influence the chemico-physical 
features of the magnetic biohybrid scaffolds and hence their performance biological 
performance.  
In vitro investigations indicate firstly the biocompatibility of these novel magnetic 
biohybrid scaffolds showing good ability to support cell adhesion and proliferation. 
Moreover, the superparamagnetic properties of the novel scaffolds are emphasized by the 
application of an external static magnetic field improving their performance in cell 
proliferation respect to the control scaffold already used in clinic.  
These first positive results constitute the necessary prerequisites for further investigations 
into the potential application of the magnetic scaffolds to control and direct osteogenesis 
and/or simultaneous chondrogenesis.  
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CHAPTER 8 
 
BIOACTIVE CALCIUM PHOSPHATE BONE 
CEMENTS: BASIC CONCEPTS 
 
Calcium phosphate cements (CPCs) are increasingly used as bone substitute materials to 
repair bone defects resulting from trauma or disease1.  
A ceramic bone cement consists in a powder mixture which upon mixing with a liquid 
phase results in a paste which spontaneously sets at body temperature. Upon mixing, 
dissolution of the calcium phosphate powders and precipitation of a new calcium 
phosphate occurs in the mixing liquid. When the new formed crystals become entangled, 
hardening occurs. Despite the large range of possible CPC starting compositions, it is 
generally agreed that only two end-products are formed: (i) brushite, also called dicalcium 
phosphate dihydrate (CaHPO4·2H2O) or (ii) an apatite with a composition close to that of 
hydroxyapatite (Ca5(PO4)3OH).  
In recent years, there has been increasing interest in the use of CPCs for the reinforcement 
of osteoporotic bone, either to fix osteo-synthesis plates2 or for vertebroplasty in which a 
cement is injected into osteoporotic vertebral bodies3,4. 	  
8.1 Features of injectable bone cement 
To be suitable for use in vertebral fracture surgery, the main parameters to consider in the 
development of bone cements are5:  
 Setting time: the time required to attain a specified degree of rigidity with 
particular reference to initial and final setting time. For clinical use a good paste 
will have a setting time in the range 10-30 minutes. The setting time of a cement 
can be modified1: 
 by changing of  the powder size: more the size of the powder is small shorter 
is the setting time; 
 by changing of the powder/liquid ratio: smaller is the amount of liquid added 
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to the powder shorter is the setting time; 
 adding rapidly available calcium and/or phosphate ions (either pre-dissolved in 
the mixing liquid or as freely soluble salt): higher salts concentrations shorter 
is the setting time; 
 by adding crystal nucleii (e.g. apatite nanocrystals for apatite cements): more 
are nucleii added shorter is setting time, 
 by adding crystal growth inhibitors: more are inhibitors added longer is setting 
time. 
 Low setting temperature: reducing potential thermal injury to surrounding bone 
or neural elements. 
 Injectability: ability of the cement paste to be extruded through a small and long 
needle without de-mixing. Demixing occurs when the mixing liquid is too fluid 
compared with the particle size of the cement powder, resulting in filter pressing: 
the liquid comes out without the CaP particles.  
 Cohesion: ability to set in a fluid without disintegrating. Good cohesiveness 
properties could be achieved maintaining a high viscosity for CaP pastes. An 
increase of the cement viscosity with the addition of a gel forming polymer into 
the mixing solution increases the cement cohesion6. 
 Bioactivity: ability of CaP phase to release ions and drugs active in osteogenesis; 
 Bioresorbability: ability of CaP phase to be progressively resorbed during bone 
remodelling; 
 Osteoconductivity: creation of an open and interconnected porosity to allow cell 
adhesion and colonization using selected bio-erodible polymer; 
 Mechanical properties: ability of paste to withstand biomechanical loads after 
injection in diseased vertebrae. During the setting reaction of the cement, CaP 
crystals grow and became partially interlocked, hence making the cement 
mechanically rigid. As CaP are brittle, the compressive strength of a CPC is 
always much grater than its tensile strength. Most CPC have a tensile strength of 
1-10 Mpa, whereas the compression strength ranges between 10-100MPa7. 
 Radioopacity: addition of radio-opacifiers into CPC might provide a better 
visualization during injection, particularly for vertebroplasty. For example, iodide-
based organic contrasting agents can be incorporated in a powder or liquid form, 
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but their slow release from the cement and the occurrence of deadly allergic 
reactions strongly impairs their use. The use of strontium carbonate appears to be 
the most suitable choice because the powder has solubility close to that of calcium 
carbonate, so the powder should be resorbable. Moreover, strontium ions have a 
good biocompatibility1. 
 
8.2 Hardening mechanism  
The present study aims at looking at these aspects using an apatite cement consisting of 
α-tricalcium phosphate (α-TCP; Ca3(PO4)2) powder and an aqueous phase. 
During the setting reaction of α-TCP-based hydraulic CPC, two main reactions occur:  
[1] the exothermic dissolution of α-TCP and [2] the endothermic precipitation of calcium 
deficient hydroxy-apatite (CDHA; Ca9(HPO4)(PO4)5OH) leading to [3] an exothermic 
global reaction (for α-TCP, this value is close to -133 kJ/mole8): 
 
         3Ca3(PO4)2 = 9Ca2+ + 6PO43-      (1)  
 
9Ca2+ + 6PO43- + H2O = Ca9(HPO4)(PO4)5OH    (2)  
 
3Ca3(PO4)2 + H2O = Ca9(HPO4)(PO4)5OH   (3) 
 
During dissolution, the raw powders release calcium and phosphate ions, generating a 
supersaturation in the solution. Once the ionic concentration reaches a critical value, the 
nucleation of the new phase occurs, generally surrounding the powder particles. 
Afterwards, the new phase keeps growing as the dissolution of the reagents goes on. 
During the first hours the setting process is controlled by the dissolution kinetics of the 
raw materials, but once the new phase surrounds the reactants, the process is controlled 
by diffusion across the new phase9. 	  
8.3 Cement microstructure and porosity 
CPCs are highly porous materials due to free spaces between precipitated crystals, with 
pore size in the nano/micrometric range. While porosity can be a limitation for the use of 
these materials in high load-bearing applications, it is crucial for other applications10. 
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Thus, porosity is sought to enhance the material’s resorbability and the extent of 
bioactivity by increasing the surface area available for reaction. In the same way, their 
inherent porosity makes these materials good carriers for controlled drug delivery 
systems. Not only the total interconnected porosity is relevant for the loading and delivery 
of drugs, but also the pore dimensions and pore size distribution within the cement, as 
well as its specific surface area. These parameters vary with the processing conditions of 
the cements, such as the liquid to powder (L/P) ratio and the particle size of the starting 
powder. Thus, the total porosity increases when the L/P ratio is increased, and otherwise 
the particle size of the starting powder conditions the shape and size of the precipitated 
crystals. In this way, it has been shown that HA needle-like crystals with high specific 
surface area are obtained when fine α-TCP powder is used, whereas plate-like crystals 
with lower specific surface area are obtained using coarser powder11. 	  
8.4 Bioactivity and resorption of calcium phosphate cements 
One of the most important properties of CPCs is bioactivity. When referring to bone 
substitutes, a bioactive material is one that is able to bind directly with the surrounding 
bone without the formation of fibrous tissue12,13. Bioactivity, together with the perfect 
adaptability of the cement paste during implantation, leads to a stable connection between 
defect and implant, speeding up bone healing process. Once implanted, CPCs can be 
resorbed by two different mechanisms. Active resorption regulated by living cells like 
macrophages or osteoclasts, and/or passive resorption via chemical dissolution or 
hydrolysis in the body fluids. Since brushite is soluble in body fluids, brushite cements 
are mainly resorbed by passive mechanism14,15 while apatites being less soluble, cause 
apatite cements to be mostly resorbed by the active mechanism16,17, i.e. macrophages and 
osteoclasts locally drop down the pH at values at which apatite becomes soluble. The 
incorporation of ionic substitutions is a method to control the degradation of CPCs. For 
example, incorporation of carbonates increases apatite lattice disorder favouring crystal 
dissolution18,19. Further factors that modulate CPC resorption are porosity and 
crystallinity among others. Besides, external factors like patient age, sex, metabolism, 
health, social habits, site of implantation, blood supply or mechanical loads, can affect 
resorption. Ideally, when CPC is resorbed, it is progressively replaced by new bone in 
vivo. The replacement arises with the resorption of the cement surface in parallel with 
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bone growth, thus avoiding gaps between implant and tissue, and guiding bone formation 
(osteoconduction)20.	  
Chapter 8. References 
 	  
	  
150 
 
 References 
1. M. Bohner, U. Gbureck, J. E. Barrale. Biomaterials, 2005, 26, 6423. 
2. M. Bohner, J. Lemaitre, J. Cordey, S. Gogolewski, T. A. Ring, S. M. Perren, 
Orthop. Trans, 1992, 16, 401. 
3. B. Bai, L. M. Jazrawi, F. J. Kummer, J. M. Spivak. Spine, 1999, 24, 1521. 
4.  P. Galibert, H. Deramond, P. Rosat, D. Le Gars, Neurochir, 1987, 33, 166. 
5. Y. W. Li, J. C. Y. Leong,W. W. Lu, K. D. K. Luk, K. M. C. Cheung, K. Y. Chiu, 
S. P. Chow, A novel injectable bioactive bone cement for spinal surgery: a 
developmental and preclinical study, 2000] 
6. K. Ishikawa, Y. Miyamoto, M. Kon, M. Nagayama, K. Asaok. Biomaterials 1995, 
16, 527. 
7. B. Bai, L. M. Jazrawi, F. J. Kummer, J. M. Spivak. Spine. 1999, 24, 1521.  
8. R. I. Martin, K. S. TenHuisen, P. Leamy, P. W. Brown. J Phys Chem B. 1997, 
101, 9375. 
9. M.P. Ginebra, E. Fernandez, F.C.M. Driessens, J.A. Planell. J. Am. Ceram. Soc, 
1999, 82, 2808. 
10. M. Espanol, R.A. Perez, E.B. Montufar, C. Marichal, A. Sacco, M.P. Ginebra. 
Acta Biomater. 2009, 5, 2752. 
11. M.P. Ginebra, F. Driessens, J.A. Planell. Biomaterials, 2004, 25, 3453.  
12.  L.L. Hench, R. Splinter, W. Allen, T. Greenlee. J. Biomed. Mater. Res. 1971, 5, 
117. 
13. W. Cao, L.L. Hench. Ceram. Int. 1996, 22, 493. 
14. L. Grover, J. Knowles, G. Fleming, J. Barralet. Biomaterials, 2003, 24, 4133. 
15.  F. Theiss, D. Apelt, B. Brand, A. Kutter, K. Zlinszky, M. Bohner, et al. 
Biomaterials, 2005, 26, 4383. 
16. E.P. Frankenburg, S.A. Goldstein, T.W. Bauer, S.A. Harris, R.D. Poser. J. Bone 
Joint Surg, 1998, 80, 1112.  
17. S. Wenisch, J.P. Stahl, U. Horas, C. Heiss, O. Kilian, K. Trinkaus, et al. J. 
Biomed. Mater. Res. A, 2003, 67, 713. 
18. I. Khairoun, M. Boltong, F. Driessens, J. Planell. J. Biomed. Mater. Res, 1997, 38, 
356.  
19. E. Fernandez, J.A. Planell, S. Best, J. Biomed. Mater. Res. 1999, 47, 466. 
Chapter 8. References 
 
 
 
151 
20. F. Driessens, J.A. Planell, M.G. Boltong, I. Khairoun, M.P. Ginebra. Proc. Inst. 
Mech. Eng. 1998, H 212, 427. 
 
 
 	  
  
 
Chapter 9 
 
 
 
153 
 
CHAPTER 9 
  
DEVELOPMENT OF BIOMIMETIC CALCIUM  
PHOSPHATE BONE CEMENT  
 
A new injectable Calcium phosphate bone cement paste with appropriate biomimetic and 
biomechanical characteristics able to regenerate the spinal region weakened by 
osteoporosis has been developed according the following step: 
1) Synthesis of metastable CaP phases which transform in ion-substituted HA (Sr, 
CO3) upon setting;  
2) Addition of organic phases (natural or bio-erodible polymers) to the ceramic paste 
to create an open and interconnected porosity; 
3) Incorporation of bio-active reinforcing phases and cross-linking of polymers to 
improve the mechanical properties of the bone cements 
 
At this purpose the ability of α-TCP to set in situ and to form, in contact with a liquid 
solution, a paste that resulting, upon hydrolysis in water, into calcium deficient 
hydroxyapatite whose composition is very close to the mineral composition of bone has 
been investigated. Ions like Strontium and Carbonate were introduced in the cement paste 
formulation to improve the biomimetic aspect of the material. The incorporation of 
selected bio-erodible natural polymer (alginate and gelatin) was studied to create an 
interconnected macroporosity in the hardened construct. Setting time, viscosity and 
injectability of the cements pastes were investigated as function of the reagents milling 
and the liquid-powder ratio. The mechanical features of harden materials was improved 
using bioactive inorganic phases (titania) as reinforcing agents and by cross-link of 
polymeric phase so to have a final material similar in the structure to that of the bone. 
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9.1 Synthesis of metastable CaP phase  
9.1.1 Synthesis of α-TCP 
Alfa tricalcium phosphate (α-TCP) is one of the three polymorphs of TCP, which is stable 
above ≈1125 °C1. It is known that the relative stability of the α- and β-polymorphs is 
highly affected by the presence of some impurities2.  
The synthesis of α-TCP requires high temperature thermal treatments and in many cases 
fast cooling or quenching to avoid reversion of the reconstructive α → β transformation.  
Alfa-tricalcium phosphate (α-TCP) was obtained by solid state reaction of a mixture of 
calcium carbonate and calcium hydrogen phosphate in the molar ratio 1:2 according to the 
following reaction: 
CaCO3 + 2CaHPO4 → Ca3(PO4)2 + H2O + CO2 
After 30 minutes mixing, the solid powder blend was fired in a Platinum crucible in an 
open atmosphere furnace at 1400°C for 1h. At the end of the soaking period, the  product 
was air quenched to room temperature to insure the formation of α form. After it was 
ground with a mechanical milling machine and sieved at 150µm.  
XRD diffractogram of pure α-TCP phase is showed in fig. 1.  	  
 
Fig.1. XRD profile of  α-TCP 
 
9.1.2 Synthesis of Srα-TCP 
Sr-αTCP (Ca(3-x)Srx(PO4)2) was obtained by solid state reaction of a mixture of calcium 
carbonate, calcium hydrogen phosphate and strontium carbonate according the following 
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reaction: 
 
2 CaHPO4 + (1-x)CaCO3 + x SrCO3  → Ca(3-x)Srx(PO4)2 + CO2 + H2O 	  
In order to clarify the influence of Sr2+ ions on the reactivity of α-TCP stoichiometric 
amount of CaHPO4, CaCO3 and SrCO3 were used to reach the respective compositions 2, 
5, 7, 10 and 20 mol% of Sr2+ replacing Ca2+ in Sr-αTCP.  
Starting by a fixed amount of CaCO3 (MW = 100,01 g/mol) equal to 20g and following 
the stoichiometric reaction above reported,  the amount of CaHPO4 (MW = 136,06 g/mol) 
and SrCO3 (MW = 147,63 g/mol) was calculated (Tab. 1). 	  
 
CaCO3 
(g) 
CaHPO4 
(g) 
SrCO3 
(g) 
α-TCP 20 54.40 - 
Sr2% α-TCP 20 57.77 1.84 
Sr5% α-TCP 20 63.44 4.92 
Sr7% α-TCP 20 67.65 7.20 
Sr10% α-TCP 20 70.77 11.06 
Sr20% α-TCP 20 108.75 29.50 	  
Table 1. Amount of reactive used to prepare Sr-αTCP samples with different amount of Sr 	  
After 30 minutes reactive mixing, the solid powder blend was fired in a Platinum crucible 
in an open atmosphere furnace for 1h at 1400°C. At the end of the soaking period, the  
product was air quenched to room temperature to insure the formation of α form, and 
further analyzed by means of X-ray powder diffraction.  
After thermal treatment powder was ground with a mechanical milling machine and 
sieved at 150µm.  
The X-ray diffraction analysis was carried out to evaluate the purity and the crystallinity 
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degree of the synthesised powders.  The XRD spectra were acquired in the 2θ range 10-
60, counting 1 second. XRD diffractogram of pure Sr-αTCP phase is showed in fig. 2. 
 
 
Fig. 2. XRD profile of Sr-αTCP 
 
The examination of the X-ray diffraction patterns of the TCP powders prepared with 
various Sr amounts reveals the presence of α-form with traces of β-form formed during 
the quenching. For each sample the amounts of α-TCP and β-TCP obtained after the 
thermal treatment and quantified by XRD analysis (RIR method) are reported in table 2. 
High amount of Sr favours the formation of β-TCP. 
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Amount of Sr 
introduced α-TCP (wt%) β-TCP (wt%) 
Sr2% α-TCP  100 0 
Sr5% α-TCP  93 7 
Sr7% α-TCP  90 9 
Sr10% α-TCP  83 17 
Sr20% α-TCP  80 20 
 
Table 2. Amount of α-TCP and β-TCP quantified by XRD analysis (RIR method) performed on Sr-αTCP 
powders characterized by increasing Sr content. 
 
The diffraction patterns of the TCP powders are slightly and continuously shifted to lower 
diffraction angles as increasing Sr amount introduced. This is characteristics of an 
increase of the lattice volume and indicates that strontium is incorporated in the structure 
(ionic radii: Sr2+ = 1.13Å, Ca2+ = 1.00Å)3. 
Rietveld refinement analyses performed on the powder data reveal an almost linear 
evolution of lattice parameters as showed in Fig. 3. 
Rietveld analysis was performed by TOPAS 4.2 software (Bruker AXS, Karlsruhe, 
Germany). 	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Fig. 3. Variation of the lattice dimension of Sr-αTCP with increasing Sr content 
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9.2 Development of biomimetic hydroxyapatite based bone cement  
The rate of the setting reaction of α-TCP-based CPCs can be modulated by the physical 
properties of the phosphate (such as particle size), powder to liquid ratio, and addition of 
small amounts of organic and polymeric additives, as well as inorganic salts4-7. It follows 
that the information acquired through the study of the hydrolysis reaction of α-TCP in the 
presence of additives, such as bioactive ions and molecules, can be usefully applied to the 
design and optimization of CPCs8. 
In this work the effect of ions substitution (Sr2+ and CO32-) and that of biopolymers on the 
hydrolysis reaction of α-TCP was studied. 
 
9.2.1 Hydrolysis of α-TCP powder: synthesis of HA cement 
Since the rate of setting of α-TCP is influenced by particle size of the powder, the α-TCP 
powder was ground using a mechanical milling machine (Pulverisette, Germany) to 
provide a fine powder (particle size < 10µm). 
The grinding reduces the particle size and increases the specific surface of the powder 
increasing its surface reactivity. In the graph (Fig. 4) relative to granulometric analysis 
performed on α-TCP powder ground at different milling time, it is possible to observe 
that the size of the particles decrease significantly by grinding the powder: the effects of 
this phenomenon decrease with increasing grinding time. In particular it can be noted that 
for grinding times greater than 50 minutes, the decrease of the particle size of the powder 
is less sensitive: d50 = 2.8 µm for powder ground for 50 minutes and d50 = 2.2 µm for the 
same powder ground for 90 minutes. For this reasons the milling time of α-TCP powder 
was fixed at 50 minutes. 	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Fig. 4. Granulometric analysis performed on α-TCP powder ground at different milling time 	  
After the milling process, α-TCP powder was hydrolyzed using a 2.5 wt% Na2HPO4 * 
2H2O accelerating setting solution at a liquid to powder ratio L/P = 0.8 ml/g. 
The obtained pastes were injected in silicon cylindrical moulds immersed in a 
thermostated bath at 37°C (Fig. 5a).  
	   	  
Fig. 5a. Thermostated bath Fig. 5b. Gillmore Needle 
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Gillmore Needles, an American Standard Test Method (ASTM C266-89) (ASTM 1993b), 
was used for the determination of the setting times for cement pastes.  
The Gillmore Needles instrument (Fig. 5b) consists of two different needles: one with a 
weight of 113 ± 0.5 g and a tip diameter of 2.12 ± 0.05 mm giving a static pressure of 0.3 
MPa used for the initial setting time and the other one with a weight of 453.6 ± 0.5 g and 
a tip diameter of 1.06 ± 0.05 mm giving a static pressure of 5 MPa used for the final 
setting time. The initial setting time (Ist) is the time required for the test specimen to bear 
the initial Gillmore needle without leaving any mark on the surface, while the time 
required for the test specimen to bear the final Gillmore needle without leaving any mark 
is the final setting time (Fst). 
The setting time was measured by injecting the paste into cylindrical forms with a 
diameter of 12 mm and a height of 20 mm (Fig. 6).  
	  
Fig. 6. Gillmore needle used to measure Ist (left) and Fst (right) 	  
The Kinetic of phase transformation of α-TCP paste into HA was studied as function of 
time (Fig. 7), using X-ray diffraction to identify the amount (%vol) of HA phase formed. 
XRD analysis (Fig. 8) performed on cement paste during α-TCP hydrolysis reaction 
indicates that the transformation of α-TCP in HA is fulfilled after 13h by the initial setting 
time.  
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Fig. 7. % vol of HA formed by α-TCP hydrolysis in function of time 
	  
	  
Fig. 8. XRD patterns of HA 
 
Morphological evaluation of the materials was performed by scanning electron 
microscopy (SEM; Stereoscan 360, Leica, Cambridge, UK) on samples coated with gold. 
After 14h soaking at 37°C, it can be noted the needle-like morphology of the crystals of 
HA originating from the dissolution of grains of α-TCP; such grains tend to dissolve 
gradually leaving characteristics cavity empty (Fig. 9a). These needles of HA tend to 
coalesce in lamellar structures (platelet-like) (Fig. 9b). 
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Fig. 9a. SEM image of HA cement after hydrolysis 
of α- TCP in Na2HPO4 * 2H2O solution at 37°C for 
14h 
	  
Fig. 9b. SEM image of HA cement: details of HA 
crystals 
 
9.2.2 Hydrolysis of Sr-αTCP powder: synthesis of SrHA cement 
Sr-αTCP powders containing different amount of Sr were milling and hydrolyzed in the 
same conditions used for α-TCP. 
From the perspective of the clinical uses, the setting time of a CPC cement paste is of 
paramount importance since it should not harden too fast to allow moulding or injection 
and should not harden too slowly to allow the surgeon to close the defect shortly after 
placement of the cement. Therefore, the CPC must have an optimal setting time in order 
to lead to an acceptable mechanical strength after hardening and to prevent migration of 
cement to undesirable sites. At this purpose, the setting time and the kinetic 
transformation of Sr-αTCP in SrHA was investigated. The hydrolysis reaction of Sr-
αTCP occurred at 37°C using a 2.5 wt% Na2HPO4 * 2H2O accelerating solution at a 
liquid to powder ratio L/P = 0.8 ml/g. 
The hydrolysis of Sr-αTCP was influenced by Sr amount present in the powder; 
increasing the amount of Sr present in the starting Sr-αTCP speed of hydrolysis reaction    
decreased with a consequent increase in the cement setting time (Table 3). These results 
are consistent with the higher solubility of Sr-substituted hydroxyapatite9. The increase in 
solubility with strontium content in Sr-substituted hydroxyapatite can be interpreted as a 
destabilization of the crystal structure by the larger Sr2+ ion10, which could justify the 
observed inhibition of crystallization. 	  
0.5	  µm	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Sample 
Ist 
(min) 
Fst 
(min) 
 Transformation in 
SrHA 
(h) 
CPC 30  40  14  
Sr2%CPC 30  40  24  
Sr5%CPC 40  60  96  
Sr7%CPC 60  100  120  
Sr10%CPC 120   240 168  
Sr20%CPC 240   1440 240 
	  
Table 3. Setting time and kinetic transformation of Sr-αTCP in SrHA   
 
The hydrated products are well crystallizated and present diffraction patterns 
characteristics of apatitic phase with small amount of unreacted β-TCP remaining from 
the cement powders containing high amount of Sr.  
Rietveld refinement analyses (Fig. 10a, 10b) performed on the starting powders and on 
the hardened cements confirm the considerable increase in the lattice parameters of SrHA 
in both the a and c axis directions (Fig. 10 )11,12. 	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Fig. 10a.  XRD pattern profiles of Sr-αTCP (Sr/Ca = 2% mol) powder before and after setting 
	  
	  
Fig. 10b.  XRD pattern profiles of Sr-αTCP (Sr/Ca = 7% mol) powder before and after setting 
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The synthesis of Sr-αTCP containing small amount of Sr (Sr/Ca = 2%mol) occurred 
without the formation of β-TCP phase; accordingly the hydrated powder formed by Sr-
αTCP hydrolysis was a pure strontium substituted hydroxyapatite (SrHA) (Fig. 10a). 
Increasing the amount of Sr introduced during the synthesis of Sr-αTCP (Sr/Ca = 7% 
mol) increases the amount of β-TCP formed as secondary phase (Fig. 10b). β-TCP phase 
does not take part in the reaction of Sr-αTCP hydrolysis and hence is present as secondary 
together with SrHA.  
As with the TCP phase, a slight shift to lower 2θ angles of the diffraction peacks of 
apatite phase can be observed indicating the incorporation of Sr in the crystals. The 
refinement results are presented in Fig. 11 and reveal an almost linear evolution of the 
lattice parameters of HA cell as increasing Sr amount introduced. 
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Fig. 11. Variation of the lattice dimension and cell volume of SrHA with increasing Sr content 
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The substitution of Sr instead of Ca site in the HA cell is also confirmed by quantitative 
evaluation (ICP-analysis) performed on the hydrated paste after the setting: the Ca/P 
molar ratio is 1.51 and the amount of Sr detected is the same nominally introduced in the 
starting Sr-αTCP, indicating that all amount of Sr introduced takes place to the hydrolysis 
reactions of Sr-αTCP. Values obtained by ICP-analysis are reported in Table 4.  
 
Sr-αTCP  HA  
Sr/Ca 
(mol %) 
Ca/P 
(mol) 
(Sr + Ca)/P 
(mol) 
Sr/Ca 
(mol %) 
2 1.44 1.46 1.8 
5 1.40 1.46 4.9 
7 1.35 1.45 6.8 
10 1.33 1.46 9.5 
20 1.21 1.44 19.0 
	  
Table 4. Chemical composition (ICP) performed on SrHA cement after the setting 	  
9.2.3 Introduction of carbonate ions during Sr-αTCP hydrolysis: synthesis of 
SrCHA cement 
The incorporation of carbonate ion during the hydrolysis reaction of Sr-αTCP was studied 
with the purpose to obtained a multi-doped HA for osteogenesis stimulation. 
Strontium carbonate hydroxyapatite (SrCHA) cement paste was obtained by the mixture 
of a solid phase made of Sr-αTCP (2%mol), calcium carbonate (CaCO3) and calcium 
dihydrogenphosphate monohydrate (Ca(H2PO4)2 * H2O) previously milling with a 2.5 
wt% Na2HPO4 * 2H2O accelerating setting solution according the following reaction: 
 
nCa(3-x)Srx(PO4)2 + aCa(H2PO4)2 * H2O + xCaCO3 + 7aH2O → Ca10-x/2Srx(PO4)6-x(CO3)x(OH)2 
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fixing the following parameters: 
(Ca + Sr)/P = (3n + x + a)/(2n + 2a) 
 
1.5 ≤ (3n + x + a)/(2n + 2a) ≤ 1.67 
 
The liquid powder molar ratio was fixed so to have L/P = 0.8 ml/g. 
The setting of the pastes was performed during their aging in a silicon moulds 
thermostated at 37°C in a closed bath and measured with Gillmore Needles. 
The presence of Carbonate ions reduces the speed of Sr-αTCP hydrolysis; in fact initial 
and final setting time is 60 and 120 min respectively, higher if compared with that of 
sample without carbonate (Sr2%CPC) (Table 3). Time required to have a completely 
transformation of Sr-αTCP in SrCHA is equal to 72h, as expected by the presence of 
carbonate ions together with strontium ions that inhibit the precipitation of SrCHA. 
X-ray diffraction spectra (Fig. 12) performed on the hardening cement samples detects a 
monophasic SrCHA phase.  
 
	  
Fig. 12. XRD profile of SrCHA cement 	  
Development of biomimetic Calcium Phosphate bone cement 
 	  
 
170 
 
Both the Sr2+ and CO32- substituting ions influence the detection of SrCHA cell 
parameters (c and a) variations, from stoichiometric HA cell parameters13. CO32- 
substituting PO42- (B-type substitution) provokes a contraction of the a axis and an 
increase of c/a ratio while Sr2+ substitution provokes an increase of both axis, so that is 
not easy to establish by XRD analysis what kind of substitutions (A-type and B-type) 
occurrs in the HA cell during the formation of SrCHA cement paste13. 
Fourier Transform Infrared Spectroscopy (FT-IR Thermo Nicolet-Avatar 320) was used 
to check the occurrence of the typical functional groups present in calcium phosphate 
phases (phosphate, hydroxyl, water (adsorbed and structural), carbonate); in particular 
FTIR spectroscopy (Fig.13) allowed to assess whether carbonation occurrs in phosphate 
(B) and/or hydroxyl (A) position in the HA paste.  
Sample was prepared by carefully mixing 1 mg of hardening cement paste powder with 
100 mg of potassium bromide by pestle and mortar; the obtained pellet was put in a 
ventilated oven at 130 °C for 2 hours prior the spectrum acquisition, in order to eliminate 
the water adsorbed on the powder surface14; prior analysis, anyway, the pellet was briefly 
exposed to air atmosphere. Following this procedure, the water detected by FTIR analysis 
is more strictly related to the structural water characterizing the specific HA powder, as 
the contribution of the water adsorbed by potassium bromide is completely eliminated 
and the H2O adsorbed by the HA surface is strongly reduced. FTIR spectra performed on 
SrCHA cement (Fig.13) was obtained by averaging 32 scans collected in the wavelength 
range 400-4000 cm-1, with a spectral resolution of 4 cm-1. 
As shown in Fig. 13, bands at 980-1050 cm-1, and 570-600 cm-1 confirm the presence of 
PO43- groups, typical of apatites. The large band at about 3400 cm-1 and the band at 1644 
cm-1 detect absorbed water and occluded water into the powder.  
Furthermore B-type carbonation is confirmed by the detection of strong typical peaks15,16: 
the stretching peaks at ≈ 1430 cm-1 and 1460 cm-1 and the bending peak at ≈ 873 cm-1. 
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Fig. 13.  FTIR spectrum of SrCHA cement 	  
The incorporation of carbonate ions in the apatite lattice was also confirmed by Thermal 
analysis that was used to explore the thermal transformation process and the thermal 
stability of the powder and to estimate the carbonate content of the apatite. The analysis 
was performed on a specimen of about 20 mg using a heating rate of 10 °C min-1 up to 
1000 °C. The extent of the powders carbonation was evaluated by the weight loss in the 
range 500-1000 °C, due to the decomposition of carbonate groups with evaporation of 
carbon dioxide, and the corresponding stoichiometric coefficient of CO3 anion was 
estimated considering that the highest possible degree of substitution of carbonate ions in 
the phosphate site (B- carbonation) is ~ 50 mol%, corresponding to ~ 21 wt% CO3 loss17. 
Thermal profile (Fig. 14) shows a weight loss occurring from about 50°C up to 500°C 
imputable to dehydration of the absorbed and occluded water and to the removal of 
absorbed species (such as CO2)18. At higher temperatures (in particular from 500 to 
1000°C), carbonate ions decompose causing a weight loss of about 2 wt% due to CO2 
elimination, allowing to estimate as about 3 wt% the starting carbonation of the powder. 
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Fig. 14.Thermal analysis profile performed on SrCHA cement  	  
9.3 Introduction of polymeric phase into calcium phosphate cement 
CPCs are composed of a powder phase and a liquid phase. Therefore, polymers can be 
added to CPC, either dissolved in the liquid phase or in a solid state as an additive to the 
powder phase. Obviously, only water-soluble polymers can be added to the CPC liquid 
phase. In this case, the polymer will be present as a continuous phase throughout the 
entire CPC and, what is more important, the solubilized polymer will be able to interact 
with the cement setting reaction, namely the dissolution of the original phase and the 
precipitation of the final product. Depending on the final CPC properties desired, the 
liquid phase properties may be altered by changing several features of the polymer, such 
as concentration, molecular weight, and polymer chain length. Conversely, when the 
polymers are added in solid form, they will act as a second and discontinuous phase in the 
cement inorganic matrix. Although the extent of chemical interaction with the setting 
reaction is expected to be lower, the morphology, size, and percentage of this second 
phase will have significant effects on the handling properties and on the final performance 
of the material. 
Therefore, the incorporation of polymers into CPC formulation appears to be an excellent 
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option to enhance CPC performance and improve not only some properties relevant for 
the clinical use of these materials, such as injectability, cohesion, or setting time, but also 
their final performance in terms of resorption rate and cell/tissue response19. In this view 
Gelatine and Sodium-Alginate were chosen as bio-soluble organic phase adding to 
ceramic paste to design CPC with an open and interconnected macroporosity. In fact the 
gradual formation of pores upon degradation of the polymer phase opens a route for cell 
colonization thus favouring bone in-growth and, later, bone remodelling.  
 
9.3.1 Calcium phosphate/gelatine bone cement 
One of the main reasons to incorporate gelatin into CPC is to enhance cell adhesion. 
Some studies have shown a positive effect of incorporating gelatin on initial cell adhesion 
and proliferation20 although other studies have reported only a small effect on cell 
proliferation21,22. 
Three methods were investigated to incorporate gelatine into ceramic paste: 
1) Dry method: consisting in a dry mixture between gelatine and milling Sr2%-
αTCP. The resulting powder was mixed with setting liquid solution Na2HPO4 * 2H2O 
(2.5 %wt) and injected.  
2) Foaming method: consisting in the melting of gelatine in the liquid setting 
solution Na2HPO4 * 2H2O (2.5 %wt) at 50-60 °C followed by the foaming of gelatine 
solution with an electrical mixer. To this mixture the inorganic phase (Sr2%-αTCP ) 
was added and gently mixed with the created foam. Thereafter, the cement foam was 
placed into a syringe and extruded in silicon moulds thermostated at 37°C.  
3) Addition of foaming agents: in order to improve the foaming ability of gelatine 
solutions, a synthetic surfactant, Tween 20, was added to gelatine suspension during 
the foaming process. To this foamed suspension the inorganic phase (Sr2%-αTCP) 
was added and gently mixed with the created foam. Thereafter, the cement foam was 
placed into a syringe and extruded in silicon moulds thermostated at 37°C. 
 
In table 5.1; 5.2 and 5.3 are reported respectively the experimental condition used to 
prepare SrHA/gelatine cement pastes according dry mixing (method 1); foaming of 
gelatine (method 2) and addition of foaming agents (method 3). In the tables setting time 
are also reported. 
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Setting time 
Sample 
code 
Gelatine/ 
Na2HPO4 * 2H2O 
(wt %) 
Gelatine/ 
powder      
(wt%) Ist Fst 
CPMG5 5 5 30 min 3 h 	  
Table 5.1. Experimental details of SrHA/Gelatine cement prepared according method 1 	  
Setting time Sample 
code 
Gelatine/ 
Na2HPO4 * 2H2O 
(wt%) 
Gelatine/powder      
(wt%) Ist Fst 
CPFG12 15 12 1h 5h 
CPFG22 15 22 2h 6h 
CPFG27 15 27 6 h 1 day 
CPFG30 15 30 1day 2day 	  
Table 5.2. Experimental details of SrHA/Gelatine cement prepared according method 2 	  
Setting time Sample 
code 
Gelatine/ 
Na2HPO4 * 2H2O 
(wt%) 
Gelatine/ 
powder 
(wt%) 
Tween20/ 
gelatine 
(wt%) Ist Fst 
CPTG 15 12 0.05 1 day 2 day 	  
Table 5.3. Experimental details of SrHA/Gelatine cement prepared according method 3 	  
Foaming process (method 2 and 3) increases setting time of the paste respect to dry 
mixing because of the presence of bubble in the foamed solution. 
SEM images (Fig.15) show the features of composites cements (SrHA/gelatine) obtained 
by the three synthesis methods tested. It is possible to observe that samples present a good 
porosity with a dimension of pores ranges between 300-150 mm for sample derived by 
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method 1 (Fig. 15a); between 500-300 mm for sample derived by method 3 (Fig. 15b) and 
between 250-100 mm for samples derived by method 2 (Fig. 15c). 
Sample in Fig. 15a presents a superficial macro-porosity: probably the no-homogeneous 
dispersion of gelatine in the inorganic phase hampered the growth of HA crystals creating 
large pore that are not interconnected. The distribution of pores in sample 15b and 15c is 
more uniform and pores present a good interconnection. 
 
	  
Fig. 15a. SEM image of SrHA/Gelatine cement obtained by method 1 	  
1mm	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Fig. 15b. SEM image of SrHA/Gelatine cement obtained by method 2 	  
 
	  
Fig. 15c. SEM image of SrHA/Gelatine cement obtained by method 3 
1mm	  
1mm	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9.3.2 Calcium phosphate/Sodium alginate bone cement 
Another polymer tested to create porosity into ceramic paste was Sodium Alginate. Two 
methods were investigated to incorporate Sodium Alginate into ceramic paste: 
1) Addition of HA/Alg (60/40 wt%) beads synthesized with different size. HA/Alg 
60/40 wt% beads were prepared mixing a solution of Sodium Alginate (1wt%) with a 
biomimetic MS-CHA (magnesium-strontium-carbonate hydroxyapatite). The 
suspension was sprayed into a solution of CaCl2 (0.07 M): Ca2+ ions cross-link 
hydroxyls group of alginate according an egg-boxes model. Beads obtained were 
milling and sieved at different size range (400-600; 400-250; < 250 mm). Pastes with 
different HA/Alg size were obtained by simply mixing of HA/Alg beads with Sr2%-
αTCP and Na2HPO4 (2.5 wt%) solution. Pastes obtained were injected in silicon 
moulds thermostated at 37°C. In table 6.1 are reported the main experimental details 
used to prepare pastes containing HA/Alg beads. 
2) Addition of Sodium Alginate solution: consisting in the mixing of Sr2%-αTCP 
with a suspension of Sodium Alginate dissolved in Na2HPO4 * 2H2O (2.5 wt%) 
solution. Pastes obtained were injected in silicon moulds thermostated at 37°C. In 
table 6.2 are reported the main experimental conditions used to prepare 
SrHA/Alginate cements. 
 
Setting time Sample 
code 
Beads Size 
(µm) 
HA-Alg/powder      
(wt%) 
Alg/powder 
(wt%) Ist Fst 
CPA<250 <250 10 4 20 min 60 min 
CPA250-400 250-400 10 4 15 min 80 min 
CPA400-600 400-600 10 4 15 min 60 min 	  
Tab. 6.1. Experimental details of SrHA/Alg cements prepared with different HA/Alg beads sizes 	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Setting time 
Sample 
code 
Alginate/ 
Na2HPO4 * 2H2O 
(wt %) 
Alginate/powder      
(wt%) Ist Fst 
CPMA2 2 2 10 min 30 min 	  
Tab. 6.2 Experimental details of cement SrHA/Alginate prepared according method 2 	  
The addition of Sodium Alginate seems not affect setting time of CPC. In fact when it is 
added as polymeric solution to Sr2%-αTCP the setting time of the paste was faster than 
Sr2%CPC without polymeric phase (see Table 3), indicating that Sodium Alginate does 
not inhibit Calcium phosphate precipitation and crystallization. When Sodium Alginate 
was added as solid phase (HA/Alg beads) in CPC, setting time of pastes increase by 
increasing the size of HA/Alg beads indicating that they act as a discontinuous phase that 
hampered the growth of HA crystals. 
The addition of HA/Alg beads in solid state, as a second phase in the CPCs, is aimed at 
achieving two main objectives. On one side, to act as a reinforcing phase that enhances 
the mechanical properties of the CPC and on the other side to create macroporosity in the 
CPC after dissolving the polymer, which promotes tissue colonization and eventually 
enhances CPC resorption. Figures 16a; 16b and 16c show the morphology (SEM images) 
of samples obtained by the mixer of the inorganic phase (Sr2%-αTCP) with HA/Alg 
beads prepared at different sizes. Sample reported in Fig. 16b shows a good and uniform 
distribution of HA/Alg beads in the inorganic matrices (pores range 250-500 µm). Sample 
reported in Fig. 16c shows a not uniform distribution of pores due to the presence of 
bigger HA/Alg beads (pores range 400-800 µm). On the contrary, by method 2, cement 
with a good uniform porosity (pore range 150-300 µm) has been obtained (Fig. 16d). 	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Fig. 16a. SEM image of SrHA cement mixed with HA/Alg beads  size < 250 µm  	  
	  
Fig. 16b. SEM image of SrHA cement mixed with HA/Alg beads size 250-400 µm  	  
1mm	  
1mm	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Fig. 16c. SEM image of SrHA cement mixed with HA/Alg beads size 400-600 µm  
	  
	  
Fig. 16d. SEM image of SrHA/Alginate cement obtained by method 2 	  
Thermal analysis (Fig. 17) applied to the sample mixer with HA/Alg beads size 250-400 
1mm	  
1mm	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µm shows that the amount of alginate present in the sample was 4 wt%, in agreement with 
the nominally value introduced in the synthesis and reported in Table 6.1, indicating that 
the mineral phase (Sr2%-αTCP) and HA/Alg beads are homogeneous mixer. 
	  
Fig. 17.Thermal analysis profile performed on SrHA cement mixed with HA/Alg beads size 250-400 µm 	  
 
9.4 Porosity measurement 
After drying in a thermal oven at 37 °C for 24 h, the total porosity of the specimens CPCs 
was measured according to the equation: 
 
ptotal = 1− ρ / ρHA 	  
where ρHA is the density of fully dense HA (3.16 g cm−3) and ρ is the apparent density of 
the specimen measured by dividing its weight by its volume. The volume of the 
parallelepiped specimens was calculated from its dimensions measured with a 
micrometer. Five specimens were measured to calculate the mean porosity and its 
standard deviation.  
The introduction of polymeric phase in CPC formulation influences the porosity of  
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materials (Table 7): sample with the highest value of porosity is that obtained by gelatin 
foaming method indicating that this method is more suitable than the simple mix method 
to generate materials with a good porosity as also previously confirmed by SEM image 
(Fig.15b). 	  
Sample  ptotal 
Sr2%CPC 0.62 ± 0.01 
CPA < 250 0.67 ± 0.03 
CPA250-400 0.68 ± 0.02 
CPA400-600 0.68 ± 0.01 
CPMA2 0.63 ± 0.01 
CPMG5 0.67 ± 0.02 
CPFG12 0.78 ± 0.01 
	  
Table 7. Porosity values of SrHA cement 	  
The presence of HA/Alg beads with different size in CPC not influence the porosity of 
materials that remains constant, otherwise when Alginate is added to CPC in form of 
liquid phase porosity decreases. 
 
9.5 Mechanical properties 
Mechanical properties of materials usually decrease with porosity, which is also the case 
for CaP materials23-25. Therefore, within a general context of material performance 
improvement and optimisation, it is important to measure the mechanical behaviour of 
such material. 	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9.5.1 Compression strength 
The compressive strength values of SrCPC are in the range of 1-24 MPa for the 
compressive strengths reported in the literature for brushite-forming cements26.  
The results (Fig. 18) show that Sr2%CPC specimen exhibits higher compressive strength 
respect the same materials containing a polymeric phase. This is in agreement with 
porosity value obtained (Table 7): the mechanical properties decrease as porosity 
increases. 
	  
Fig. 18. Compressive Strength of SrHA cement 	  
The presence of HA/Alg beads into CPC formulation influences negatively the 
mechanical properties of materials since microbeads helped the formation of macro-
channels in the CPC, which stimulate vascularization in vivo and help bio-degradation of 
material27. Moreover, the presence of macro-channels in the CPCs caused an increase of 
the setting time of materials resulting in a decrease of CPC mechanical properties. It is 
reasonable that the mechanical strength compression decreases by increasing the 
dimension of HA/Alg beads introduced into CPC formulation.  
The addition of Alginate in form of liquid phase seems to help the hardening reaction of 
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CPC. In fact the alginate added should come into contact with the calcium ions, which are 
abundant in the CPC, consequently being cross-linked through the ionic exchange of 
sodium by calcium. The cross-link assures a fast setting time of the material resulting in 
an hardened cement with the highest mechanical properties (Fig. 18). 
Gelatin also affects CPC mechanical properties, although in different ways depending on 
the amount of gelatin incorporated. In literature28 is reported that Gelatin increases the 
compressive strength of an α-TCP cement fourfold, which is related to a decrease in 
sample porosity. Compressive strength increases linearly as a function of gelatin 
concentration29. Nevertheless, the general trend is that the highest strengths are obtained 
with low gelatin concentrations rather than with high gelatin concentrations.  
When gelatin is added in form of solid phase (CPMG5) mechanical properties are slower 
than values reported in literature28 for the same amount of gelatine incorporated into CPC 
in form of liquid phase. In fact, when gelatine is incorporated as solid phase, acts as a 
second and discontinuous phase in the cement inorganic matrix causing a decrease of 
mechanical properties. Gelatin is also used as foaming agent in CPC. Self-setting Sr(2%)-
αTCP/gelatin foams are obtained by mixing Sr2%-αTCP with a foamed gelatin solution, 
which after setting results in a HA solid foam, with high macro-porosity that influences 
negatively the mechanical features of bone cements that collapse at values of 1-2 MPa. 
 
9.5.2 Young’s Modulus 
An adequate value of the elasticity modulus is a requirement of fundamental importance 
in the development of ceramic materials to use in the realization of bone substitutes. It is 
indeed necessary that the mechanical properties of the system are as similar as possible to 
those of human bone; high value of the Young’s modulus corresponds to a high rigidity 
and thus to a high fragility of the material. Moreover, Young’s modulus values of CPC 
have not to be high to avoid a fracture of adjacent vertebrae when cement is injected in a 
vertebral site. In fact, excessive cement rigidity reduces the endplate bulge of the 
augmented vertebra, thereby reducing the local spinal joint flexibility. As a consequence 
of the reduced joint flexibility there is an increase in the pressure on the intervertebral 
disc leading to an abnormal mechanical load transfer on the adjacent vertebral body with 
increased risk of fracture. It is also generally believed that the relatively hard bone cement 
leaks out from the vertebral body into the intervertebral disc resulting in new fractures as 
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a consequence of the excessive stimulation of the adjacent endplate. 
The incorporation of polymer in SrCPC formulation increases ductility and plasticity of 
the materials, allowing for a higher deformation before breaking. In fact Young’s 
modulus (Fig. 19) calculated for SrCPC/polymer cements result slower than cement 
without polymeric phase (Sr2%CPC). However, all SrCPC formulations present good 
Young’s modulus values that are less than 1GPa. 
 
	  
Fig. 19: Young's Modulus values of SrHA cement 	  
9.6 Route to enhance the mechanical properties of CaP bone cement 
As already discussed in paragraph 8.2, a critical problem that limits wider clinical 
application of Calcium phosphate ceramic cements is their mechanical properties, as they 
are brittle and have low impact resistance and relatively low tensile strength (6 to 10 
MPa). After the injection in the vertebral body in fact, cement should harden quickly to 
achieve a compressive strength at least of 30 Mpa so that the individual can be stand up. 
In order to improve the mechanical strength of CPC two routes have been experimented: 
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1) Incorporation of bio-active reinforcing phase (TiO2)30 into Sr2%-αTCP paste. 
2) Cross-link of Sodium Alginate suspension. 
 
9.6.1 Incorporation of TiO2 as bio-active reinforcing phase  
TiO2 (Degussa) was mixed with Sr2%-αTCP trough a ball milling in Ethanol for two 
hours. Wet mixture was dried and mixed with a solution of Na2HPO4 * 2H2O (2.5 wt%) to 
form a paste that was injected in silicon moulds thermostated at 37°C. In table 8 are 
reported the main experimental details used to prepare SrHA/TiO2 pastes. 	  
Setting time Sample 
code 
TiO2 
(wt %) 
Sr2%-αTCP 
(wt %) 
L/P 
ml/g Ist Fst 
CPTi95/5 5 95 0.6 5 min 15 min 
CPTi90/10 10 90 0.6 5 min 15 min 	  
Table 8. Experimental details of SrHA/TiO2 cement  	  
Sr2%-αTCP/TiO2 cement pastes show a faster setting time indicating that TiO2 does not 
influence the setting process of the paste.  
In table 9 are reported the mechanical features and porosity values obtained for cement 
paste containing different amount of Titania. Porosity values of both cement paste 
containing Titania are equal to that obtained for Sr2%CPC cement, indicating that Titania 
does not affect the porosity of materials. Moreover, Titania does not influence the 
compressive strengths of the cements but only their stiffness; in fact Young’s modulus 
values are higher if compared to that of Sr2%CPC. 	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Sample 
code 
ptotal 
σcomp  
(MPa) 
E  
(GPa) 
CPTi95/5 0.63 ± 0.01 12 ± 2 0.9 ± 0.03 
CPTi90/10 0.63 ± 0.01 10 ± 2 0.9 ± 0.03 	  
Table 9. Porosity values and mechanical features of SrHA/TiO2 cement  
 
9.6.2 Sodium Alginate cross-linking 
As previously discussed, the addition of Sodium Alginate enhanced the hardening 
reaction of CPCs showing shorter setting time.  
In order to improve the mechanical strength of Sr2%CPC, the addition of a cross-linked 
Sodium Alginate suspension to Sr2%-αTCP phase was investigated. Sodium Alginate in 
fact is soluble in aqueous media and become cross-linked with divalent cations including 
Ca2+ through the ionic interaction between the ions and glucuronate groups. Moreover the 
addition of a cross-linked Sodium Alginate suspension could also improve the 
injectability and the cohesiveness of Sr2%CPC when immersed in a simulated body fluid 
(SBF) at 37°C. 
In details, Sr2%-αTCP powder was mixed with a suspension made of 2 w% of Sodium 
Alginate dissolved in Na2HPO4 * 2H2O (2.5 wt%); this last used as accelerating setting. 
Soon after, the obtained paste was cross-linked with a solution of CaCl2 (5 wt%) and 
injected in cylindrical teflon mould immersed in SBF solution stored at 37°C. The mixing 
ratio of power-to-liquid was 0.8 ml/g.  
In fig. 20 is reported the synthesis scheme for the development of Sr2%CPC/Alg cement. 
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Fig. 20. Synthesis scheme of Sr2%CPC/Alg cement 
 
The effect of the addition of Alginate on the setting time of Sr2%-αTCP was observed by 
the Gillmore Needle test. The initial setting time was 15 minutes while the final setting 
time was 30 minutes. After the hardening, Sr2%CPC/Alg cement was removed by 
cylindrical teflon mould and soaked in SBF solution stored at 37°C for 3 days. The 
surface morphology of Sr2%CPC/Alg cement after the incubation period in SBF was 
observed by SEM (Fig. 21a). 
The hardened cement showed a completely phase transformation of the initial Sr(2%)-
αTCP into a nano-crystallite HA in a simulated biological fluid, as deduced by SEM 
morphology (Fig. 21b) that showed HA crystallite with a plate-like morphology. 
The properties of crystalline HA formed during the incubation in a fluid, such as the 
degree of crystallization and the crystal morphology should play important roles in the 
mechanical properties of the cement. The HA nano-crystallites form an interconnected 
network within the porous structure of the CPCs, leading to an improvement in strength. 
Therefore, the increase in strength is highly associated with the HA nano-crystalline 
formation. 
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Fig. 21a. SEM surface morphology of Sr2%CPC/Alg cement after the hardening. 	  
Fig. 21b. Details of Apatitic crystallite of Sr2%CPC/Alg cement: after the incubation in SBF, apatitic 
crystallites were well developed and showed a plate-like morphology. 
 
2µm	  
2µm	  
Development of biomimetic Calcium Phosphate bone cement 
 	  
 
190 
 
The mechanical properties of cross-linked Sr2%CPC/Alg cement samples after 3 day of 
incubation time in SBF were investigated based on compressive strength. The 
compressive strengthes of Sr2%CPC/Alg cements are in the range 30-35 Mpa while their 
elastic modulus are close to 1 Gpa. In Fig. 22 are showed three stress-strain curves typical 
of Sr2%CPC/Alg hardened cement. 
 
 
Fig. 22. Stress-strain curves of Sr2%CPC/Alg cement. 	  
Injectability and cohesiveness 
Injectability is the ability of a paste to be extruded through a needle without demixing. 
Water-soluble polymers, such as Sodium-Alginate was used also to enhance CPC 
injectability and to increase cohesion time. 
Cohesion is the ability of a paste to set in a fluid without disintegrating. Nevertheless, 
disintegration of the cement paste, in addition to preventing the cement from setting, can 
provoke an inflammatory response and cell apoptosis31. For this reason, the cohesion time 
should be lower than the initial setting time to guarantee the structural integrity of the 
cement paste when injected in liquid solution32. In general, adding soluble polymers 
during the liquid phase tends to enhance CPC cohesion. The mechanism underlying this 
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phenomenon is the increased viscosity of the CPC paste, which prevents penetration of 
the surrounding fluid. 
The cross-link of Sr2%CPC/Alg paste with CaCl2 solution, before the injection in SBF 
solution, increases the cohesiveness of the paste since Sodium-Alginate forms with Ca2+ 
ions an insoluble hydrogel, calcium alginate, that inhibits the decay of cements paste in 
liquid solution (Fig. 23a). In fact after the hardening in SBF at 37°C, the paste does not 
disintegrate in liquid phase keeping its original shape (Fig. 23b). Moreover the presence 
of Sodium-Alginate in CPC formulation improves the injectability of the cement paste 
that was easily injected through a needle having a cannula with a diameter of 0.8 mm 
without demixing. 	  
	  
Fig. 23a. Morphology of Sr2%CPC/Alg paste after the injection in SBF solution at 37°C (before setting) 
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Fig. 23b. Morphology of Sr2%CPC/Alg cement after the hardening in SBF solution at 37°C (after setting) 	  
 
9.7 Conclusion 
Inorganic and hybrid CaP cements were successfully synthesized through the controlled 
setting of Sr-αTCP phases into SrHA. Sr2+ ion exerts an active role in the hydrolysis of α-
TCP: in the presence of increasing amounts of Sr2+ in solution, the speed of the 
conversion reaction of α-TCP into SrHA is highly reduced and the formation of β-TCP as 
secondary phase is favoured. Moreover, increasing strontium substitution for calcium in 
the HA structure provokes a linear variation of the cell parameters in agreement with the 
increasing mean dimensions of the cation. Carbonate ion was also introduced into SrHA 
cement formulation to obtain cement with enhanced biomimetic property.  
The combination of polymers with CPC, either solubilized in the liquid phase or as a 
second solid phase, has proven to be an interesting strategy for the development of bone 
substitutes with improved performance. The addition of gelatin and sodium alginate into 
Sr-αTCP phases enhances the porosity of material that is necessary to allow cell 
colonization and hence to improve cement resorption and bone remodelling. Gelatin 
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cements exhibit high setting time, high porosity and low mechanical properties. Instead, 
the addition of alginate enhances the hardening reaction of CPCs showing shorter setting 
times. When immersed in a body simulating fluid the Alginate/CPC fully induces a 
formation of an apatite crystalline phase. The compressive and tensile strengths of the 
Alginate/CPCs greatly improve after the cross-link of the paste with a calcium chloride 
solution. Moreover, alginate improves the injecatbility of the paste and its cohesiveness in 
liquid solution so that the paste hardens without disintegrates. 
In order to assess the effect of Strontium amount on cell response and the osteogenic 
aspect of the development cement an in vitro cell cytotoxicity test must be carried out.  
Moreover, the regenerative properties of developed cements in terms of biomaterial 
resorption rate and the quality of newly formed bone have to be evaluated by in vivo test. 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Chapter 9. References 
 	  
 
194 
 
References 
1. Elliott JC. Structure and chemistry of the apatites and other calcium 
orthophosphates. Amsterdam: Elsevier; 1994. 
2. Ando J. B. Chem. Soc. Jpn. 1958, 31, 196.  
3. Saint-Jean SJ, Camiré CL, Nevsten P, Hansen S, Ginebra MP. J. Mater. Sci. 
Mater. Med. 2005, 16, 993.  
4. Durucan C, Brown PW.  J. Mater. Sci. 2002, 37, 96. 
5. Camiré CL, Gbureck U, Hirsiger W, Bohner M. Biomaterials 2005, 26, 2787.  
6. Bohner M, Malsy AK, Camiré CL, Gbureck U. Acta Biomater. 2006, 2, 343. 
7.  Brunner TJ, Grass RN, Bohner M, Stark WJ. J. Mater. Chem. 2007, 17, 4072. 
8. Iogo Y, Ito A, Kamo M, Sakurai T, Onuma K, Ichinose N, et al.  Mater. Sci. Eng. 
C 2004,  24, 709. 
9. Pan H, Li Z, Lam WM, Wong JC, Darvell BW, Luk KDK, et al. Acta Biomater. 
2009, 5, 1678. 
10. Bigi A, Panzavolta S, Rubini K. Chem. Mater. 2004, 16, 3740. 
11. Shannon RD, Prewitt CT. Acta Crystallogr. Struct. Crystallogr. Cryst. Chem. 
1969, 25, 925. 
12. Kim HW, Koh YH, Kong YM, Kang JG, Kim HE. J. Mater. Sci. Mater. Med. 
2004, 15, 1129. 
13. Landi E, Sprio S, Sandri M, Celotti G, Tampieri A. Acta Biomaterialia 2008, 
4,656. 
14. Bertinetti L. Nanomateriali per applicazioni biomediche: sintesi e 
caratterizzazione delle funzionalità di superficie. PhD thesis, University of Torino. 
15. Gibson IR, Bonfield W. J Mat Sci: Mat Med. 2002, 13, 685. 
16. Gibson IR, Bonfield W. J Biomed Mater Res. 2002, 59, 697. 
17. LeGeros RZ. In: Myers KH, editor. Calcium phosphates in oral biology and 
medicine, Monographs in oral science. Vol. 15. Basel, Switzerland: AG 
Publishers, 1991, 82-107.  
18. E. Landi, A. Tampieri, G. Celotti, L. Vichi, M. Sandri. Biomaterials, 2004, 25, 
1763. 
19. RA Perez, HW Kim, MP Ginebra, J. Tissue Eng. 2012 DOI:10.1177/ 
2041731412439555 
Chapter 9. References 
 
 
 
195 
20. Perez RA, Del Valle S, Altankov. J. Biomed. Mater. Res. B 2011, 97, 156. 
21. Chiang TY, Ho CC, Chen DC. Mater. Chem. Phys. 2010, 120, 282. 
22. Bigi A, Panzavolta S, Sturba L. J. Biomed. Mater. Res. A 2006, 78, 739. 
23. M. Bouler, M. Trécant, J. Delécrin, J. Royer, N. Passuti, G. Daculsi, Journal of 
Biomedical Materials Research 1996, 32, 603.  
24. K. De Groot, Annals of the New York Academy of Sciences 1988, 523, 227.  
25. Xu HHK, Quinn JB, Takagi S, Chow LC, Eichmiller FC, Journal of Biomedical 
Materials Research 2001, 57, 457. 
26. Bohner M. Injury Int. J. Care Injured 2000, 31, 37. 
27. Lian Q, Li DC, He JK. Proc. Inst. Mech. Eng. H. 2008, 222, 347.   
28. Bigi A, Bracci B and Panzavolta S. Biomaterials 2004, 25, 2893. 
29. Bigi A, Centelli I, Panzavolta S. J. Appl. Biomater. Biomech. 2004, 2, 81. 
30. Dapporto M. Progettazione e caratterizzazione di compositi bomimetici rinforzati 
a base apatitica per la realizzazione di impianti per sostituti ossei, Tesi di Laurea, 
2009, Università di Bologna. 
31. Pioletti DP, Takei H, Lin T, et al. Biomaterials 2000, 21, 1103. 
32. Driessens FC, Planell JA, Boltong MG, et al. Proc. Inst. Mech. Eng. H. 1998, 212, 
42
	  	  
 
 
Conclusion and Future Perspective 
 
 
 
197 
 
Conclusion and Future Perspective 
 
The aim of this work was to design and produce newly conceived biomimetic nano-
structured biomaterials as scaffolds for bone and osteochondral regeneration as new 
solutions towards the local treatment of hard tissues affected by degenerative diseases 
such as Osteoarthritis (OA) and Osteoporosis (OP). Since bone and cartilage are highly 
organised over multiple length scales, approaches such as self-assembly and biomimetic 
mineralisation have been used to control scaffold nanostructure and mechanics; in this 
way materials endowed with the ability to guide and enhance bone regeneration have 
been developed.  
Following the biomineralization approach, magnetic biohybrid composites (FeHA/Coll) 
have been realized nucleating a nano sized iron doped hydroxyapatite (FeHA), with an 
intrinsic superparamagnetic property, directly on collagen fibres. At this purpose, a 
synthetic procedure to obtain a magnetic (Fe2+/Fe3+)-lattice substituted HA, minimizing 
the formation of magnetite as secondary phase, have been developed and optimized 
showing that it possible to introduce both iron species into the HA lattice at different Ca 
sites with a specific coordination generating two different sublattices whose interaction 
could induce superparamagnetic behavior.  
The introduction of the iron ions into the apatitic lattice during the stage of HA nucleation 
induces in the final composite (FeHA/Coll) those chemico-physical, structural and 
morphological features typical of newly formed bone along with superparamagnetic 
properties. The synthesis temperatures influence the chemico-physical features of the 
magnetic biohybrid scaffolds and hence their biological performance.  
In vitro investigations performed on these novel biomimetic magnetic scaffolds indicate 
firstly their biocompatibility showing their good ability to support cell adhesion and 
proliferation. Moreover, in vitro results show that not only the novel magnetic scaffolds 
are biocompatible, but moreover if they are subjected to a static magnetic field (SMF) 
application, their performance in cell proliferation is even improved respect to the control 
scaffold already used in clinic. These results underline how the superparamagnetic 
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properties of the novel scaffolds which are emphasized by the application of an external 
static magnetic field enhancing cell proliferation. 
Taking into consideration the good results coming from the pre-clinical and clinical 
application of Maioregen® as one of the most effective scaffold used in the current 
innovative orthopaedic practise, a three-layered structure resembling the sub-chondral 
bone, the tide-mark and the cartilagineous layer has been designed and developed 
nucleating FeHA instead HA as the mineral component of the composite. Soon, this 
three-leyered scaffold will be implanted in the sheep femoral condyle and its regenerative 
properties under the application of an external magnetic field will be evaluated. 
Therefore, magnetic biohybrid scaffolds developed in this work are promising candidates 
for the regeneration of osteochondral region and hence for regeneration of tissues 
damaged by OA since they have not only the potential to provide a tissue-conductive 
system that mimics the three-dimensional environment of the extracellular matrix (ECM), 
but also, thanks to their magnetic properties, they give the osteoinductive stimuli 
necessary for a faster and significant bone regeneration directly and specifically in the 
target site. 
Moreover, the magnetic property of the FeHA phase together with its biocompatibility 
open the door of the regenerative medicine to a conceptually new family of biomimetic 
scaffolds able to be biologically manipulated or activated in situ by means of an external 
magnetic field. Additionally, the high hyperthermia value obtained for FeHA powder 
offers a true advantage with respect to the present solutions in anti-cancer therapies: the 
benefits foreseen are not only the more intense and rapid local effect, but most of all its 
biocompatibility/degradability, which overcome the side effects of long-term cytotoxicity.  
Bioactive and bioresorbable calcium phosphate bone cements have been also investigated 
as biomaterials to use in regenerative vertebroplasty to treat tissue damaged by OP.  
In this work the ability of Sr-αTCP to set in situ and to form, in contact with a liquid 
solution, a paste that resulting, upon hydrolysis in water, into strontium calcium deficient 
hydroxyapatite has been investigated. 
Sr2+ ion exerts an active role in the hydrolysis of α-TCP: in the presence of increasing 
amounts of Sr2+ in solution, the speed of the conversion reaction of α-TCP into HA is 
highly reduced. Moreover, increasing strontium substitution for calcium in the HA 
structure provokes a linear variation of the cell parameters in agreement with the 
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increasing mean dimensions of the cation. However, the resulting apatitic phase contains 
significant amounts of Sr2+ suggesting that the addition of Sr2+ to CPC formulation could 
be successfully exploited for its local delivery in bone defects. 
Carbonate ion was also introduced into SrHA cement formulation to obtain cement with 
enhanced biomimetic property. The combination of polymers with CPC, either 
solubilized in the liquid phase or as a second solid phase, has proven to be an interesting 
strategy for the development of bone substitutes with improved performance. The results 
obtained indicated that the addition of gelatin and sodium alginate into Sr-αTCP phases 
enhances the porosity of material that is necessary to allow cell colonization and hence to 
improve cement resorption and bone remodelling. Fast setting time (15-30 minutes), high 
mechanical performance (compressive strength 30-35MPa), good cohesiveness and 
injectability have been achieved adding to CPC formulation an alginate suspension cross-
linked with calcium chloride solution. 
Despite the numerous scientific articles on CPCs, there is still a lot to be done to reach a 
better understanding of the physical, chemical and biological properties of CPC. 
Additionally, the gap between CPC research and clinical use should be decreased, for 
example by studying and defining the needs of specific applications (e.g. vertebroplasty: 
injectability, radio-opacity, viscosity, absence of clotting) in terms of cement properties 
and by finding adequate solutions. Recent and future developments will enable the 
commercialisation of better and more differentiated products that should improve the 
clinical outcome and hence the patient life quality. Further, CPCs await a major role as 
model cold setting systems for the study of inorganic/organic molecule interactions as 
interest in hard tissue mimetics grows in materials science. Main trends are in the field of 
drug delivery (e.g. bone morphogenetic proteins), synthesis of granules and blocks with 
improved biological properties, more resorbable cements (e.g. via macropores or using 
brushite CPC), better handling (e.g. mixing, injection) and novel organic–inorganic 
hybrid materials with properties yet to be evaluated. 
 	  
	  
 
 
 
 
 
 
 
 
 
 
 
 	  	  
